

10/596,503

=> d his

(FILE 'HOME' ENTERED AT 12:30:08 ON 26 AUG 2008)

FILE 'REGISTRY' ENTERED AT 12:30:16 ON 26 AUG 2008

L1 STRUCTURE UPLOADED  
L2 43429 S C6-C6N/EA  
L3 41 S C3-C6-C6N/EA  
L4 81 S C4-C6-C6N/EA  
L5 713 S C5-C6-C6N/EA  
L6 16282 S C6-C6-C6N/EA  
L7 82 S C6-C6N-C7/EA  
L8 17199 S L3 OR L4 OR L5 OR L6 OR L7  
L9 909 S L8 AND SPIRO  
L10 44338 S L9 OR L2  
L11 50 S L1 SUB=L10 SAM  
L12 13163 S L1 SUB=L10 FUL

FILE 'CAPLUS' ENTERED AT 12:41:55 ON 26 AUG 2008

FILE 'REGISTRY' ENTERED AT 12:43:25 ON 26 AUG 2008

FILE 'CAPLUS' ENTERED AT 12:45:01 ON 26 AUG 2008

FILE 'REGISTRY' ENTERED AT 12:53:09 ON 26 AUG 2008

FILE 'CAPLUS' ENTERED AT 12:57:40 ON 26 AUG 2008

FILE 'REGISTRY' ENTERED AT 12:58:59 ON 26 AUG 2008

FILE 'CAPLUS' ENTERED AT 13:02:26 ON 26 AUG 2008

FILE 'REGISTRY' ENTERED AT 13:05:19 ON 26 AUG 2008

L13 STRUCTURE UPLOADED  
L14 10188 S L13 SUB=L12 FUL  
L15 STRUCTURE UPLOADED  
L16 1173 S L15 SUB=L14 FUL


FILE 'CAPLUS' ENTERED AT 13:16:02 ON 26 AUG 2008

L17 32 S L16

=> d l1

L1 HAS NO ANSWERS

L1 STR




Structure attributes must be viewed using STN Express query preparation.

10/596,503

=> d 113

L13 HAS NO ANSWERS

L13 STR




Structure attributes must be viewed using STN Express query preparation.

=> d 115

L15 HAS NO ANSWERS

L15 STR



Structure attributes must be viewed using STN Express query preparation.

=> d ibib abs hitstr total

L17 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:804087 CAPLUS

DOCUMENT NUMBER: 149:119663

TITLE: EEG-based determination of histamine 3 (H3) receptor bioactivity

INVENTOR(S): Radek, Richard J.; Bitner, R. Scott; Cowart, Marlon D.; Brioni, Jorge D.; Esbenshade, Timothy A.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: U.S. Pat. Appl. Publ., 15pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080159958	A1	20080703	US 2007-950560	20071205
PRIORITY APPLN. INFO.:			US 2006-877275P	P 20061227

AB The invention discloses an in vivo method for determining the bioactivity of chemical compds. as histamine 3 receptor (H3R) ligands, and provides animal models to determine such bioactivity. The invention further discloses methods for screening therapeutic compds. demonstrating a desired property, using such methods and models described. Preparation of H3R antagonist (3aR, 6aR)-2-[4'-(5-methylhexahydropyrrolo[3,4-b]pyrrol-1-yl)biphenyl-4-yl]-2H-pyridazin-3-one is described.


IT 720690-73-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(GSK 189254A; EEG-based determination of histamine 3 (H3) receptor bioactivity)

RN 720690-73-3 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



L17 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:647855 CAPLUS

DOCUMENT NUMBER: 149:167749

TITLE: Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists

AUTHOR(S): Le, Siyuan; Gruner, John A.; Mathiasen, Joanne R.; Marino, Michael J.; Schaffhauser, Herve

CORPORATE SOURCE: World Wide Discovery Research, CNS Biology, Cephalon, Inc., West Chester, PA, USA

SOURCE: Journal of Pharmacology and Experimental Therapeutics (2008), 325(3), 902-909

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The histamine H3 receptor (H3R) modulates the release of neurotransmitters that are involved in vigilance, cognition, and sleepwake regulation. H3R antagonism has been proposed as a novel approach to the treatment of cognitive and attention deficit as well as sleep disorders. It is apparent that H3R antagonists produce pharmacol. effects in preclin. animal models across a wide dose range. Several H3R antagonists were reported to be effective at producing cognitive enhancing effects at low doses, while producing robust wake enhancement at higher doses. To better understand the effect of H3R antagonists across a broad dose range, an ex vivo receptor binding assay has been used to estimate the degree of H3R occupancy in vivo. The H3R antagonists ciproxifan, thioperamide, GSK189254, and ABT-239 produced wake-promoting activity in vivo and a dose-dependent inhibition of H3R binding ex vivo. For ciproxifan, thioperamide, and GSK189254, a relatively low level of cumulative wake activity was linearly correlated with up to 80% of the receptor occupancy. In contrast, an abrupt break from linearity and a robust increase of waking activity was observed at doses that produce greater than 80% occupancy. Our results suggest a relatively small increase of waking activity at low levels of receptor occupancy that may be consistent with reported enhancement of attention and cognitive function. Robust waking activity at higher levels of H3R occupancy may be mechanistically different from activities at low levels of H3R occupancy.

IT 945493-87-8, GSK 189254


RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists)

RN 945493-87-8 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)

10/596,503



● HCl

REFERENCE COUNT:

39

THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:208237 CAPLUS

DOCUMENT NUMBER: 148:246365

TITLE: Polymorphic form of 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzoo[d]azepin-7-yloxy)-N-methyl-nicotinamide hydrochloride for use in therapy

INVENTOR(S): Borrett, Gary Thomas; Wilson, David Matthew; Bailey, Nicholas; Steadman, Jon Graham

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: Brit. UK Pat. Appl., 20pp.

CODEN: BAXXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
GB 2441014	A	20080220	GB 2006-18135	20060914
PRIORITY APPLN. INFO.:			GB 2006-18135	20060914

AB A polymorphic form of 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-N-methyl-nicotinamide hydrochloride (I) is characterized by one or both of the following: an X-ray powder diffraction spectrum comprising peaks at 5% or greater relative intensity of 2  $\theta$  box = 4.6 and 9.2 (corresponding to lattice spacings of 19.2 angstrom and 9.6 angstrom, resp.) an onset of melting in the range 233-240°C, as measured by DSC. The polymorph may be prepared by treating a solution of the free base, 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-N-methyl-nicotinamide, in methanol with one equivalent of a chloride source (such as acetyl chloride or HCl), followed by crystallization with at least 1.5 vols. of Et

acetate. The polymorph may be used in medicine to treat neurol., psychiatric, sleep and gastrointestinal disorders, pain, epilepsy and obesity. Preparation of I according to above method is disclosed, yield=77%.


IT 720690-73-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(polymorphic form of cyclobutylbenzodiazepin nicotinamide hydrochloride derivative for the treatment of neurol. diseases)

RN 720690-73-3 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



IT 945493-87-8P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(polymorphic form of cyclobutylbenzodiazepin nicotinamide hydrochloride derivative for the treatment of neurol. diseases)

RN 945493-87-8 CAPLUS

10/596,503

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1237132 CAPLUS

DOCUMENT NUMBER: 147:502375

TITLE: Benzylphthalazinone derivs. as histamine-H1 and histamine-H3 antagonists and their preparation, pharmaceutical compositions and use in the treatment of allergic diseases

INVENTOR(S): Gore, Paul Martin; Hancock, Ashley Paul; Hodgson, Simon Teanby; Kindon, Leanda Jane; Procopiou, Panayiotis Alexandrou

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 148pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007122156	A1	20071101	WO 2007-EP53773	20070418
WO 2007122156	A9	20080124		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
US 20080039444	A1	20080214	US 2007-736602	20070418
PRIORITY APPLN. INFO.:			GB 2006-7839	A 20060420
			GB 2007-6160	A 20070329
			GB 2007-6176	A 20070329
OTHER SOURCE(S):	MARPAT 147:502375			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to compds. of formula I and salts thereof, processes for their preparation, compns. containing them and their use in the treatment of


various disorders, such as allergic rhinitis. Compds. of formula I wherein A is N and CH; R1 and R2 are independently halo, C1-6 alkyl(oxy), OH and CF3; y and z are independently 0-2; R3 is C1-3 alkylamines, substituted (methyl)-cyclic amines; and their salts thereof, are claimed. Example compound II was prepared by amination of 4-[(4-chlorophenyl)methyl]-2-[[ (2R)-1-(4-{4-[(3-chloropropyl)oxy]phenyl}butyl)-2-pyrrolidinyl]methyl]-1(2H)-phthalazinone with hexamethylenimine. All the invention compds. were evaluated for their H1 and H3 receptor antagonistic activity. From




the assays, it was determined that compound II exhibited an average PKi (PKb) at H1 of approx. 7.8 and at H3 of approx. 9.6.

IT 955359-63-4P 955359-65-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate and intermediate; preparation of benzylphthalazinone derivs. as H1 and H3 antagonists useful in the treatment of allergic diseases)

RN 955359-63-4 CAPLUS  
 CN 1H-3-Benzazepine-7-carboxamide, N-[2-[4-[4-[(4-chlorophenyl)methyl]-1-oxo-2(1H)-phthalazinyl]hexahydro-1H-azepin-1-yl]ethyl]-3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 955359-65-6 CAPLUS  
 CN 1H-3-Benzazepine-7-carboxamide, N-[3-[4-[4-[(4-chlorophenyl)methyl]-1-oxo-2(1H)-phthalazinyl]hexahydro-1H-azepin-1-yl]propyl]-3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



IT 955359-56-5P 955359-58-7P 955359-60-1P  
 955359-62-3P 955359-64-5P 955359-66-7P

10/596,503

955359-68-9P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzylphthalazinone derivs. as H1 and H3 antagonists useful in the treatment of allergic diseases)

RN 955359-56-5 CAPLUS


CN Formic acid, compd. with 4-[(4-chlorophenyl)methyl]-2-[[ (2S)-1-[3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]propyl]-2-pyrrolidinyl]methyl]-1(2H)-phthalazinone (2:1) (CA INDEX NAME)

CM 1

CRN 955359-55-4

CMF C37 H43 Cl N4 O2

Absolute stereochemistry.



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH

RN 955359-58-7 CAPLUS

CN Formic acid, compd. with 4-[(4-chlorophenyl)methyl]-2-[[ (2R)-1-[3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]propyl]-2-pyrrolidinyl]methyl]-1(2H)-phthalazinone (2:1) (CA INDEX NAME)


CM 1

CRN 955359-57-6

CMF C37 H43 Cl N4 O2

Absolute stereochemistry.


10/596,503



CM 2

CRN 64-18-6

CMF C H2 O2




RN 955359-60-1 CAPLUS

CN Formic acid, compd. with 4-[(4-chlorophenyl)methyl]-2-[1-[3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]propyl]hexahydro-1H-azepin-4-yl]-1(2H)-phthalazinone (1:1) (CA INDEX NAME)

CM 1

CRN 955359-59-8

CMF C38 H45 Cl N4 O2



CM 2

10/596,503


CRN 64-18-6  
CMF C H2 O2

O=CH-OH

RN 955359-62-3 CAPLUS  
CN Formic acid, compd. with 4-[(4-chlorophenyl)methyl]-2-[1-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]hexahydro-1H-azepin-4-yl]-1(2H)-phthalazinone (2:1) (CA INDEX NAME)

CM 1

CRN 955359-61-2  
CMF C36 H41 Cl N4 O



CM 2

CRN 64-18-6  
CMF C H2 O2


O=CH-OH

RN 955359-64-5 CAPLUS  
CN Formic acid, compd. with N-[2-[4-[4-[(4-chlorophenyl)methyl]-1-oxo-2(1H)-phthalazinyl]hexahydro-1H-azepin-1-yl]ethyl]-3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-carboxamide (2:1) (CA INDEX NAME)

CM 1

CRN 955359-63-4  
CMF C38 H44 Cl N5 O2

10/596,503



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH


RN 955359-66-7 CAPLUS

CN Formic acid, compd. with N-[3-[4-[4-[(4-chlorophenyl)methyl]-1-oxo-2(1H)-phthalazinyl]hexahydro-1H-azepin-1-yl]propyl]-3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-carboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 955359-65-6

CMF C39 H46 Cl N5 O2



CM 2

10/596,503


CRN 64-18-6  
CMF C H2 O2

O=CH-OH

RN 955359-68-9 CAPLUS  
CN Formic acid, compd. with N-[4-[4-[4-[(4-chlorophenyl)methyl]-1-oxo-2(1H)-phthalazinyl]hexahydro-1H-azepin-1-yl]butyl]-3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-carboxamide (2:1) (CA INDEX NAME)

CM 1

CRN 955359-67-8  
CMF C40 H48 Cl N5 O2




CM 2

CRN 64-18-6  
CMF C H2 O2

O=CH-OH


IT 955360-15-3P 955360-16-4P 955360-17-5P  
955360-18-6P 955360-19-7P 955360-21-1P  
955360-22-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of benzylphthalazinone derivs. as H1 and H3 antagonists useful in the treatment of allergic diseases)  
RN 955360-15-3 CAPLUS  
CN 1-Propanol, 3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-(CA INDEX NAME)

10/596,503




RN 955360-16-4 CAPLUS

CN 1-Propanol, 3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-, 1-methanesulfonate (CA INDEX NAME)




RN 955360-17-5 CAPLUS

CN 1H-3-Benzazepine, 7-(3-chloropropoxy)-3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 955360-18-6 CAPLUS


CN 1H-3-Benzazepine-7-carboxaldehyde, 3-cyclobutyl-2,3,4,5-tetrahydro-6-hydroxy- (CA INDEX NAME)



RN 955360-19-7 CAPLUS


CN 1H-3-Benzazepine-7-carboxaldehyde, 3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)

10/596,503




RN 955360-21-1 CAPLUS

CN 1H-3-Benzazepine-7-carboxylic acid, 3-cyclobutyl-2,3,4,5-tetrahydro-, ethyl ester (CA INDEX NAME)



RN 955360-22-2 CAPLUS

CN 1H-3-Benzazepine-7-carboxylic acid, 3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




IT 720689-55-4, 3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of benzylphthalazinone derivs. as H1 and H3 antagonists useful in the treatment of allergic diseases)

RN 720689-55-4 CAPLUS

CN 1H-3-Benzazepin-7-ol, 3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L17 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:653910 CAPLUS

DOCUMENT NUMBER: 147:226988

TITLE: GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models

AUTHOR(S): Medhurst, Andrew D.; Atkins, Alan R.; Beresford, Isabel J.; Brackenborough, Kim; Briggs, Michael A.; Calver, Andrew R.; Cilia, Jackie; Cluderay, Jane E.; Crook, Barry; Davis, John B.; Davis, Rebecca K.; Davis, Robert P.; Dawson, Lee A.; Foley, Andrew G.; Gartlon, Jane; Gonzalez, M. Isabel; Heslop, Teresa; Hirst, Warren D.; Jennings, Carol; Jones, Declan N. C.; Lacroix, Laurent P.; Martyn, Abbe; Ociepa, Sandrine; Ray, Alison; Regan, Ciaran M.; Roberts, Jennifer C.; Schogger, Joanne; Southam, Eric; Stean, Tania O.; Trail, Brenda K.; Upton, Neil; Wadsworth, Graham; Wald, Jeffrey A.; White, Trevor; Witherington, Jason; Woolley, Marie L.; Worby, Angela; Wilson, David M.

CORPORATE SOURCE: Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline, Harlow, Essex, UK

SOURCE: Journal of Pharmacology and Experimental Therapeutics (2007), 321(3), 1032-1045

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics


DOCUMENT TYPE: Journal

LANGUAGE: English

AB 6[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) is a novel histamine H3 receptor antagonist with high affinity for human ( $pK_i = 9.59-9.90$ ) and rat ( $pK_i = 8.51-9.17$ ) H3 receptors. GSK189254 is >10,000-fold selective for human H3 receptors vs. other targets tested, and it exhibited potent functional antagonism ( $pA_2 = 9.06$  vs. agonist-induced changes in cAMP) and inverse agonism [ $pIC_{50} = 8.20$  vs. basal guanosine 5'-O-(3-[35S]thio)triphosphate binding] at the human recombinant H3 receptor. In vitro autoradiog. demonstrated specific [3H]GSK189254 binding in rat and human brain areas, including cortex and hippocampus. In addition, dense H3 binding was detected in medial temporal cortex samples from severe cases of Alzheimer's disease, suggesting for the first time that H3 receptors are preserved in late-stage disease. After oral administration, GSK189254 inhibited cortical ex vivo R-(-)- $\alpha$ -methyl[imidazole-2,5(n)-3H]histamine dihydrochloride ([3H]R- $\alpha$ -methylhistamine) binding ( $ED_{50} = 0.17$  mg/kg) and increased c-Fos immunoreactivity in prefrontal and somatosensory cortex (3 mg/kg). Microdialysis studies demonstrated that GSK189254 (0.3-3 mg/kg p.o.) increased the release of acetylcholine, noradrenaline, and dopamine in the anterior cingulate cortex and acetylcholine in the dorsal hippocampus. Functional antagonism of central H3 receptors was demonstrated by blockade of R- $\alpha$ -methylhistamine-induced dipsogenia in rats ( $ID_{50} = 0.03$  mg/kg p.o.). GSK189254 significantly improved performance of rats in diverse cognition paradigms, including passive avoidance (1 and 3 mg/kg p.o.), water maze (1 and 3 mg/kg p.o.), object recognition (0.3 and 1 mg/kg p.o.), and attentional set shift (1 mg/kg p.o.). These data suggest that GSK189254 may have therapeutic potential for the symptomatic treatment of dementia in

10/596,503

Alzheimer's disease and other cognitive disorders.  
IT 945493-87-8, GSK 189254  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(GSK189254, a novel H3 receptor antagonist that binds to histamine H3  
receptors in Alzheimer's disease brain and improves cognitive  
performance in preclin. models)  
RN 945493-87-8 CAPLUS  
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-  
7-yl)oxy]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:320547 CAPLUS

DOCUMENT NUMBER: 146:513700

TITLE: Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats

AUTHOR(S): Medhurst, Andrew D.; Briggs, Michael A.; Bruton, Gordon; Calver, Andrew R.; Chessell, Iain; Crook, Barry; Davis, John B.; Davis, Robert P.; Foley, Andrew G.; Heslop, Teresa; Hirst, Warren D.; Medhurst, Stephen J.; Ociepa, Sandrine; Ray, Alison; Regan, Ciaran M.; Sargent, Becky; Schogger, Joanne; Stean, Tania O.; Trail, Brenda K.; Upton, Neil; White, Trevor; Orlek, Barry; Wilson, David M.

CORPORATE SOURCE: Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline, Essex, CM19 5AW, UK

SOURCE: Biochemical Pharmacology (2007), 73(8), 1182-1194  
CODEN: BCPA6; ISSN: 0006-2952

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB GSK207040 (5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-2-pyrazinecarboxamide) and GSK334429 (1-(1-methylethyl)-4-({1-[6-(trifluoromethyl)-3-pyridinyl]-4-piperidinyl}carbonyl)hexahydro-1H-1,4-diazepine) are novel and selective non-imidazole histamine H3 receptor antagonists from distinct chemical series with high affinity for human ( $pK_i = 9.67 \pm 0.06$  and  $9.49 \pm 0.09$ , resp.) and rat ( $pK_i = 9.08 \pm 0.16$  and  $9.12 \pm 0.14$ , resp.) H3 receptors expressed in cerebral cortex. At the human recombinant H3 receptor, GSK207040 and GSK334429 were potent functional antagonists ( $pA_2 = 9.26 \pm 0.04$  and  $8.84 \pm 0.04$ , resp. vs. H3 agonist-induced changes in cAMP) and exhibited inverse agonist properties ( $pIC_{50} = 9.20 \pm 0.36$  and  $8.59 \pm 0.04$  vs. basal GTP $\gamma$ S binding). Following oral administration, GSK207040 and GSK334429 potently inhibited cortical ex vivo [3H]-R- $\alpha$ -methylhistamine binding ( $ED_{50} = 0.03$  and  $0.35$  mg/kg, resp.). Functional antagonism of central H3 receptors was demonstrated by blockade of R- $\alpha$ -methylhistamine-induced dipsogenia in rats ( $ID_{50} = 0.02$  and  $0.11$  mg/kg p.o. for GSK207040 and GSK334429, resp.). In more pathophysiol. relevant pharmacodynamic models, GSK207040 (0.1, 0.3, 1 and 3 mg/kg p.o.) and GSK334429 (0.3, 1 and 3 mg/kg p.o.) significantly reversed amnesia induced by the cholinergic antagonist scopolamine in a passive avoidance paradigm. In addition, GSK207040 (0.1, 0.3 and 1 mg/kg p.o.) and GSK334429 (3 and 10 mg/kg p.o.) significantly reversed capsaicin-induced redns. in paw withdrawal threshold, suggesting for the first time that blockade of H3 receptors may be able to reduce tactile allodynia. Novel H3 receptor antagonists such as GSK207040 and GSK334429 may therefore have therapeutic potential not only in dementia but also in neuropathic pain.

IT 720690-77-7, GSK 207040


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats)

RN 720690-77-7 CAPLUS

CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)

10/596,503



REFERENCE COUNT:

78

THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:83853 CAPLUS

DOCUMENT NUMBER: 146:184380

TITLE: Preparation of 5-azabenzocycloheptenes as factor Xa inhibitors

INVENTOR(S): Gerlach, Kai; Priepke, Henning; Pfau, Roland; Wienen, Wolfgang; Schuler-Metz, Annette; Dahmann, Georg

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. &amp; Co. K.-G.

SOURCE: PCT Int. Appl., 170pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007009963	A1	20070125	WO 2006-EP64302	20060717
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20070032473	A1	20070208	US 2006-485152	20060712
CA 2615447	A1	20070125	CA 2006-2615447	20060717
EP 1910345	A1	20080416	EP 2006-764178	20060717
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			EP 2005-15588	A 20050719
			WO 2006-EP64302	W 20060717
OTHER SOURCE(S):		MARPAT 146:184380		
GI				



AB Title compds. I [X = M-L-D; D = substituted bicyclic ring with provisos; L

= substituted pyrrolidone; R3 = H, alkyl; M = CH2, CHR3, CR3R3, etc.; W = S, O; B = substituted thiophene with provisos] and their pharmaceutically acceptable salts and formulations were prepared. For example, the TFA salt of azabenzocycloheptene II was prepared from 3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-amine in 6-steps. Compds. I are claimed useful as factor Xa inhibitors.

IT 921751-85-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azabenzocycloheptenes as factor Xa inhibitors)

RN 921751-85-1 CAPLUS


CN 2-Thiophenecarboxamide, 5-chloro-N-[(3R)-1-(3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-oxo-3-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 921751-84-0

CMF C22 H24 Cl N3 O2 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:35810 CAPLUS

DOCUMENT NUMBER: 146:142521

TITLE: Preparation of 2,3,4,5-tetrahydro-1H-3-benzazepines as antithrombotic agents

INVENTOR(S): Priepke, Henning; Dahmann, Georg; Gerlach, Kai; Pfau, Roland; Wienen, Wolfgang; Schuler-Metz, Annette; Handschuh, Sandra; Nar, Herbert

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH &amp; Co. KG

SOURCE: PCT Int. Appl., 185pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007003536	A1	20070111	WO 2006-EP63611	20060628
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006265216	A1	20070111	AU 2006-265216	20060628
CA 2613059	A1	20070111	CA 2006-2613059	20060628
EP 1899330	A1	20080319	EP 2006-763910	20060628
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU			
NO 2007005186	A	20080214	NO 2007-5186	20071011
IN 2007DN09037	A	20080104	IN 2007-DN9037	20071123
MX 200716253	A	20080307	MX 2007-16253	20071218
CN 101213195	A	20080702	CN 2006-80024267	20080102
KR 2008033318	A	20080416	KR 2008-702478	20080130
PRIORITY APPLN. INFO.:			EP 2005-14270	A 20050630
			WO 2006-EP63611	W 20060628

OTHER SOURCE(S): MARPAT 146:142521

GI



AB Title compds. I [D = substituted bicyclic ring system with provisos; R3 = H, alkyl; R4, R5 = H, alkyl, alkenyl, etc.; M = substituted thiophene with provisos] and their pharmaceutically acceptable salts and formulations were prepared. For example, benzazepine II was prepared from 3-trifluoroacetyl-7-nitro-2,3,4,5-tetrahydro-1H-benzo(d)azepine in 6-steps. Compds. I are claimed useful as antithrombotic agents.


IT 919097-12-4P 919097-25-9P 919097-50-0P  
919097-51-1P 919097-52-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrahydrobenzazepines as antithrombotic agents)


RN 919097-12-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[2-[(3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)amino]-1,1-dimethyl-2-oxoethyl]- (CA INDEX NAME)




RN 919097-25-9 CAPLUS

CN 2-Thiophenecarboxamide, N-[2-[(3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)amino]-1,1-dimethyl-2-oxoethyl]-5-ethynyl- (CA INDEX NAME)



RN 919097-50-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)amino]-1,1-dimethyl-2-oxoethyl]- (CA INDEX NAME)




RN 919097-51-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[1-[[3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)amino]carbonyl]cyclopentyl]- (CA INDEX NAME)




10/596,503



RN 919097-52-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[1-[(3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)amino]carbonyl]cyclopentyl]- (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1157169 CAPLUS

DOCUMENT NUMBER: 145:471519

TITLE: Preparation of pyrazole compounds as EP1 prostaglandin receptor antagonists

INVENTOR(S): Conway, Elizabeth Ann; Giblin, Gerard Martin Paul; Gibson, Mairi; Hall, Adrian; Hayhow, Thomas George Christopher; Healy, Mark Patrick; Hurst, David Nigel; Kilford, Ian Reginald; McKeown, Stephen Carl; Naylor, Alan; Price, Helen Susanne; Rawlings, Derek Anthony

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 203pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006114313	A1	20061102	WO 2006-EP3919	20060424
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1874303	A1	20080109	EP 2006-742719	20060424
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
PRIORITY APPLN. INFO.:			GB 2005-8472	A 20050426
			WO 2006-EP3919	W 20060424
OTHER SOURCE(S):			MARPAT 145:471519	
GI				



AB Pyrazoles (shown as I; variables defined below; e.g. 1,1-dimethylethyl [1-[[5-chloro-2-[(phenylmethyl)oxy]phenyl]methyl]-5-methyl-1H-pyrazol-3-

yl]carbamate (1)) or a pharmaceutically acceptable derivative thereof, a process for the preparation of such compds., pharmaceutical compns. comprising such compds. and the use of such compds. in medicine are disclosed.

Although the methods of preparation are not claimed, prepns. and/or characterization data for .apprx.500 examples of I are included. For example, 1 was prepared from 1-[[5-chloro-2-[(phenylmethyl)oxy]phenyl]methyl]-5-methyl-1H-pyrazole-3-carboxylic acid, Et<sub>3</sub>N, and Ph<sub>2</sub>P(O)N<sub>3</sub> in tBuOH; the starting acid was prepared by saponification of the Et ester, which was

prepared

by O-benylation of Et 1-[(5-chloro-2-hydroxyphenyl)methyl]-5-methyl-1H-pyrazole-3-carboxylate (preparation of similar compound described). For I: Z

is

O, S, SO or SO<sub>2</sub>; Rx is (un)substituted C<sub>2</sub>-10alkyl, C<sub>2</sub>-10alkenyl, C<sub>2</sub>-10alkynyl, CQaQb-heterocyclyl, CQaQb-bicyclic heterocyclyl, or CQaQb-aryl; R<sub>1</sub> is CONR<sub>3</sub>R<sub>4</sub>, NR<sub>3</sub>CO<sub>2</sub>R<sub>5</sub>, NR<sub>3</sub>COR<sub>6</sub>, OCONR<sub>3</sub>R<sub>7</sub>, tetrazolyl, oxazolin-2-yl, oxazol-2-yl, benzoxazol-2-yl, pyrrolidinonyl, isoindoledionyl, dihydroisoindolonyl, or (un)substituted SO<sub>2</sub>NHCOaryl; or R<sub>1</sub> is (un)substituted imidazolyl or 1,2,4-triazolyl wherein optionally the imidazole or 1,2,4-triazole ring is fused to give an (un)substituted bicyclic or tricyclic ring system; or R<sub>1</sub> = 4-R<sub>9</sub>-2-oxopiperazin-1-yl. R<sub>2a</sub> and R<sub>2b</sub> = H, halo, CN, SO<sub>2</sub>alkyl, SR<sub>3</sub>, NO<sub>2</sub>, or (un)substituted alkyl or alkoxy; R<sub>3</sub> is H or C<sub>1</sub>-4alkyl; R<sub>4</sub> is H, OH, (un)substituted alkyl, aryl, heterocyclyl, bicyclic heterocyclyl, CQcQdaryl, CQcQdheterocyclyl, or CQcQdbicyclic heterocyclyl, or SO<sub>2</sub>R<sub>8</sub>; R<sub>5</sub> is (un)substituted C<sub>1</sub>-4alkyl, substituted cyclohexyl, Ph, et al.; R<sub>6</sub> is alkyl or (un)substituted aryl, heterocyclyl, bicyclic heterocyclyl, CQcQd-Y-aryl, CQcQd-Y-heterocyclyl or CQcQd-Y-bicyclic heterocyclyl; R<sub>7</sub> is (un)substituted alkyl, alkenyl, aryl, or CQcQdaryl; R<sub>8</sub> is (un)substituted alkyl, aryl or heterocyclyl. R<sub>9</sub> is (un)substituted alkyl, alkenyl, (un)substituted CQcQd-Y-aryl, (un)substituted CQcQd-Y-heterocyclyl or (un)substituted CQcQd-Y-bicyclic heterocyclyl; R<sub>10</sub> and R<sub>11</sub> = H, F and alkyl; or R<sub>10</sub> and R<sub>11</sub> together with the C to which they are attached form a cycloalkyl ring, optionally containing up to one heteroatom = O, S, NH or N-alkyl; and Y is CH<sub>2</sub> or a bond; Qa and Qb = H, CH<sub>3</sub> and F; Qc and Qd = H, CH<sub>3</sub> and F; addnl. details including provisos are given in the claims. Results are summarized for a binding assay for the human prostanoid EP<sub>1</sub> receptor, a human EP<sub>1</sub> Ca mobilization assay and for a human EP<sub>3</sub> Ca mobilization assay for many examples of I.

IT 913568-82-8P, N-[1-[[5-Chloro-2-[(2-methylpropyl)oxy]phenyl]methyl]-5-methyl-1H-pyrazol-3-yl]-3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-carboxamide monohydrochloride


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazole compds. as EP<sub>1</sub> prostaglandin receptor antagonists)

RN 913568-82-8 CAPLUS

CN 1H-3-Benzazepine-7-carboxamide, N-[1-[[5-chloro-2-(2-methylpropoxy)phenyl]methyl]-5-methyl-1H-pyrazol-3-yl]-3-cyclobutyl-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)

10/596,503



● HCl

REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:678394 CAPLUS

DOCUMENT NUMBER: 145:124480

TITLE: Process for the preparation of 6-(2,3,4,5-tetrahydrohydro-1H-benzo[d]azepin-7-yloxy)nicotinamide derivatives as radio-labelled ligands for the human histamine H3 receptor

INVENTOR(S): Plisson, Christophe

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 16 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006072596	A1	20060713	WO 2006-EP112	20060105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2594383	A1	20060713	CA 2006-2594383	20060105
EP 1836171	A1	20070926	EP 2006-700405	20060105
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
US 20080166298	A1	20080710	US 2007-813357	20070705
PRIORITY APPLN. INFO.:			GB 2005-283	A 20050107
			GB 2005-592	A 20050112
			WO 2006-EP112	W 20060105
OTHER SOURCE(S):		CASREACT 145:124480; MARPAT 145:124480		
GI				



I

AB Isotopomers of 6-(2,3,4,5-tetrahydrohydro-1H-benzo[d]azepin-7-yloxy)nicotinamide derivs. [I; R1 = a radio-labeled group and X = CO, or

R1 = C2-6 alkyl and X =  $^{11}\text{C}$ ; e.g., ( $^{11}\text{C}$ -N-methyl)-6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)nicotinamide] are prepared which demonstrate a high binding affinity to the human histamine H3 receptor (e.g.,  $\text{pK}_i = 9.59$ ) and are useful for the labeling and diagnostic imaging (e.g., PET scans) of human histamine H3 receptors.


IT 720690-56-2 720691-59-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(in a process for the preparation of 6-(2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)nicotinamide derivs. as radio-labeled ligands for the human histamine H3 receptor)


RN 720690-56-2 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720691-59-8 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(5-iodo-2-pyridinyl)oxy]- (CA INDEX NAME)



IT 836611-32-6P 897928-06-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(process for the preparation of

6-(2,3,4,5-tetrahydro-1H-benzo[d]azepin-

7-yloxy)nicotinamide derivs. as radio-labeled ligands for the human histamine H3 receptor)

RN 836611-32-6 CAPLUS

CN 3-Pyridinecarboxamide- $^{11}\text{C}$ , 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- ( $^{9}\text{CI}$ ) (CA INDEX NAME)




RN 897928-06-2 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-

10/596,503

7-yl)oxy]-N-(methyl-11C)- (9CI) (CA INDEX NAME)




REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060116364	A1	20060601	US 2005-158245	20050622
WO 2004058682	A1	20040715	WO 2003-JP16808	20031225
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			JP 2002-378729	A 20021226
			WO 2003-JP16808	A2 20031225
OTHER SOURCE(S):		MARPAT 145:7883		
GI				





AB The title compds. I [wherein T = a single bond, (un)substituted alkylene, alkenylene, or alkynylene; A = a single bond, (un)substituted heterocycle, (hetero)arylene, or cycloalkyl; Y = a single bond, O, S, etc.; Z = CH<sub>2</sub>O, O, S, etc.; ring G = (hetero)arylene, heterocycle, etc.; Q1 and Q2 = independently N or C; Ra and Rb = independently H, (un)substituted alkyl, alkenyl, alkynyl, etc.; W = a single bond, CO, (un)substituted alkylene, NH, etc.; R' = H, O, S, etc.; R'' = H, OH, halo, etc.; R = H, OH, halo, etc.; L = a single bond, (un)substituted alkylene, alkenylene, or alkynylene] or salts, or hydrates thereof are prepared as selective estrogen receptor modulators. For example, the compound II was prepared in a multi-step synthesis. Representative compds. I showed K<sub>i</sub> of 0.2 to 94 nM when tested in in vitro estrogen receptor binding assay.


IT 722519-31-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of naphthalene derivs. as selective estrogen receptor modulators)

RN 722519-31-5 CAPLUS

CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-[5-hydroxy-2-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]phenyl]- (CA INDEX NAME)




IT 722536-24-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of naphthalene derivs. as selective estrogen receptor modulators)

RN 722536-24-5 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-[5-methoxy-2-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]phenyl]- (CA INDEX NAME)



L17 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:164593 CAPLUS

DOCUMENT NUMBER: 144:232933

TITLE: Preparation of tetrahydrobenzazepines as histamine H3 antagonists and/or reverse agonists.

INVENTOR(S): Parr, Christopher Allan; Pickering, Paula Louise; Sehmi, Sanjeet Singh; Wilson, David Matthew

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018260	A1	20060223	WO 2005-EP8841	20050812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1778643	A1	20070502	EP 2005-771678	20050812
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
JP 2008509955	T	20080403	JP 2007-526371	20050812
US 20070208005	A1	20070906	US 2007-573732	20070215
PRIORITY APPLN. INFO.:			GB 2004-18267	A 20040816
			WO 2005-EP8841	W 20050812
OTHER SOURCE(S):		MARPAT 144:232933		
GI				



AB Title compds. [I; R1 = alkyl, cycloalkyl, alkylcycloalkyl; R2 = (substituted) aryl, heteroaryl, cycloalkylcycloalkyl, cycloalkylaryl, etc.; R3 = halo, alkyl, alkoxy, cyano, amino, CF3; n = 0-2; A = bond, O, S, imino], were prepared Thus, 4-(2,3,4,5-tetrahydro-1H-benzazepin-7-ylmethyl)benzonitrile (preparation given) was stirred 1 h with cyclobutanone in CH2Cl2/HOAc; NaBH(OAc)3 was added followed by stirring for 3 h to give

4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]benzonitrile. The latter and addnl. I showed fpKi >9.5 in a histamine H3 functional antagonist assay.


IT 876517-77-0P 876517-78-1P 876517-79-2P  
 876517-80-5P 876517-81-6P 876517-82-7P  
 876517-83-8P 876517-85-0P 876517-86-1P  
 876517-88-3P 876517-89-4P 876517-90-7P  
 876517-91-8P 876517-92-9P 876517-93-0P  
 876517-94-1P 876517-95-2P 876517-96-3P  
 876517-97-4P 876517-99-6P 876518-00-2P  
 876518-01-3P 876518-02-4P 876518-03-5P  
 876518-04-6P 876518-05-7P 876518-06-8P  
 876518-07-9P 876518-08-0P 876518-09-1P  
 876518-11-5P 876518-12-6P 876518-13-7P  
 876518-14-8P 876518-15-9P 876518-16-0P  
 876518-17-1P 876518-18-2P 876518-19-3P  
 876518-20-6P 876518-21-7P 876518-22-8P  
 876518-23-9P 876518-24-0P 876518-25-1P  
 876518-26-2P 876518-27-3P 876518-28-4P  
 876518-29-5P 876518-30-8P 876518-31-9P  
 876518-32-0P 876518-33-1P 876518-34-2P  
 876518-35-3P 876518-36-4P 876518-37-5P  
 876518-38-6P 876518-39-7P 876518-40-0P  
 876518-41-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrahydrobenzazepines as histamine H3 antagonists and/or reverse agonists)


RN 876517-77-0 CAPLUS

CN Benzonitrile, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]- (CA INDEX NAME)



RN 876517-78-1 CAPLUS


CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methoxy]-N-methyl- (CA INDEX NAME)



RN 876517-79-2 CAPLUS


CN 2-Pyrazinecarboxamide, 5-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methoxy]-N-methyl- (CA INDEX NAME)

10/596,503




RN 876517-80-5 CAPLUS

CN 1H-3-Benzazepine, 7-[(5-bromo-2-pyridinyl)methyl]-3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 876517-81-6 CAPLUS

CN 2-Pyrrolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-3-pyridinyl]- (CA INDEX NAME)



RN 876517-82-7 CAPLUS


CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methoxy]-N-methyl- (CA INDEX NAME)



RN 876517-83-8 CAPLUS


CN 3-Pyridinecarboxamide, 6-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methoxy]-N-methyl- (CA INDEX NAME)

10/596,503




RN 876517-85-0 CAPLUS

CN 3-Pyridazinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methoxy]-N-methyl- (CA INDEX NAME)




RN 876517-86-1 CAPLUS

CN 3-Pyridazinecarboxamide, 6-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methoxy]-N-methyl- (CA INDEX NAME)



RN 876517-88-3 CAPLUS


CN 2-Pyridinecarbonitrile, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]- (CA INDEX NAME)



RN 876517-89-4 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]- (CA INDEX NAME)

10/596,503




RN 876517-90-7 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[6-(3-methyl-1,2,4-oxadiazol-5-yl)-3-pyridinyl]methyl]- (CA INDEX NAME)




RN 876517-91-8 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyrazinyl]methyl]- (CA INDEX NAME)




RN 876517-92-9 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyridinyl]methyl]- (CA INDEX NAME)




RN 876517-93-0 CAPLUS


CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 876517-94-1 CAPLUS  
 CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]phenyl]-1-piperidinyl- (CA INDEX NAME)



RN 876517-95-2 CAPLUS  
 CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]phenyl]-4-morpholinyl- (CA INDEX NAME)




RN 876517-96-3 CAPLUS  
 CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-2-pyrazinyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 876517-97-4 CAPLUS  
 CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-(1-methylethyl)- (CA INDEX NAME)

10/596,503




RN 876517-99-6 CAPLUS

CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 876518-00-2 CAPLUS

CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 876518-01-3 CAPLUS

CN 2-Pyrazinecarboxamide, N-(cyanomethyl)-5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]- (CA INDEX NAME)




RN 876518-02-4 CAPLUS

CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]- (CA INDEX NAME)




10/596,503




RN 876518-03-5 CAPLUS

CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-methyl- (CA INDEX NAME)




RN 876518-04-6 CAPLUS

CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]- (CA INDEX NAME)



RN 876518-05-7 CAPLUS


CN 2-Pyrrolidinone, 1-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]phenyl]- (CA INDEX NAME)




RN 876518-06-8 CAPLUS

CN 2-Pyrrolidinone, 1-[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-2-pyridinyl]- (CA INDEX NAME)


10/596,503




RN 876518-07-9 CAPLUS  
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(2-pyrazinylmethyl)-  
(CA INDEX NAME)




RN 876518-08-0 CAPLUS  
CN 2-Pyrrolidinone, 1-[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-2-pyrazinyl]- (CA INDEX NAME)



RN 876518-09-1 CAPLUS  
CN Acetamide, N-[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-2-pyrazinyl]- (CA INDEX NAME)




RN 876518-11-5 CAPLUS  
CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-methyl- (CA INDEX NAME)



10/596,503

RN 876518-12-6 CAPLUS


CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 876518-13-7 CAPLUS

CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-ethyl- (CA INDEX NAME)




RN 876518-14-8 CAPLUS

CN 2-Pyrazinecarboxamide, 5-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-methyl- (CA INDEX NAME)



RN 876518-15-9 CAPLUS


CN 2-Pyrrolidinone, 1-[4-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]phenyl]- (CA INDEX NAME)



RN 876518-16-0 CAPLUS


10/596,503

CN 2-Pyrrolidinone, 1-[5-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-2-pyridinyl]- (CA INDEX NAME)




RN 876518-17-1 CAPLUS

CN 1H-3-Benzazepine, 7-[(6-bromo-3-pyridinyl)methyl]-3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 876518-18-2 CAPLUS

CN 2-Oxazolidinone, 3-[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-2-pyridinyl]- (CA INDEX NAME)



RN 876518-19-3 CAPLUS


CN 2-Imidazolidinone, 1-[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-2-pyridinyl]-3-methyl- (CA INDEX NAME)



RN 876518-20-6 CAPLUS


CN 3-Pyridinecarbonitrile, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]- (CA INDEX NAME)

10/596,503




RN 876518-21-7 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-methyl- (CA INDEX NAME)




RN 876518-22-8 CAPLUS

CN Methanone, [6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-3-pyridinyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 876518-23-9 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]- (CA INDEX NAME)



RN 876518-24-0 CAPLUS


CN Benzoic acid, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]- (CA INDEX NAME)



10/596,503


RN 876518-25-1 CAPLUS

CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]- (CA INDEX NAME)




RN 876518-26-2 CAPLUS

CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-methyl- (CA INDEX NAME)



RN 876518-27-3 CAPLUS


CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-ethyl- (CA INDEX NAME)



RN 876518-28-4 CAPLUS


CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)

10/596,503




RN 876518-29-5 CAPLUS

CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 876518-30-8 CAPLUS

CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-(1-methylethyl)- (CA INDEX NAME)



RN 876518-31-9 CAPLUS


CN 2-Pyridinecarboxylic acid, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]- (CA INDEX NAME)



RN 876518-32-0 CAPLUS


CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-(1-methylethyl)- (CA INDEX NAME)

10/596,503




RN 876518-33-1 CAPLUS

CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-2-pyridinyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 876518-34-2 CAPLUS

CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 876518-35-3 CAPLUS

CN 2-Pyridinecarboxamide, N-(4-cyanophenyl)-5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]- (CA INDEX NAME)



RN 876518-36-4 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]- (CA INDEX NAME)






10/596,503


RN 876518-37-5 CAPLUS

CN 1,2,4-Oxadiazol-5(2H)-one, 3-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]phenyl]- (CA INDEX NAME)




RN 876518-38-6 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[4-(1H-pyrazol-1-yl)phenyl]methyl]- (CA INDEX NAME)




RN 876518-39-7 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[4-(1H-1,2,4-triazol-1-yl)phenyl]methyl]- (CA INDEX NAME)



RN 876518-40-0 CAPLUS


CN 1H-Imidazole-5-carboxamide, 1-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-methyl- (CA INDEX NAME)




RN 876518-41-1 CAPLUS

CN 1H-Imidazole-4-carboxamide, 1-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)methyl]-N-methyl- (CA INDEX NAME)

10/596,503



IT 876518-68-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of tetrahydrobenzazepines as histamine H3 antagonists and/or  
reverse agonists)  
RN 876518-68-2 CAPLUS  
CN 1H-3-Benzazepine-7-acetonitrile,  $\alpha$ -(5-bromo-2-pyridinyl)-3-  
cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1354902 CAPLUS

DOCUMENT NUMBER: 144:69750

TITLE: Preparation of 3-cycloalkylbenzazepine derivatives as histamine H3 antagonists for treatment of neurological disease

INVENTOR(S): Bamford, Mark James; Pickering, Paula Louise; Wilson, David Matthew

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123723	A1	20051229	WO 2005-EP6861	20050616
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1756094	A1	20070228	EP 2005-755373	20050616
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV			
JP 2008502644	T	20080131	JP 2007-515905	20050616
US 20070232590	A1	20071004	US 2006-570383	20061211
PRIORITY APPLN. INFO.:			GB 2004-13757	A 20040618
			GB 2004-13758	A 20040618
			GB 2004-13763	A 20040618
			GB 2004-13764	A 20040618
			GB 2004-13765	A 20040618
			GB 2004-13766	A 20040618
			GB 2004-13768	A 20040618
			GB 2004-13769	A 20040618
			GB 2004-13770	A 20040618
			WO 2005-EP6861	W 20050616

OTHER SOURCE(S): CASREACT 144:69750; MARPAT 144:69750

GI




AB The title benzazepine derivs. I [wherein R = cycloalkyl; Ar = (un)substituted aryl or heteroaryl] or pharmaceutically acceptable salts thereof were prepared as histamine H3 antagonists for treatment of neurol. disease. For example, the compound II was prepared in a multi-step synthesis in good yield. II showed antagonistic activity with fPKi of 10.1 against histamine H3.

IT 871737-37-0P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of 3-cycloalkylbenzazepine derivs. as histamine H3 antagonists)

RN 871737-37-0 CAPLUS


CN 2-Pyrrolidinone, 1-[6-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



IT 871737-38-1P 871737-39-2P 871737-40-5P  
 871737-41-6P 871737-42-7P 871737-43-8P  
 871737-44-9P 871737-45-0P 871737-46-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of 3-cycloalkylbenzazepine derivs. as histamine H3 antagonists)


RN 871737-38-1 CAPLUS

CN 2-Pyrrolidinone, 1-[5-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]- (CA INDEX NAME)




RN 871737-39-2 CAPLUS

CN 2-Imidazolidinone, 1-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-fluorophenyl]-3-methyl- (CA INDEX NAME)




RN 871737-40-5 CAPLUS

CN 2-Pyrrolidinone, 1-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]phenyl]- (CA INDEX NAME)




RN 871737-41-6 CAPLUS

CN 2-Oxazolidinone, 3-[6-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridazinyl]- (CA INDEX NAME)



RN 871737-42-7 CAPLUS


CN 2-Pyrrolidinone, 1-[6-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridazinyl]- (CA INDEX NAME)



RN 871737-43-8 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyrazinyl]oxy]- (CA INDEX NAME)

10/596,503




RN 871737-44-9 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyridinyl]oxy]- (CA INDEX NAME)




RN 871737-45-0 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyridinyl]oxy]- (CA INDEX NAME)



RN 871737-46-1 CAPLUS

CN 2-Pyrrolidinone, 1-[6-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 720689-52-1P 720689-55-4P 720689-56-5P

720692-27-3P 871737-48-3P 871737-49-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of 3-cycloalkylbenzazepine derivs. as histamine H3 antagonists)

RN 720689-52-1 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(phenylmethoxy)- (CA


10/596,503

INDEX NAME)




RN 720689-55-4 CAPLUS

CN 1H-3-Benzazepin-7-ol, 3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 720689-56-5 CAPLUS

CN 1H-3-Benzazepin-7-ol, 3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 720692-27-3 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-7-(2-fluoro-4-iodophenoxy)-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 871737-48-3 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(4-iodophenoxy)- (CA INDEX NAME)



10/596,503

RN 871737-49-4 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[(6-iodo-3-pyridazinyl)oxy]- (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT




L17 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1050865 CAPLUS  
 DOCUMENT NUMBER: 143:347172  
 TITLE: Preparation of imidazoles as inhibitors of glutaminyll cyclase.  
 INVENTOR(S): Schilling, Stephan; Buchholz, Mirko; Niestroj, Andre Johannes; Heiser, Ulrich; Demuth, Hans-Ulrich  
 PATENT ASSIGNEE(S): Probiodrug Ag, Germany  
 SOURCE: U.S. Pat. Appl. Publ., 53 pp., Cont.-in-part of U.S. Ser. No. 838,993.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050215573	A1	20050929	US 2005-51760	20050204
US 7304086	B2	20071204		
US 20040224875	A1	20041111	US 2004-838993	20040505
US 7371871	B2	20080513		

PRIORITY APPLN. INFO.:  
 US 2004-542133P P 20040205  
 US 2004-838993 A2 20040505  
 US 2004-634364P P 20041208  
 US 2003-468014P P 20030505

OTHER SOURCE(S): CASREACT 143:347172; MARPAT 143:347172  
 GI




AB Title compds. [I; A = (Ph-, cycloalkyl-interrupted) alkylene, alkenylene, alkynylene; B = NHC(:X)NHD, C(:X)NHD, C(:X)SD, etc.; D = alkyl, alkenyl, alkynyl, cycloalkyl, aryl, acyl, heterocyclyl, etc.; X = O, S, imino, (substituted) CH<sub>2</sub>], with specific exceptions, were prepared Thus, 3,4-methylenedioxyphenyl isothiocyanate and 3-(1H-imidazol-1-yl)propylamine were refluxed together for 2 h in EtOH to give 51.3% 1-[3-(1H-imidazol-1-yl)propyl]-3-(3,4-dimethoxyphenyl)thiourea. The latter showed an IC<sub>50</sub> = 0.22 μM for inhibition of glutaminyll cyclase. Peptide inhibitors of dipeptidyl peptidase IV were also prepared

IT 720690-73-3, GSK 189254A  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of imidazoles as inhibitors of glutaminyll cyclase)

RN 720690-73-3 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)

10/596,503



REFERENCE COUNT:

57

THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1021741 CAPLUS

DOCUMENT NUMBER: 143:326234

TITLE: Preparation of benzazepine derivatives as antagonists of histamine H1 and H3

INVENTOR(S): Bamford, Mark James; Heightman, Thomas Daniel; Wilson, David Matthew; Witherington, Jason

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 84 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005087746	A1	20050922	WO 2005-GB939	20050310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1730114	A1	20061213	EP 2005-718000	20050310
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
JP 2007528887	T	20071018	JP 2007-502403	20050310
US 20070185089	A1	20070809	US 2006-598759	20060911
PRIORITY APPLN. INFO.:			GB 2004-5628	A 20040312
			WO 2005-GB939	W 20050310
OTHER SOURCE(S):			CASREACT 143:326234; MARPAT 143:326234	
GI				




- AB Title compds. I [R1 = (un)substituted cycloalkyl; R2 = aryl, heteroaryl, heterocycle, etc.; R3 = H, alkoxy, CN, etc.; n = 0-2] and their pharmaceutically acceptable salts, are prepared and disclosed as antagonists of histamine H1 and H3. Thus, e.g., II was prepared by coupling of 3-cyclobutyl-7-(1-piperazinyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (preparation given) with 3-bromobenzonitrile. The activity of I was evaluated in the histamine H3 functional antagonist assay and selected compds. of the invention displayed a pKb in the range of >6.5 and >9.0. I as antagonists of histamine H1 and H3 should prove useful in the treatment of neurol. diseases. Pharmaceutical compns. comprising I are disclosed.
- IT 865111-39-3P 865111-53-1P 865111-54-2P  
 865111-55-3P 865111-56-4P 865111-57-5P  
 865111-58-6P 865111-59-7P 865111-60-0P  
 865111-61-1P 865111-62-2P 865111-63-3P  
 865111-64-4P 865111-65-5P 865111-66-6P  
 865111-67-7P 865111-68-8P 865111-69-9P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of benzazepine derivs. as antagonists of histamine H1 and H3)
- RN 865111-39-3 CAPLUS
- CN 2-Pyrazinecarboxylic acid, 5-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-, methyl ester (CA INDEX NAME)

10/596,503




RN 865111-53-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, phenylmethyl ester (CA INDEX NAME)




RN 865111-54-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, phenylmethyl ester (CA INDEX NAME)



RN 865111-55-3 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-(1-piperazinyl)- (CA INDEX NAME)



RN 865111-56-4 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(1-piperazinyl)- (CA INDEX NAME)

10/596,503




RN 865111-57-5 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3,6-dihydro-, phenylmethyl ester (CA INDEX NAME)




RN 865111-58-6 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(4-piperidinyl)- (CA INDEX NAME)



RN 865111-59-7 CAPLUS


CN 3-Pyridinecarboxylic acid, 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, methyl ester (CA INDEX NAME)



RN 865111-60-0 CAPLUS


CN 3-Pyridinecarboxylic acid, 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/596,503




RN 865111-61-1 CAPLUS

CN 2-Pyrazinecarboxylic acid, 5-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-, methyl ester (CA INDEX NAME)




RN 865111-62-2 CAPLUS

CN 2-Pyrazinecarboxylic acid, 5-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 865111-63-3 CAPLUS


CN 2-Pyridinecarboxylic acid, 5-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 865111-64-4 CAPLUS


CN 2-Pyridinecarboxylic acid, 5-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]- (CA INDEX NAME)

10/596,503




RN 865111-65-5 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[1-(5-iodo-2-pyridinyl)-4-piperidinyl]- (CA INDEX NAME)




RN 865111-66-6 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-(4-pyridinyl)- (CA INDEX NAME)



RN 865111-67-7 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-(4-piperidinyl)- (CA INDEX NAME)



RN 865111-68-8 CAPLUS

CN 2-Pyrazinecarboxylic acid, 5-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]- (CA INDEX NAME)






RN 865111-69-9 CAPLUS

CN 2-Oxazolidinone, 3-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(hydroxymethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



IT	865107-79-5P	865107-80-8P	865107-81-9P
	865107-82-0P	865107-83-1P	865107-84-2P
	865107-85-3P	865107-86-4P	865107-87-5P
	865107-88-6P	865107-89-7P	865107-90-0P
	865107-91-1P	865107-92-2P	865107-93-3P
	865107-94-4P	865107-95-5P	865107-96-6P
	865107-97-7P	865107-98-8P	865107-99-9P
	865108-00-5P	865108-01-6P	865108-02-7P
	865108-03-8P	865108-04-9P	865108-05-0P
	865108-06-1P	865108-07-2P	865108-08-3P
	865108-09-4P	865108-10-7P	865108-11-8P
	865108-12-9P	865108-13-0P	865108-14-1P
	865108-15-2P	865108-16-3P	865108-17-4P
	865108-18-5P	865108-19-6P	865108-20-9P
	865108-21-0P	865108-22-1P	865108-23-2P
	865108-24-3P	865108-25-4P	865108-26-5P
	865108-27-6P	865108-28-7P	865108-29-8P
	865108-30-1P	865108-31-2P	865108-32-3P
	865108-33-4P	865108-34-5P	865108-35-6P
	865108-36-7P	865108-37-8P	865108-38-9P
	865108-39-0P	865108-40-3P	865108-41-4P
	865108-42-5P	865108-43-6P	865108-44-7P
	865108-45-8P	865108-46-9P	865108-47-0P
	865108-48-1P	865108-49-2P	865108-50-5P
	865108-51-6P	865108-52-7P	865108-53-8P
	865108-54-9P	865108-55-0P	865108-56-1P
	865108-57-2P	865108-58-3P	865108-59-4P
	865108-60-7P	865108-61-8P	865108-62-9P
	865108-63-0P	865108-64-1P	865108-65-2P
	865108-66-3P	865108-67-4P	865108-68-5P
	865108-69-6P	865108-70-9P	865108-71-0P

865108-73-2P 865108-75-4P 865108-77-6P  
 865108-79-8P 865108-81-2P 865108-83-4P  
 865108-85-6P 865108-87-8P 865108-89-0P  
 865108-91-4P 865108-93-6P 865108-95-8P  
 865108-97-0P 865108-99-2P 865109-01-9P  
 865109-03-1P 865109-05-3P 865109-07-5P  
 865109-09-7P 865109-11-1P 865109-13-3P  
 865109-15-5P 865109-17-7P 865109-19-9P  
 865109-21-3P 865109-23-5P 865109-25-7P  
 865109-27-9P 865109-29-1P 865109-31-5P  
 865109-33-7P 865109-35-9P 865109-37-1P  
 865109-39-3P 865109-41-7P 865109-43-9P  
 865109-45-1P 865109-47-3P 865109-49-5P  
 865109-51-9P 865109-53-1P 865109-55-3P  
 865109-57-5P 865109-59-7P 865109-61-1P  
 865109-63-3P 865109-65-5P 865109-67-7P  
 865109-69-9P 865109-71-3P 865109-73-5P  
 865109-75-7P 865109-77-9P 865109-79-1P  
 865109-81-5P 865109-83-7P 865109-85-9P  
 865109-87-1P 865109-89-3P 865109-91-7P  
 865109-93-9P 865109-95-1P 865109-97-3P  
 865109-99-5P 865110-01-6P 865110-03-8P  
 865110-05-0P 865110-06-1P 865110-08-3P  
 865110-10-7P 865110-12-9P 865110-15-2P  
 865110-18-5P 865110-21-0P 865110-24-3P  
 865110-27-6P 865110-30-1P 865110-33-4P  
 865110-36-7P 865110-39-0P 865110-42-5P  
 865110-45-8P 865110-48-1P 865110-51-6P  
 865110-54-9P 865110-57-2P 865110-60-7P  
 865110-63-0P 865110-66-3P 865110-69-6P  
 865110-70-9P 865110-71-0P 865110-72-1P  
 865110-73-2P 865110-74-3P 865110-75-4P  
 865110-76-5P 865110-77-6P 865110-79-8P  
 865110-81-2P 865110-83-4P 865110-85-6P  
 865110-87-8P 865110-89-0P 865110-91-4P  
 865110-93-6P 865110-95-8P 865110-97-0P  
 865111-00-8P 865111-01-9P 865111-03-1P  
 865111-05-3P 865111-07-5P 865111-09-7P  
 865111-11-1P 865111-13-3P 865111-15-5P  
 865111-18-8P 865111-19-9P 865111-20-2P  
 865111-21-3P 865111-22-4P 865111-23-5P  
 865111-24-6P 865111-25-7P 865111-26-8P  
 865111-27-9P 865111-28-0P 865111-29-1P  
 865111-30-4P 865111-31-5P 865111-32-6P  
 865111-33-7P 865111-34-8P 865111-35-9P  
 865111-36-0P 865111-37-1P 865111-38-2P  
 865111-40-6P 865111-41-7P 865111-42-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of benzazepine derivs. as antagonists of histamine H1 and H3)

RN 865107-79-5 CAPLUS


CN Benzonitrile, 3-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-  
 1-piperazinyl]- (CA INDEX NAME)

10/596,503




RN 865107-80-8 CAPLUS

CN Benzonitrile, 4-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]- (CA INDEX NAME)




RN 865107-81-9 CAPLUS

CN Benzonitrile, 2-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]- (CA INDEX NAME)



RN 865107-82-0 CAPLUS


CN Methanone, (2-chlorophenyl)[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]- (CA INDEX NAME)



RN 865107-83-1 CAPLUS


CN Methanone, [4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

10/596,503




RN 865107-84-2 CAPLUS

CN Benzonitrile, 4-[[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]carbonyl]- (CA INDEX NAME)




RN 865107-85-3 CAPLUS

CN Methanone, 2,1,3-benzoxadiazol-5-yl[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]- (CA INDEX NAME)




RN 865107-86-4 CAPLUS

CN 1H-3-Benzazepine, 7-[4-[(2-chlorophenyl)sulfonyl]-1-piperazinyl]-3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 865107-87-5 CAPLUS

CN Methanone, [4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-4-morpholinyl- (CA INDEX NAME)




RN 865107-88-6 CAPLUS

CN 1-Piperazinecarboxamide, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-phenyl- (CA INDEX NAME)




RN 865107-89-7 CAPLUS

CN 1-Piperazinecarboxamide, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-(4-methoxyphenyl)- (CA INDEX NAME)



RN 865107-90-0 CAPLUS

CN 1-Piperazinecarboxamide, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-(3-methoxyphenyl)- (CA INDEX NAME)




RN 865107-91-1 CAPLUS

CN 1-Piperazinecarboxamide, N-(4-chlorophenyl)-4-(3-cyclobutyl-2,3,4,5-


10/596,503

tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 865107-92-2 CAPLUS

CN 1-Piperazinecarboxamide, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-(4-ethylphenyl)- (CA INDEX NAME)




RN 865107-93-3 CAPLUS

CN Ethanone, 1-[4-[[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]carbonyl]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 865107-94-4 CAPLUS

CN 1-Propanone, 1-[4-[[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 865107-95-5 CAPLUS

CN Methanone, [4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl][4-(3-pyridinyl)phenyl]- (CA INDEX NAME)




RN 865107-96-6 CAPLUS

CN Methanone, [4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](2-methyl-5-phenyl-4-thiazolyl)- (CA INDEX NAME)



RN 865107-97-7 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-7-[4-[(3,4-dichlorophenyl)sulfonyl]-1-piperazinyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)



10/596,503


RN 865107-98-8 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-(2-thienylsulfonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 865107-99-9 CAPLUS

CN Benzonitrile, 4-[[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]sulfonyl]- (CA INDEX NAME)



RN 865108-00-5 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-7-[4-[(3,4-dihydro-4-methyl-2H-1,4-benzoxazin-7-yl)sulfonyl]-1-piperazinyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 865108-01-6 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[(4-phenoxyphenyl)sulfonyl]-1-piperazinyl]- (CA INDEX NAME)






RN 865108-02-7 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-7-[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-1-piperazinyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 865108-03-8 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-7-[4-[(3,4-dimethoxyphenyl)sulfonyl]-1-piperazinyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 865108-04-9 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[(3-methoxyphenyl)sulfonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 865108-05-0 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[(4-methoxyphenyl)sulfonyl]-1-piperazinyl]- (CA INDEX NAME)


10/596,503

methoxyphenyl)sulfonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 865108-06-1 CAPLUS

CN Phenol, 2,6-dichloro-4-[[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]sulfonyl]- (CA INDEX NAME)



RN 865108-07-2 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-(8-quinolinylsulfonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 865108-08-3 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-(5-isoquinolinylsulfonyl)-1-piperazinyl]- (CA INDEX NAME)

10/596,503




RN 865108-09-4 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 865108-10-7 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-7-[4-[(2,4-dimethyl-5-thiazolyl)sulfonyl]-1-piperazinyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 865108-11-8 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 865108-12-9 CAPLUS


10/596,503

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-(3-thienylsulfonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 865108-13-0 CAPLUS

CN 1H-3-Benzazepine, 7-[4-(benzo[b]thien-3-ylsulfonyl)-1-piperazinyl]-3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 865108-14-1 CAPLUS

CN 1-Piperazinesulfonamide, 4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N,N-dimethyl- (CA INDEX NAME)



RN 865108-15-2 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-(thieno[2,3-b]pyridin-2-ylsulfonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 865108-16-3 CAPLUS


10/596,503

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[(2,2,2-trifluoroethyl)sulfonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 865108-17-4 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[(phenylmethyl)sulfonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 865108-18-5 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[(1-methylethyl)sulfonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 865108-19-6 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[(4-methylphenyl)sulfonyl]-1-piperazinyl]- (CA INDEX NAME)

10/596,503




RN 865108-20-9 CAPLUS

CN 1H-3-Benzazepine, 7-[4-[(4-chlorophenyl)sulfonyl]-1-piperazinyl]-3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 865108-21-0 CAPLUS

CN 1H-3-Benzazepine, 7-[4-[(2-chlorophenyl)sulfonyl]-1-piperazinyl]-3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 865108-22-1 CAPLUS


CN 1H-3-Benzazepine, 7-[4-[(3-chlorophenyl)sulfonyl]-1-piperazinyl]-3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 865108-23-2 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-7-[4-[(2,3-dichlorophenyl)sulfonyl]-1-

piperazinyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 865108-24-3 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-7-[4-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-piperazinyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 865108-25-4 CAPLUS

CN Acetamide, N-[4-[[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]sulfonyl]phenyl]- (CA INDEX NAME)



RN 865108-26-5 CAPLUS


CN Ethanone, 1-[4-[[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]sulfonyl]phenyl]- (CA INDEX NAME)



10/596,503


RN 865108-27-6 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[[2-(1-naphthalenyl)ethyl]sulfonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 865108-28-7 CAPLUS

CN Benzoic acid, 4-[[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]sulfonyl]- (CA INDEX NAME)



RN 865108-29-8 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[[4-(trifluoromethyl)phenyl]sulfonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 865108-30-1 CAPLUS


CN 1H-3-Benzazepine, 7-[4-([1,1'-biphenyl]-4-ylsulfonyl)-1-piperazinyl]-3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)






RN 865108-31-2 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[[5-(5-oxazolyl)-2-thienyl]sulfonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 865108-32-3 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-(2-naphthalenylsulfonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 865108-33-4 CAPLUS

CN 1-Naphthalenamine, 5-[[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]sulfonyl]-N,N-dimethyl- (CA INDEX NAME)




10/596,503

RN 865108-34-5 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[[ (1E)-2-phenylethenyl]sulfonyl]-1-piperazinyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 865108-35-6 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[[4-(1-methylethyl)phenyl]sulfonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 865108-36-7 CAPLUS


CN 1H-3-Benzazepine, 7-[4-[(3-chloro-2-methylphenyl)sulfonyl]-1-piperazinyl]-3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 865108-37-8 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-(1-naphthalenylsulfonyl)-1-piperazinyl]- (CA INDEX NAME)

10/596,503




RN 865108-38-9 CAPLUS

CN 1H-3-Benzazepine, 7-[4-[(5-chloro-2-thienyl)sulfonyl]-1-piperazinyl]-3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 865108-39-0 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-(methylsulfonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 865108-40-3 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[[3-(trifluoromethyl)phenyl]sulfonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 865108-41-4 CAPLUS


10/596,503

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[[5-(2-pyridinyl)-2-thienyl]sulfonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 865108-42-5 CAPLUS

CN 1H-3-Benzazepine, 7-[4-[(4-chlorobenzo[b]thien-2-yl)sulfonyl]-1-piperazinyl]-3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 865108-43-6 CAPLUS

CN 1H-3-Benzazepine, 7-[4-(2,1,3-benzoxadiazol-4-ylsulfonyl)-1-piperazinyl]-3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 865108-44-7 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-7-[4-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-1-piperazinyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 865108-45-8 CAPLUS

CN Acetamide, N-[5-[[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]sulfonyl]-4-methyl-2-thiazolyl]- (CA INDEX NAME)




RN 865108-46-9 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-7-[4-[(3,5-dichlorophenyl)sulfonyl]-1-piperazinyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 865108-47-0 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[[4-(trifluoromethoxy)phenyl]sulfonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 865108-48-1 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[[2-(trifluoromethyl)phenyl]sulfonyl]-1-piperazinyl]- (CA INDEX NAME)

10/596,503




RN 865108-49-2 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-7-[4-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-1-piperazinyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 865108-50-5 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[(6-phenoxy-3-pyridinyl)sulfonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 865108-51-6 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-(phenylsulfonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 865108-52-7 CAPLUS


10/596,503

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[(5-methyl-1-phenyl-1H-pyrazol-4-yl)sulfonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 865108-53-8 CAPLUS

CN 1H-3-Benzazepine, 7-[4-[[[4-chlorophenyl)methyl]sulfonyl]-1-piperazinyl]-3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 865108-54-9 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[[[4-(trifluoromethyl)phenyl)methyl]sulfonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 865108-55-0 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-7-[4-[(2,3-dihydro-5-benzofuranyl)sulfonyl]-1-piperazinyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)



10/596,503


RN 865108-56-1 CAPLUS

CN 2H-1-Benzopyran-2-one, 6-[[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]sulfonyl]- (CA INDEX NAME)




RN 865108-57-2 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[[5-(3-isoxazolyl)-2-thienyl]sulfonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 865108-58-3 CAPLUS

CN 1H-3-Benzazepine, 7-[4-(2,1,3-benzothiadiazol-5-ylsulfonyl)-1-piperazinyl]-3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 865108-59-4 CAPLUS

CN 1H-3-Benzazepine, 7-[4-[(5-chloro-2-methoxyphenyl)sulfonyl]-1-piperazinyl]-3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




10/596,503




RN 865108-60-7 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-7-[4-[(5-fluoro-2-methylphenyl)sulfonyl]-1-piperazinyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 865108-61-8 CAPLUS

CN 1H-3-Benzazepine, 7-[4-[(4-bromo-2-ethylphenyl)sulfonyl]-1-piperazinyl]-3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 865108-62-9 CAPLUS


CN 1H-3-Benzazepine, 7-[4-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-1-piperazinyl]-3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



10/596,503


RN 865108-63-0 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[[3-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]sulfonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 865108-64-1 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-7-[4-[(2,5-dimethyl-3-thienyl)sulfonyl]-1-piperazinyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 865108-65-2 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[(2-methoxy-4-methylphenyl)sulfonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 865108-66-3 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[[2-(3-methylphenyl)ethyl]sulfonyl]-1-piperazinyl]- (CA INDEX NAME)



10/596,503


RN 865108-67-4 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[[4-(methylsulfonyl)phenyl]sulfonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 865108-68-5 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[4-[(3,4,5-trimethylphenyl)sulfonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 865108-69-6 CAPLUS


CN Benzonitrile, 4-[[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]carbonyl]- (CA INDEX NAME)



RN 865108-70-9 CAPLUS


CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-4-pyridinyl- (CA INDEX NAME)

10/596,503



RN 865108-71-0 CAPLUS

CN Methanone, cyclopentyl[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]- (CA INDEX NAME)




RN 865108-73-2 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-1H-indol-3-yl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865108-72-1


CMF C28 H34 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 865108-75-4 CAPLUS


10/596,503

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](2-phenoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865108-74-3


CMF C32 H37 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865108-77-6 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865108-76-5

CMF C27 H35 N3 O2




CM 2

CRN 76-05-1

10/596,503


CMF C2 H F3 O2



RN 865108-79-8 CAPLUS  
CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](3,4-dichlorophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 865108-78-7  
CMF C26 H31 Cl2 N3 O



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 865108-81-2 CAPLUS  
CN 1-Propanone, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865108-80-1  
CMF C28 H37 N3 O


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865108-83-4 CAPLUS

CN Ethanone, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-[4-(1H-pyrazol-1-yl)phenyl]-, 2,2,2-trifluoroacetate (1:1)  
(CA INDEX NAME)

CM 1

CRN 865108-82-3

CMF C30 H37 N5 O




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/596,503




RN 865108-85-6 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](4-methyl-2-phenyl-3-furanyl)-, 2,2,2-trifluoroacetate (1:1)  
(CA INDEX NAME)

CM 1

CRN 865108-84-5


CMF C31 H37 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 865108-87-8 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl][4-(1,1-dimethylethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1)  
(CA INDEX NAME)


CM 1

CRN 865108-86-7

CMF C30 H41 N3 O




10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865108-89-0 CAPLUS

CN Piperazine, 4-(3-benzoylbenzoyl)-1-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 865108-88-9


CMF C33 H37 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/596,503


RN 865108-91-4 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](2,3-dihydro-2-benzofuranyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865108-90-3


CMF C28 H35 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865108-93-6 CAPLUS

CN Methanone, [1,1'-biphenyl]-4-yl[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865108-92-5


CMF C32 H37 N3 O



10/596,503

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 865108-95-8 CAPLUS  
CN Methanone, (5-chlorobenzo[b]thien-2-yl)[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 865108-94-7  
CMF C28 H32 Cl N3 O S



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 865108-97-0 CAPLUS  
CN Methanone, benzo[b]thien-2-yl[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865108-96-9  
CMF C28 H33 N3 O S


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865108-99-2 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](5-methyl-4-phenyl-2-thienyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865108-98-1

CMF C31 H37 N3 O S




CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/596,503



RN 865109-01-9 CAPLUS  
CN Methanone, 6-benzothiazolyl[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 865109-00-8  
CMF C27 H32 N4 O S



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 865109-03-1 CAPLUS  
CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-02-0  
CMF C26 H33 N3 O


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865109-05-3 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-naphthalenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-04-2

CMF C30 H35 N3 O




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/596,503




RN 865109-07-5 CAPLUS

CN Ethanone, 1-[4-[[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]carbonyl]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-06-4


CMF C28 H35 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 865109-09-7 CAPLUS


CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl][4-(1-methylethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-08-6

CMF C29 H39 N3 O


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865109-11-1 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl][4-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:1)  
(CA INDEX NAME)

CM 1

CRN 865109-10-0

CMF C27 H32 F3 N3 O




CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/596,503




RN 865109-13-3 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl][3-(trifluoromethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-12-2


CMF C27 H32 F3 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 865109-15-5 CAPLUS


CN Methanone, (2-bromo-5-methoxyphenyl)[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-14-4

CMF C27 H34 Br N3 O2


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865109-17-7 CAPLUS

CN Benzamide, N-[2-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-oxoethyl]-2-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-16-6

CMF C29 H38 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/596,503




RN 865109-19-9 CAPLUS

CN Ethanone, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-(1,3-dihydro-2H-isoindol-2-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-18-8


CMF C29 H38 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 865109-21-3 CAPLUS


CN Methanone, (3-chlorophenyl)[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-20-2

CMF C26 H32 Cl N3 O


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865109-23-5 CAPLUS

CN Methanone, (4-chlorophenyl)[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-22-4

CMF C26 H32 Cl N3 O




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/596,503




RN 865109-25-7 CAPLUS

CN Methanone, (2-chlorophenyl)[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-24-6


CMF C26 H32 Cl N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 865109-27-9 CAPLUS


CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](4-nitrophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-26-8

CMF C26 H32 N4 O3


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865109-29-1 CAPLUS

CN Acetamide, N-[4-[[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]carbonyl]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-28-0

CMF C28 H36 N4 O2




CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/596,503



RN 865109-31-5 CAPLUS  
CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl][4-(dimethylamino)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 865109-30-4  
CMF C28 H38 N4 O



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 865109-33-7 CAPLUS  
CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](3-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-32-6  
CMF C27 H35 N3 O2


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865109-35-9 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](4-propoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-34-8

CMF C29 H39 N3 O2




CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/596,503




RN 865109-37-1 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](4-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-36-0


CMF C27 H35 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 865109-39-3 CAPLUS


CN Methanone, (3-chloro-5-methoxyphenyl)[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-38-2

CMF C27 H34 Cl N3 O2


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865109-41-7 CAPLUS

CN Ethanone, 2-(1,3-benzodioxol-5-yl)-1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-40-6

CMF C28 H35 N3 O3




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/596,503




RN 865109-43-9 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl][5-(phenylmethyl)-2-furanyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-42-8


CMF C31 H37 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 865109-45-1 CAPLUS


CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-3-furanyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-44-0

CMF C24 H31 N3 O2


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865109-47-3 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl][3-(2-furanyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-46-2


CMF C30 H35 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/596,503


RN 865109-49-5 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]cyclopropyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-48-4


CMF C23 H33 N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865109-51-9 CAPLUS

CN 1-Butanone, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-3,3-dimethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-50-8


CMF C25 H39 N3 O



CM 2

10/596,503

CRN 76-05-1  
CMF C2 H F3 O2




RN 865109-53-1 CAPLUS  
CN 2-Propen-1-one, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-3-phenyl-, (2E)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 865109-52-0  
CMF C28 H35 N3 O

Double bond geometry as shown.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 865109-55-3 CAPLUS  
CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl][cis-4-(1,1-dimethylethoxy)cyclohexyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 865109-54-2

10/596,503

CMF C30 H47 N3 O2


Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865109-57-5 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl][1-(1-methylethyl)-4-piperidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-56-4

CMF C28 H44 N4 O




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/596,503




RN 865109-59-7 CAPLUS

CN 2-Piperidinone, 1-[2-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-oxoethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-58-6


CMF C26 H38 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 865109-61-1 CAPLUS

CN Ethanone, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-(1-methylethoxy)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 865109-60-0

CMF C24 H37 N3 O2




10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 865109-63-3 CAPLUS


CN Acetamide, N-[(1R)-2-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-oxo-1-phenylethyl]-, 2,2,2-trifluoroacetate (1:1)  
(CA INDEX NAME)

CM 1

CRN 865109-62-2

CMF C29 H38 N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/596,503




RN 865109-65-5 CAPLUS  
CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl][(2S)-1-(phenylmethyl)-2-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 865109-64-4  
CMF C31 H42 N4 O

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 865109-67-7 CAPLUS  
CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](2,3-dihydro-1H-inden-2-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-66-6  
CMF C29 H37 N3 O


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865109-69-9 CAPLUS

CN 1-Butanone, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-3-methyl-2-(phenylmethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-68-8

CMF C31 H43 N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/596,503




RN 865109-71-3 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](3,4-dihydro-1,1-dioxido-2H-1-benzothiopyran-6-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-70-2


CMF C29 H37 N3 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 865109-73-5 CAPLUS


CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl][4-(methylsulfonyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-72-4

CMF C27 H35 N3 O3 S


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865109-75-7 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](3,4-dihydro-2H-1-benzopyran-2-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-74-6

CMF C29 H37 N3 O2




CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/596,503



RN 865109-77-9 CAPLUS  
CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](2,3-dihydro-7-benzofuranyl)-, 2,2,2-trifluoroacetate (1:1)  
(CA INDEX NAME)


CM 1

CRN 865109-76-8  
CMF C28 H35 N3 O2



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 865109-79-1 CAPLUS  
CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl][4-(3-pyridinyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-78-0  
CMF C31 H36 N4 O


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865109-81-5 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-3-quinolinyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-80-4


CMF C29 H34 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/596,503


RN 865109-83-7 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]pyrazolo[1,5-a]pyridin-3-yl-, 2,2,2-trifluoroacetate (1:1)  
(CA INDEX NAME)

CM 1

CRN 865109-82-6


CMF C27 H33 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865109-85-9 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-5-isoquinolinyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-84-8

CMF C29 H34 N4 O






10/596,503

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865109-87-1 CAPLUS

CN Methanone, benzo[b]thien-3-yl[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-86-0


CMF C28 H33 N3 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 865109-89-3 CAPLUS


CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl][5-(2-pyridinyl)-2-thienyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-88-2

CMF C29 H34 N4 O S


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865109-91-7 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](1,3-dimethyl-1H-thieno[2,3-c]pyrazol-5-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-90-6


CMF C27 H35 N5 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/596,503


RN 865109-93-9 CAPLUS

CN Ethanone, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-(4-methyl-2-phenyl-5-thiazolyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-92-8


CMF C31 H38 N4 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865109-95-1 CAPLUS

CN Methanone, 2-benzothiazolyl[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-94-0


CMF C27 H32 N4 O S



CM 2

10/596,503


CRN 76-05-1  
CMF C2 H F3 O2



RN 865109-97-3 CAPLUS  
CN Ethanone, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-imidazo[2,1-b]thiazol-5-yl-, 2,2,2-trifluoroacetate (1:1)  
(CA INDEX NAME)


CM 1

CRN 865109-96-2  
CMF C26 H33 N5 O S



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 865109-99-5 CAPLUS  
CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl][4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865109-98-4  
CMF C31 H39 N5 O


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 865110-01-6 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](2,4-dimethyl-5-oxazolyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865110-00-5

CMF C25 H34 N4 O2




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/596,503




RN 865110-03-8 CAPLUS

CN Ethanone, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-(4-pyridinyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865110-02-7


CMF C26 H34 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 865110-05-0 CAPLUS


CN 2(1H)-Quinolinone, 6-[2-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-oxoethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865110-04-9

CMF C30 H36 N4 O2


10/596,503



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 865110-06-1 CAPLUS

CN Ethanone, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-phenyl- (CA INDEX NAME)



RN 865110-08-3 CAPLUS

CN Piperazine, 1-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-[[4-(1-methylethyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 865110-10-7 CAPLUS

CN Ethanone, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-


10/596,503

piperazinyll-2-(2-naphthalenyl)- (CA INDEX NAME)




RN 865110-12-9 CAPLUS

CN Ethanone, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyll-2,2-diphenyl- (CA INDEX NAME)




RN 865110-15-2 CAPLUS

CN Ethanone, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyll-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 865110-18-5 CAPLUS

CN Ethanone, 2-(4-chlorophenyl)-1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyll- (CA INDEX NAME)






10/596,503


RN 865110-21-0 CAPLUS

CN Piperazine, 1-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-  
[(4-methoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 865110-24-3 CAPLUS

CN Ethanone, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-  
piperazinyl]-2-(3-thienyl)- (CA INDEX NAME)




RN 865110-27-6 CAPLUS

CN Ethanone, 2-benzo[b]thien-4-yl-1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-  
benzazepin-7-yl)-1-piperazinyl]- (CA INDEX NAME)




RN 865110-30-1 CAPLUS

CN Methanone, [4-[[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-  
1-piperazinyl]carbonyl]phenyl]-1-piperidinyl- (CA INDEX NAME)




RN 865110-33-4 CAPLUS

CN Methanone, 4-benzofuranyl[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]- (CA INDEX NAME)




RN 865110-36-7 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-furanyl- (CA INDEX NAME)



RN 865110-39-0 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](2,5-dimethyl-3-furanyl)- (CA INDEX NAME)




10/596,503

RN 865110-42-5 CAPLUS


CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl][(2S)-1-methyl-2-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 865110-45-8 CAPLUS

CN Ethanone, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-phenoxy- (CA INDEX NAME)




RN 865110-48-1 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-thienyl- (CA INDEX NAME)




RN 865110-51-6 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-3-thienyl- (CA INDEX NAME)




RN 865110-54-9 CAPLUS

CN Ethanone, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-(2,4-dimethyl-5-thiazolyl)- (CA INDEX NAME)




RN 865110-57-2 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-5-thiazolyl- (CA INDEX NAME)




RN 865110-60-7 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-(5-phenyl-4-thiazolyl)- (CA INDEX NAME)




RN 865110-63-0 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-4-thiazolyl- (CA INDEX NAME)




RN 865110-66-3 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]pyrazolo[1,5-a]pyrimidin-3-yl- (CA INDEX NAME)




RN 865110-69-6 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](1-methyl-1H-indazol-3-yl)- (CA INDEX NAME)




RN 865110-70-9 CAPLUS

CN Methanone, 2,1,3-benzoxadiazol-5-yl[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]- (CA INDEX NAME)




RN 865110-71-0 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 865110-72-1 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](1-methyl-3-phenyl-1H-pyrazol-4-yl)- (CA INDEX NAME)




RN 865110-73-2 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl](3,5-dimethyl-4-isoxazolyl)- (CA INDEX NAME)



RN 865110-74-3 CAPLUS

CN Ethanone, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-(4-methyl-1,2,5-oxadiazol-3-yl)- (CA INDEX NAME)




RN 865110-75-4 CAPLUS

CN Ethanone, 1-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-2-(4-methyl-1,2,5-oxadiazol-3-yl)- (CA INDEX NAME)


10/596,503

piperazinyll-2-(1-methyl-1H-imidazol-2-yl)- (CA INDEX NAME)




RN 865110-76-5 CAPLUS

CN Methanone, [4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyll(1-methyl-1H-imidazol-2-yl)- (CA INDEX NAME)




RN 865110-77-6 CAPLUS

CN 1-Piperazinecarboxamide, 4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-2-thienyl- (CA INDEX NAME)



RN 865110-79-8 CAPLUS

CN Benzonitrile, 4-[[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]carbonyl]- (CA INDEX NAME)




10/596,503

RN 865110-81-2 CAPLUS


CN Benzonitrile, 4-[[ (5R)-3-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 865110-83-4 CAPLUS

CN Benzonitrile, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 865110-85-6 CAPLUS

CN Benzamide, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-methyl- (CA INDEX NAME)




RN 865110-87-8 CAPLUS

CN 2-Propanone, 1-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)phenyl]- (CA INDEX NAME)




10/596,503




RN 865110-89-0 CAPLUS

CN Benzeneacetamide, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-methyl- (CA INDEX NAME)




RN 865110-91-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-methyl- (CA INDEX NAME)



RN 865110-93-6 CAPLUS


CN Methanone, [6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-pyridinyl]-4-morpholinyl- (CA INDEX NAME)



RN 865110-95-8 CAPLUS


CN Benzamide, 3-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-methyl- (CA INDEX NAME)

10/596,503




RN 865110-97-0 CAPLUS

CN 2-Furancarbonitrile, 5-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 865111-00-8 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(2-thiazolyl)- (CA INDEX NAME)




RN 865111-01-9 CAPLUS

CN Benzamide, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N,3-dimethyl- (CA INDEX NAME)




RN 865111-03-1 CAPLUS

CN Benzamide, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-fluoro-N-methyl- (CA INDEX NAME)




RN 865111-05-3 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)phenoxy]-N-methyl- (CA INDEX NAME)




RN 865111-07-5 CAPLUS

CN Methanone, [4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 865111-09-7 CAPLUS

CN 2-Pyridinecarbonitrile, 5-[[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]carbonyl]- (CA INDEX NAME)




RN 865111-11-1 CAPLUS

CN Benzonitrile, 3-[[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]carbonyl]- (CA INDEX NAME)




RN 865111-13-3 CAPLUS

CN Methanone, [4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-2-pyrazinyl- (CA INDEX NAME)




RN 865111-15-5 CAPLUS

CN Methanone, [4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-(4-fluorophenyl)- (CA INDEX NAME)




RN 865111-18-8 CAPLUS

CN Methanone, 2,1,3-benzoxadiazol-5-yl[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]- (CA INDEX NAME)




RN 865111-19-9 CAPLUS

CN Methanone, [4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-[6-(trifluoromethyl)-3-pyridinyl]- (CA INDEX NAME)




RN 865111-20-2 CAPLUS

CN Methanone, [4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-4-thiazolyl- (CA INDEX NAME)




RN 865111-21-3 CAPLUS

CN Methanone, [4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-(2-fluorophenyl)- (CA INDEX NAME)



RN 865111-22-4 CAPLUS


CN Methanone, [4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-2-pyridinyl- (CA INDEX NAME)



RN 865111-23-5 CAPLUS


CN Methanone, [4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-3-pyridinyl- (CA INDEX NAME)

10/596,503




RN 865111-24-6 CAPLUS

CN Methanone, [4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]pyrazolo[1,5-a]pyrimidin-3-yl- (CA INDEX NAME)



RN 865111-25-7 CAPLUS


CN Methanone, [4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-6-quinoxaliny- (CA INDEX NAME)



RN 865111-26-8 CAPLUS


CN Methanone, [4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-5-quinoxaliny- (CA INDEX NAME)

10/596,503




RN 865111-27-9 CAPLUS

CN Methanone, [4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidiny] (6-methyl-3-pyridinyl)- (CA INDEX NAME)




RN 865111-28-0 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[1-(6-methyl-3-pyridinyl)-4-piperidiny] (CA INDEX NAME)




RN 865111-29-1 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[1-[6-(trifluoromethyl)-3-pyridinyl]-4-piperidiny] (CA INDEX NAME)




RN 865111-30-4 CAPLUS

CN Benzonitrile, 3-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]- (CA INDEX NAME)




RN 865111-31-5 CAPLUS

CN Benzonitrile, 4-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]- (CA INDEX NAME)




RN 865111-32-6 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-N-methyl- (CA INDEX NAME)



RN 865111-33-7 CAPLUS

CN 2-Pyrazinecarboxamide, 5-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-N-methyl- (CA INDEX NAME)




RN 865111-34-8 CAPLUS

CN 2-Pyridinecarboxamide, 5-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-N-methyl- (CA INDEX NAME)




10/596,503




RN 865111-35-9 CAPLUS

CN 2-Pyrrolidinone, 1-[6-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-3-pyridinyl]- (CA INDEX NAME)




RN 865111-36-0 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(4-pyridinyl)- (CA INDEX NAME)



RN 865111-37-1 CAPLUS


CN 3-Pyridinecarboxamide, 6-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-N-methyl- (CA INDEX NAME)



RN 865111-38-2 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[1-[6-(trifluoromethyl)-3-pyridinyl]-4-piperidinyl]- (CA INDEX NAME)

10/596,503




RN 865111-40-6 CAPLUS

CN 2-Pyrazinecarboxamide, 5-[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]-N-methyl- (CA INDEX NAME)




RN 865111-41-7 CAPLUS

CN Benzonitrile, 4-[[4-[2,3,4,5-tetrahydro-3-(2-methylcyclopentyl)-1H-3-benzazepin-7-yl]-1-piperidinyl]carbonyl]- (CA INDEX NAME)



RN 865111-42-8 CAPLUS

CN Benzonitrile, 4-[[4-(3-cyclohexyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]carbonyl]- (CA INDEX NAME)



IT 865111-43-9P 865111-44-0P 865111-45-1P  
865111-46-2P 865111-47-3P 865111-48-4P  
865111-49-5P 865111-50-8P 865111-51-9P  
865111-52-0P


10/596,503

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzazepine derivs. as antagonists of histamine H1 and H3)


RN 865111-43-9 CAPLUS

CN Benzonitrile, 4-[[4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]carbonyl]- (CA INDEX NAME)




RN 865111-44-0 CAPLUS

CN 1-Piperidinecarboxamide, N-(4-cyanophenyl)-4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 865111-45-1 CAPLUS

CN 1-Piperidinecarbothioamide, N-(4-cyanophenyl)-4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 865111-46-2 CAPLUS

CN Methanone, [4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperazinyl]-1-naphthalenyl- (CA INDEX NAME)




RN 865111-47-3 CAPLUS

CN 1-Piperazinecarboxamide, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-(4-fluorophenyl)- (CA INDEX NAME)




RN 865111-48-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-(4-methoxyphenyl)- (CA INDEX NAME)



RN 865111-49-5 CAPLUS


CN 1-Piperidinecarboxamide, N-(3-cyanophenyl)-4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



10/596,503


RN 865111-50-8 CAPLUS

CN Methanone, [4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl](1,3-dihydro-2H-isoindol-2-yl)- (CA INDEX NAME)




RN 865111-51-9 CAPLUS

CN 1-Piperidinecarboxamide, N-(6-cyano-3-pyridinyl)-4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 865111-52-0 CAPLUS

CN Benzamide, 4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-3-pyridinyl- (CA INDEX NAME)



IT 856905-08-3P 856905-09-4P 865111-75-7P

865111-76-8P 865111-79-1P 865111-80-4P

865111-87-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzazepine derivs. as antagonists of histamine H1 and H3)

RN 856905-08-3 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-nitro- (CA INDEX NAME)

10/596,503




RN 856905-09-4 CAPLUS

CN 1H-3-Benzazepin-7-amine, 3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 865111-75-7 CAPLUS


CN Carbamic acid, (3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 865111-76-8 CAPLUS

CN 2-Oxazolidinone, 3-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-[[[(methanesulfonyl)oxy]methyl]-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865111-79-1 CAPLUS


CN Methanesulfonic acid, 1,1,1-trifluoro-, 3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl ester (CA INDEX NAME)

10/596,503




RN 865111-80-4 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (CA INDEX NAME)



RN 865111-87-1 CAPLUS

CN 2-Pyrazinecarbonyl chloride, 5-[4-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-piperidinyl]- (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:823672 CAPLUS

DOCUMENT NUMBER: 143:229851

TITLE: Preparation of imidazolyl thiourea derivatives as inhibitors of glutaminy cyclase

INVENTOR(S): Schilling, Stephan; Buchholz, Mirko; Niestroj, Andre Johannes; Demuth, Hans-Ulrich; Heiser, Ulrich

PATENT ASSIGNEE(S): Probiodrug A.-G., Germany

SOURCE: PCT Int. Appl., 122 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005075436	A2	20050818	WO 2005-EP1153	20050204
WO 2005075436	A3	20051208		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040224875	A1	20041111	US 2004-838993	20040505
US 7371871	B2	20080513		
AU 2005210004	A1	20050818	AU 2005-210004	20050204
CA 2554809	A1	20050818	CA 2005-2554809	20050204
EP 1713780	A2	20061025	EP 2005-707206	20050204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1918131	A	20070221	CN 2005-80004289	20050204
BR 2005007485	A	20070710	BR 2005-7485	20050204
JP 2007520520	T	20070726	JP 2006-551809	20050204
IN 2006KN02139	A	20070518	IN 2006-KN2139	20060728
MX 2006PA08868	A	20061030	MX 2006-PA8868	20060804
PRIORITY APPLN. INFO.:			US 2004-542133P	P 20040205
			US 2004-838993	A 20040505
			US 2004-634364P	P 20041208
			US 2003-468014P	P 20030505
			WO 2005-EP1153	W 20050204
OTHER SOURCE(S):			CASREACT 143:229851; MARPAT 143:229851	
GI				





- AB Title compds. I [A = alkyl, alkenyl, alkynyl, etc.; B = substituted thiourea, urea, amide, etc.] and their pharmaceutical acceptable salts, are prepared and disclosed as glutaminyl cyclase inhibitors. Thus, e.g., II was prepared by coupling of 1H-imidazole-1-propanamine with the corresponding isothiocyanate. The inhibitory activity of I towards DP IV was evaluated using chromogenic enzyme assay and it was revealed that selected compds. of the invention displayed  $K_i$  values in the range of 0.06 up to 204.5  $\mu\text{M}$ . I as glutaminyl cyclase inhibitors should prove useful in the treatment of Alzheimer's disease, depression and dementia. Pharmaceutical compns. comprising I are disclosed.
- IT 720690-73-3, GSK 189254A  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (claimed co-drugs; preparation of imidazolyl thiourea derivs. as inhibitors of glutaminyl cyclase)
- RN 720690-73-3 CAPLUS
- CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



L17 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:570815 CAPLUS

DOCUMENT NUMBER: 143:97282

TITLE: Tetrahydrobenzazepines as dopamine D3 receptor modulators, their preparation, pharmaceutical compositions and use in the treatment of CNS disorders and renal function disorders

INVENTOR(S): Braje, Wilfried; Haupt, Andreas; Lubisch, Wilfried; Grandel, Roland; Drescher, Karla; Geneste, Herve; Unger, Liliane; Sauer, Daryl R.

PATENT ASSIGNEE(S): Abbott G.m.b.H. &amp; Co. K.-G., Germany

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058328	A1	20050630	WO 2004-EP14428	20041217
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20050137186	A1	20050623	US 2003-740092	20031218
CA 2550053	A1	20050630	CA 2004-2550053	20041217
EP 1694334	A1	20060830	EP 2004-820441	20041217
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS			
JP 2007514696	T	20070607	JP 2006-544363	20041217
MX 2006PA06858	A	20060904	MX 2006-PA6858	20060616
PRIORITY APPLN. INFO.:			US 2003-530806P	P 20031218
			US 2003-740092	A 20031218
			WO 2004-EP14428	W 20041217

OTHER SOURCE(S): CASREACT 143:97282; MARPAT 143:97282

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to tetrahydrobenzazepines I, which are selective modulators of dopamine D3 receptors. In compds. I, A is a bond or CH<sub>2</sub>; B is a bond or (un)substituted N; Y is a bond, CH<sub>2</sub>, or (un)substituted N, where A, B, and Y are not simultaneously a bond; Ar is (un)substituted aryl or (un)substituted 5- or 6-membered heteroaryl containing 1-4 heteroatoms independently selected from O, N, and S; R<sub>1</sub> is (un)substituted C<sub>1</sub>-8 alkyl, H, C<sub>1</sub>-8 haloalkyl, C<sub>2</sub>-8 alkenyl, etc.; and R<sub>2</sub> is H, halo, C<sub>1</sub>-4 alkyl, C<sub>1</sub>-4

alkoxy, OH, nitro, cyano, etc.; including the corresponding N-oxides of I and all physiol. tolerated acid addition salts. The invention also relates to pharmaceutical compns. that comprise at least one tetrahydrobenzazepine I, the physiol. tolerated acid addition salt of I, the N-oxide of compound I and/or the physiol. tolerated acid addition salts of the N-oxides of I, together with physiol. acceptable carriers and/or excipients, as well as to the use of compound I for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 receptor agonists. The compds. of the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders.


1,2-Benzenediacetic acid was esterified, followed by reduction, mesylation and heterocyclization with n-propylamine to give benzazepine II. II underwent carboxylation with oxalyl chloride and hydride reduction to give alc. III. Chlorination of III followed by substitution with (4-isopropyl)thiophenol, oxidation to the sulfone, and salt formation with hydrochloric acid resulted in the formation of compound IV. The compds. of the invention have a high affinity for dopamine D3 receptors with many of the compds. exhibiting  $K_i$  values lower than 5 nM, and many of them having a 100-fold selectivity for D3 receptors over D2L receptors [ $K_i(D2L)/K_i(D3)$ ]. Compound IV has a  $K_i$  value for binding to dopamine D3 receptors of 1 nM and 446-fold selectivity for D3 over D2L.

IT 854680-36-7P, N-(3-Cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)benzenesulfonamide hydrochloride  
854680-40-3P, N-(3-Cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)benzenesulfonamide  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of tetrahydrobenzazepines as dopamine D3 receptor modulators)

RN 854680-36-7 CAPLUS


CN Benzenesulfonamide, N-(3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854680-40-3 CAPLUS


CN Benzenesulfonamide, N-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)




IT 690206-52-1P, 7-Nitro-3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepine 777035-67-3P, 3-Cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-amine 854678-36-7P, 3-Cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepine 854678-43-6P, 3-Cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepine 854678-82-3P, 7-Nitro-3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepine 854679-17-7P, 3-Cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-amine  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of tetrahydrobenzazepines as dopamine D3 receptor modulators)  
 RN 690206-52-1 CAPLUS  
 CN 1H-3-Benzazepine, 3-cyclopropyl-2,3,4,5-tetrahydro-7-nitro- (CA INDEX NAME)



RN 777035-67-3 CAPLUS  
 CN 1H-3-Benzazepin-7-amine, 3-cyclopropyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 854678-36-7 CAPLUS  
 CN 1H-3-Benzazepine, 3-cyclopropyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 854678-43-6 CAPLUS  
 CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)

10/596,503




RN 854678-82-3 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-nitro- (CA INDEX NAME)



RN 854679-17-7 CAPLUS

CN 1H-3-Benzazepin-7-amine, 3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:564644 CAPLUS

DOCUMENT NUMBER: 143:97280

TITLE: Preparation of benzazepine derivatives as histamine H3 antagonists

INVENTOR(S): Bailey, Nicholas; Bamford, Mark James; Dean, David  
Kenneth; Pickering, Paula Louise; Wilson, David  
Matthew; Witherington, Jason

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058837	A1	20050630	WO 2004-EP14380	20041215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1713778	A1	20061025	EP 2004-803989	20041215
EP 1713778	B1	20080116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
JP 2007514690	T	20070607	JP 2006-544347	20041215
AT 384050	T	20080215	AT 2004-803989	20041215
ES 2299896	T3	20080601	ES 2004-803989	20041215
US 20070060566	A1	20070315	US 2006-596503	20060615
PRIORITY APPLN. INFO.:			GB 2003-29214	A 20031217
			WO 2004-EP14380	W 20041215
OTHER SOURCE(S):			CASREACT 143:97280; MARPAT 143:97280	
GI				




- AB Title compds. I [R1 = (un)substituted cycloalkyl; R2 = H, alkyl, cycloalkyl, etc.; X = a bond, CO, CO2, etc.; R3 = halo, alkoxy, CN, etc.; R4 = H, aryl, heteroaryl, etc.; n = 0-2] and their pharmaceutically acceptable salts, are prepared and disclosed as antagonists of histamine H3. Thus, e.g., II was prepared by reductive amination of N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-morpholinecarboxamide (preparation given) with cyclobutanone. The activity of I was evaluated in the histamine H3 functional antagonist assay and it was revealed that numerous compds. of the invention possessed antagonism > 6.5 pKb. I as histamine H3 antagonists should prove useful in the treatment of neurol. disorders. Pharmaceutical compns. comprising I are disclosed.
- IT 856901-13-8P 856901-14-9P 856901-16-1P  
856901-35-4P 856901-52-5P 856902-29-9P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of benzazepine derivs. as histamine H3 antagonists)
- RN 856901-13-8 CAPLUS
- CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(2-pyridinyl)- (CA INDEX NAME)




- RN 856901-14-9 CAPLUS
- CN 2-Pyrazinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4,5-dihydro-5-oxo- (CA INDEX NAME)

10/596,503




RN 856901-16-1 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-iodo-  
(CA INDEX NAME)




RN 856901-35-4 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(5-  
pyrimidinyl)- (CA INDEX NAME)



RN 856901-52-5 CAPLUS


CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(2-  
pyrimidinyl)- (CA INDEX NAME)



RN 856902-29-9 CAPLUS

CN 3-Pyridinecarboxamide, 5-bromo-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-  
benzazepin-7-yl)- (CA INDEX NAME)





IT	856901-06-9P	856901-07-0P	856901-08-1P
	856901-09-2P	856901-10-5P	856901-11-6P
	856901-12-7P	856901-15-0P	856901-17-2P
	856901-19-4P	856901-20-7P	856901-21-8P
	856901-22-9P	856901-23-0P	856901-24-1P
	856901-25-2P	856901-26-3P	856901-27-4P
	856901-28-5P	856901-29-6P	856901-30-9P
	856901-31-0P	856901-32-1P	856901-33-2P
	856901-34-3P	856901-36-5P	856901-37-6P
	856901-38-7P	856901-39-8P	856901-40-1P
	856901-41-2P	856901-42-3P	856901-43-4P
	856901-44-5P	856901-45-6P	856901-46-7P
	856901-47-8P	856901-48-9P	856901-49-0P
	856901-50-3P	856901-51-4P	856901-53-6P
	856901-54-7P	856901-55-8P	856901-56-9P
	856901-57-0P	856901-58-1P	856901-59-2P
	856901-60-5P	856901-61-6P	856901-62-7P
	856901-63-8P	856901-64-9P	856901-65-0P
	856901-66-1P	856901-67-2P	856901-68-3P
	856901-69-4P	856901-70-7P	856901-71-8P
	856901-72-9P	856901-73-0P	856901-74-1P
	856901-75-2P	856901-76-3P	856901-77-4P
	856901-78-5P	856901-79-6P	856901-80-9P
	856901-81-0P	856901-82-1P	856901-83-2P
	856901-84-3P	856901-85-4P	856901-86-5P
	856901-87-6P	856901-88-7P	856901-89-8P
	856901-90-1P	856901-91-2P	856901-92-3P
	856901-93-4P	856901-94-5P	856901-95-6P
	856901-96-7P	856901-97-8P	856901-98-9P
	856901-99-0P	856902-00-6P	856902-01-7P
	856902-02-8P	856902-03-9P	856902-04-0P
	856902-05-1P	856902-06-2P	856902-07-3P
	856902-08-4P	856902-09-5P	856902-10-8P
	856902-11-9P	856902-12-0P	856902-13-1P
	856902-14-2P	856902-15-3P	856902-16-4P
	856902-17-5P	856902-18-6P	856902-19-7P
	856902-20-0P	856902-21-1P	856902-22-2P
	856902-23-3P	856902-24-4P	856902-25-5P
	856902-26-6P	856902-27-7P	856902-28-8P
	856902-30-2P	856902-31-3P	856902-32-4P
	856902-33-5P	856902-34-6P	856902-35-7P
	856902-36-8P	856902-37-9P	856902-38-0P
	856902-39-1P	856902-40-4P	856902-41-5P
	856902-42-6P	856902-43-7P	856902-44-8P
	856902-45-9P	856902-46-0P	856902-47-1P
	856902-48-2P	856902-49-3P	856902-50-6P
	856902-51-7P	856902-52-8P	856902-53-9P


856902-54-0P 856902-55-1P 856902-56-2P  
 856902-57-3P 856902-58-4P 856902-59-5P  
 856902-60-8P 856902-61-9P 856902-62-0P  
 856902-63-1P 856902-64-2P 856902-65-3P  
 856902-66-4P 856902-67-5P 856902-68-6P  
 856902-69-7P 856902-70-0P 856902-71-1P  
 856902-72-2P 856902-73-3P 856902-74-4P  
 856902-75-5P 856902-76-6P 856902-77-7P  
 856902-78-8P 856902-79-9P 856902-80-2P  
 856902-81-3P 856902-82-4P 856902-84-6P  
 856902-86-8P 856902-88-0P 856902-90-4P  
 856902-92-6P 856902-94-8P 856902-96-0P  
 856902-98-2P 856903-00-9P 856903-02-1P  
 856903-04-3P 856903-06-5P 856903-09-8P  
 856903-12-3P 856903-15-6P 856903-18-9P  
 856903-21-4P 856903-24-7P 856903-27-0P  
 856903-30-5P 856903-33-8P 856903-36-1P  
 856903-39-4P 856903-43-0P 856903-46-3P  
 856903-49-6P 856903-52-1P 856903-56-5P  
 856903-59-8P 856903-62-3P 856903-66-7P  
 856903-70-3P 856903-73-6P 856903-78-1P  
 856903-82-7P 856903-84-9P 856903-86-1P  
 856903-88-3P 856903-90-7P 856903-92-9P  
 856903-94-1P 856903-96-3P 856903-98-5P  
 856904-00-2P 856904-02-4P 856904-04-6P  
 856904-06-8P 856904-08-0P 856904-10-4P  
 856904-12-6P 856904-14-8P 856904-16-0P  
 856904-18-2P 856904-20-6P 856904-22-8P  
 856904-24-0P 856904-26-2P 856904-28-4P  
 856904-30-8P 856904-32-0P 856904-34-2P  
 856904-36-4P 856904-38-6P 856904-40-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of benzazepine derivs. as histamine H3 antagonists)

RN 856901-06-9 CAPLUS


CN 4-Morpholinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-  
 benzazepin-7-yl)- (CA INDEX NAME)



RN 856901-07-0 CAPLUS


CN Benzamide, 4-cyano-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-  
 yl)- (CA INDEX NAME)

10/596,503




RN 856901-08-1 CAPLUS

CN 2H-Pyran-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)tetrahydro- (CA INDEX NAME)




RN 856901-09-2 CAPLUS

CN Acetamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856901-10-5 CAPLUS


CN Cyclopropanecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856901-11-6 CAPLUS


CN Methanesulfonamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/596,503




RN 856901-12-7 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)amino]-N-methyl- (CA INDEX NAME)




RN 856901-15-0 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(4-oxazolyl)- (CA INDEX NAME)



RN 856901-17-2 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(3-pyridinyl)- (CA INDEX NAME)



RN 856901-19-4 CAPLUS


CN 1H-Pyrazole-4-carboxamide, N-(3-cyclohexyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-methyl-1-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856901-18-3

CMF C27 H32 N4 O


10/596,503



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 856901-20-7 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(5-oxazolyl)- (CA INDEX NAME)




RN 856901-21-8 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(3,5-dimethyl-4-isoxazolyl)- (CA INDEX NAME)




RN 856901-22-9 CAPLUS


CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-imidazo[1,2-a]pyridin-2-yl- (CA INDEX NAME)




RN 856901-23-0 CAPLUS  
 CN 1,2,5-Oxadiazole-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856901-24-1 CAPLUS  
 CN 3-Isioxazolecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856901-25-2 CAPLUS  
 CN Cyclohexanecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856901-26-3 CAPLUS  
 CN Cyclopentaneacetamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/596,503




RN 856901-27-4 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-methyl- (CA INDEX NAME)




RN 856901-28-5 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-fluoro- (CA INDEX NAME)



RN 856901-29-6 CAPLUS


CN 2-Thiophenecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-methyl- (CA INDEX NAME)



RN 856901-30-9 CAPLUS


CN Bicyclo[4.2.0]octa-1,3,5-triene-7-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/596,503




RN 856901-31-0 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-methyl- (CA INDEX NAME)




RN 856901-32-1 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-methyl- (CA INDEX NAME)



RN 856901-33-2 CAPLUS

CN Butanamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-ethyl- (CA INDEX NAME)




RN 856901-34-3 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-fluoro- (CA INDEX NAME)




10/596,503




RN 856901-36-5 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(methylsulfonyl)- (CA INDEX NAME)




RN 856901-37-6 CAPLUS

CN 6-Quinoxalinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856901-38-7 CAPLUS


CN 1,6-Naphthyridine-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-methyl- (CA INDEX NAME)



RN 856901-39-8 CAPLUS


CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(1H-tetrazol-1-yl)- (CA INDEX NAME)

10/596,503




RN 856901-40-1 CAPLUS

CN Benzamide, 4-(6-cyano-3-pyridinyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856901-41-2 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-(trifluoromethyl)- (CA INDEX NAME)




RN 856901-42-3 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-methyl- (CA INDEX NAME)




RN 856901-43-4 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-6-methyl- (CA INDEX NAME)




RN 856901-44-5 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856901-45-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 856901-46-7 CAPLUS


CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-6-(1H-pyrazol-1-yl)- (CA INDEX NAME)



RN 856901-47-8 CAPLUS


CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-6-(trifluoromethyl)- (CA INDEX NAME)

10/596,503




RN 856901-48-9 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(5-methyl-1H-tetrazol-1-yl)- (CA INDEX NAME)




RN 856901-49-0 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(3-pyridinyl)- (CA INDEX NAME)



RN 856901-50-3 CAPLUS


CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-6-(4-morpholinyl)- (CA INDEX NAME)



RN 856901-51-4 CAPLUS


CN 1H-Benzotriazole-6-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/596,503




RN 856901-53-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-methyl- (CA INDEX NAME)




RN 856901-54-7 CAPLUS

CN 5-Quinoxalinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856901-55-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856901-56-9 CAPLUS


CN 5-Pyrimidinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/596,503




RN 856901-57-0 CAPLUS

CN 4-Pyridazinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856901-58-1 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(5-pyrimidinyl)- (CA INDEX NAME)




RN 856901-59-2 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(2-pyrazinyl)- (CA INDEX NAME)




RN 856901-60-5 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(4-pyrimidinyl)- (CA INDEX NAME)




RN 856901-61-6 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(4-pyrimidinyl)- (CA INDEX NAME)




RN 856901-62-7 CAPLUS

CN 3-Isioxazolecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-methyl- (CA INDEX NAME)




RN 856901-63-8 CAPLUS

CN 3-Pyridinecarboxamide, 6-cyano-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856901-64-9 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(1H-imidazol-1-yl)- (CA INDEX NAME)




RN 856901-65-0 CAPLUS

CN 2-Pyrazinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856901-66-1 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-methyl- (CA INDEX NAME)



RN 856901-67-2 CAPLUS

CN 2-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-methyl- (CA INDEX NAME)




RN 856901-68-3 CAPLUS

CN 3-Thiophenecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




10/596,503




RN 856901-69-4 CAPLUS

CN 3-Furancarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856901-70-7 CAPLUS

CN 3-Furancarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-methyl- (CA INDEX NAME)



RN 856901-71-8 CAPLUS


CN 3-Furancarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2,5-dimethyl- (CA INDEX NAME)



RN 856901-72-9 CAPLUS


CN 3-Furancarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-methyl-5-phenyl- (CA INDEX NAME)

10/596,503




RN 856901-73-0 CAPLUS

CN 1,2,3-Thiadiazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-methyl-2-phenyl- (CA INDEX NAME)




RN 856901-74-1 CAPLUS

CN 4-Thiazolecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-methyl-2-phenyl- (CA INDEX NAME)




RN 856901-75-2 CAPLUS

CN 2H-1,2,3-Triazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-methyl-2-phenyl- (CA INDEX NAME)




RN 856901-76-3 CAPLUS

CN 1H-Imidazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-methyl- (CA INDEX NAME)




RN 856901-77-4 CAPLUS

CN 1H-1,2,3-Triazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-methyl- (CA INDEX NAME)




RN 856901-78-5 CAPLUS

CN 4-Oxazolecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-phenyl- (CA INDEX NAME)




RN 856901-79-6 CAPLUS

CN 2H-1,2,3-Triazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-phenyl- (CA INDEX NAME)




RN 856901-80-9 CAPLUS

CN 4-Thiazolecarboxamide, 2-(2,1,3-benzoxadiazol-5-yl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856901-81-0 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,5-dimethyl- (CA INDEX NAME)




RN 856901-82-1 CAPLUS

CN 1,2,5-Thiadiazole-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856901-83-2 CAPLUS


CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-6-(1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)



RN 856901-84-3 CAPLUS


CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-6-phenyl- (CA INDEX NAME)

10/596,503




RN 856901-85-4 CAPLUS

CN [3,3'-Bipyridine]-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856901-86-5 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 856901-87-6 CAPLUS

CN 4-Isioxazolecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-methyl- (CA INDEX NAME)




RN 856901-88-7 CAPLUS

CN 2-Pyrazinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-methyl- (CA INDEX NAME)




RN 856901-89-8 CAPLUS

CN 2-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 856901-90-1 CAPLUS

CN 5-Thiazolecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2,4-dimethyl- (CA INDEX NAME)




RN 856901-91-2 CAPLUS

CN 4-Thiazolecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-phenyl- (CA INDEX NAME)




RN 856901-92-3 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(1,1-dioxido-2-isothiazolidinyl)- (CA INDEX NAME)




RN 856901-93-4 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(2-oxo-1-pyrrolidinyl)- (CA INDEX NAME)




RN 856901-94-5 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(2-oxo-1-imidazolidinyl)- (CA INDEX NAME)



RN 856901-95-6 CAPLUS


CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(1H-pyrazol-1-yl)- (CA INDEX NAME)



RN 856901-96-7 CAPLUS


CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)

10/596,503




RN 856901-97-8 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(2-oxo-1-pyrrolidinyl)- (CA INDEX NAME)




RN 856901-98-9 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(1,1-dioxido-2-isothiazolidinyl)- (CA INDEX NAME)



RN 856901-99-0 CAPLUS


CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(2-oxo-1-imidazolidinyl)- (CA INDEX NAME)



RN 856902-00-6 CAPLUS


CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(1H-pyrazol-1-yl)- (CA INDEX NAME)






RN 856902-01-7 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)




RN 856902-02-8 CAPLUS

CN 2,5-Pyrazinedicarboxamide, N2-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N5-methyl- (CA INDEX NAME)




RN 856902-03-9 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(4-pyridinyl)- (CA INDEX NAME)




RN 856902-04-0 CAPLUS

CN 3-Pyridinecarboxamide, 6-(4-cyanophenyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856902-05-1 CAPLUS

CN [2,3'-Bipyridine]-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856902-06-2 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-6-(5-pyrimidinyl)- (CA INDEX NAME)



RN 856902-07-3 CAPLUS


CN 3-Pyridinecarboxamide, 6-(3-cyanophenyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856902-08-4 CAPLUS


CN 2-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(4-fluorophenyl)- (CA INDEX NAME)

10/596,503




RN 856902-09-5 CAPLUS

CN 2-Pyridinecarboxamide, 5-(4-cyanophenyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856902-10-8 CAPLUS

CN [3,3'-Bipyridine]-6-carboxamide, 6'-cyano-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856902-11-9 CAPLUS


CN 2-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(5-pyrimidinyl)- (CA INDEX NAME)



RN 856902-12-0 CAPLUS


CN 2-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(2-pyrazinyl)- (CA INDEX NAME)

10/596,503




RN 856902-13-1 CAPLUS

CN [2,3'-Bipyridine]-6'-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856902-14-2 CAPLUS

CN 2-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(1H-pyrazol-1-yl)- (CA INDEX NAME)



RN 856902-15-3 CAPLUS


CN 2-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(1H-imidazol-1-yl)- (CA INDEX NAME)



RN 856902-16-4 CAPLUS


CN 2-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)

10/596,503




RN 856902-17-5 CAPLUS

CN 2-Pyrazinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(4-morpholinyl)- (CA INDEX NAME)




RN 856902-18-6 CAPLUS

CN 2-Pyrazinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 856902-19-7 CAPLUS


CN 2-Pyrazinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(1-piperidinyl)- (CA INDEX NAME)



RN 856902-20-0 CAPLUS


CN 2-Pyrazinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)

10/596,503




RN 856902-21-1 CAPLUS

CN 2-Pyrazinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-phenoxy- (CA INDEX NAME)




RN 856902-22-2 CAPLUS

CN 2-Pyrazinecarboxamide, 5-(4-cyanophenyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856902-23-3 CAPLUS


CN 2-Pyrazinecarboxamide, 5-(3-cyanophenyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856902-24-4 CAPLUS


CN 4-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/596,503




RN 856902-25-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856902-26-6 CAPLUS

CN Benzamide, 3-cyano-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856902-27-7 CAPLUS


CN 1H-Pyrazole-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,3-dimethyl- (CA INDEX NAME)



RN 856902-28-8 CAPLUS


CN 4-Isoxazolecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3,5-dimethyl- (CA INDEX NAME)

10/596,503




RN 856902-30-2 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(1H-imidazol-1-yl)- (CA INDEX NAME)




RN 856902-31-3 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-methyl-4-(2-pyrazinyl)- (CA INDEX NAME)



RN 856902-32-4 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-methyl-4-(2-pyridinyl)- (CA INDEX NAME)




RN 856902-33-5 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-methyl-4-(5-pyrimidinyl)- (CA INDEX NAME)




10/596,503




RN 856902-34-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N,6-dimethyl- (CA INDEX NAME)




RN 856902-35-7 CAPLUS

CN Urea, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N'-phenyl- (CA INDEX NAME)




RN 856902-36-8 CAPLUS

CN Urea, N-(4-cyanophenyl)-N'-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856902-37-9 CAPLUS


CN Urea, N-1,3-benzodioxol-5-yl-N'-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



10/596,503


RN 856902-38-0 CAPLUS

CN Urea, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N'-cyclohexyl- (CA INDEX NAME)




RN 856902-39-1 CAPLUS

CN Urea, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N'-(1-methylethyl)- (CA INDEX NAME)




RN 856902-40-4 CAPLUS

CN Urea, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N'-(2-methoxyphenyl)- (CA INDEX NAME)



RN 856902-41-5 CAPLUS


CN Urea, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N'-8-quinolinyl- (CA INDEX NAME)



RN 856902-42-6 CAPLUS


CN Urea, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N'-(2,2-difluoro-1,3-benzodioxol-4-yl)- (CA INDEX NAME)

10/596,503




RN 856902-43-7 CAPLUS

CN Urea, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N'-3-pyridinyl- (CA INDEX NAME)




RN 856902-44-8 CAPLUS

CN Urea, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N'-4-pyridinyl- (CA INDEX NAME)



RN 856902-45-9 CAPLUS


CN Urea, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N'-(2-ethoxyphenyl)- (CA INDEX NAME)



RN 856902-46-0 CAPLUS


CN Urea, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N'-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

10/596,503




RN 856902-47-1 CAPLUS

CN Urea, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N'-(2-methoxy-6-methylphenyl)- (CA INDEX NAME)




RN 856902-48-2 CAPLUS

CN Urea, N-(3-cyanophenyl)-N'-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856902-49-3 CAPLUS

CN Urea, N-(5-chloro-2-methoxyphenyl)-N'-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856902-50-6 CAPLUS

CN 1-Piperazinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(2-pyrazinyl)- (CA INDEX NAME)




RN 856902-51-7 CAPLUS

CN 1-Piperazinecarboxamide, 4-(5-cyano-2-pyridinyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856902-52-8 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2,3-dihydro- (CA INDEX NAME)




RN 856902-53-9 CAPLUS

CN 1H-Indole-1-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2,3-dihydro- (CA INDEX NAME)




RN 856902-54-0 CAPLUS

CN 1(2H)-Quinolinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3,4-dihydro- (CA INDEX NAME)




RN 856902-55-1 CAPLUS

CN 2H-Isoindole-2-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,3-dihydro- (CA INDEX NAME)




RN 856902-56-2 CAPLUS

CN 2(1H)-Isoquinolinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3,4-dihydro- (CA INDEX NAME)



RN 856902-57-3 CAPLUS


CN 1-Piperidinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-phenyl- (CA INDEX NAME)



RN 856902-58-4 CAPLUS


CN 1-Piperidinecarboxamide, 4-(4-cyanophenoxy)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/596,503




RN 856902-59-5 CAPLUS

CN 1-Piperidinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(2-pyridinyl)- (CA INDEX NAME)




RN 856902-60-8 CAPLUS

CN 1-Piperidinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(4-pyridinyl)- (CA INDEX NAME)



RN 856902-61-9 CAPLUS


CN 1-Piperazinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-phenyl- (CA INDEX NAME)



RN 856902-62-0 CAPLUS


CN 1-Piperazinecarboxamide, 4-(4-cyanophenyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/596,503




RN 856902-63-1 CAPLUS

CN 1-Piperidinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856902-64-2 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856902-65-3 CAPLUS

CN 1H-Indole-1-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-fluoro-2,3-dihydro- (CA INDEX NAME)




RN 856902-66-4 CAPLUS

CN 1-Piperidinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(4-fluorophenyl)- (CA INDEX NAME)




10/596,503




RN 856902-67-5 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-phenyl- (CA INDEX NAME)




RN 856902-68-6 CAPLUS

CN 1H-Indole-1-carboxamide, 5-cyano-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2,3-dihydro- (CA INDEX NAME)




RN 856902-69-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-cyanophenyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856902-70-0 CAPLUS

CN 3H-3-Benzazepine-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,2,4,5-tetrahydro- (CA INDEX NAME)




RN 856902-71-1 CAPLUS

CN 1-Piperazinecarboxamide, 4-(3-cyano-2-pyrazinyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856902-72-2 CAPLUS

CN 4H-1,4-Benzoxazine-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2,3-dihydro- (CA INDEX NAME)



RN 856902-73-3 CAPLUS


CN 1-Piperidinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(4-methoxyphenoxy)- (CA INDEX NAME)



RN 856902-74-4 CAPLUS


CN 1-Piperidinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(4-fluorophenoxy)- (CA INDEX NAME)

10/596,503




RN 856902-75-5 CAPLUS

CN 1-Piperidinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-phenoxy- (CA INDEX NAME)




RN 856902-76-6 CAPLUS

CN 1-Piperidinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(2-pyridinyloxy)- (CA INDEX NAME)




RN 856902-77-7 CAPLUS

CN 1-Piperidinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(3-pyridinyloxy)- (CA INDEX NAME)




RN 856902-78-8 CAPLUS


CN 4H-1,4-Benzoxazine-4-carboxamide, 7-cyano-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2,3-dihydro- (CA INDEX NAME)




RN 856902-79-9 CAPLUS  
 CN Urea, N-(4-cyanophenyl)-N'-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-N-methyl- (CA INDEX NAME)



RN 856902-80-2 CAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridine-1-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2,3-dihydro- (CA INDEX NAME)




RN 856902-81-3 CAPLUS  
 CN 2H-Isoindole-2-carboxamide, 5-cyano-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,3-dihydro- (CA INDEX NAME)



RN 856902-82-4 CAPLUS  
 CN 2-Pyrrolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)amino]-3-pyridinyl]- (CA INDEX NAME)

10/596,503




RN 856902-84-6 CAPLUS

CN 1,3-Benzodioxole-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856902-83-5


CMF C22 H24 N2 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856902-86-8 CAPLUS

CN 1H-Benzimidazole-6-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856902-85-7

CMF C23 H26 N4 O




10/596,503

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856902-88-0 CAPLUS

CN 2-Quinoxalinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856902-87-9


CMF C23 H24 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856902-90-4 CAPLUS


CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-methoxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856902-89-1

CMF C22 H26 N2 O2


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856902-92-6 CAPLUS

CN Pyrazolo[1,5-a]pyridine-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856902-91-5


CMF C22 H24 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856902-94-8 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-(4-methoxyphenyl)-5-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

10/596,503


CM 1

CRN 856902-93-7  
CMF C26 H30 N4 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 856902-96-0 CAPLUS  
CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-methoxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856902-95-9  
CMF C22 H26 N2 O2




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



10/596,503




RN 856902-98-2 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856902-97-1


CMF C23 H24 N2 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856903-00-9 CAPLUS

CN 2-Naphthalenecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856902-99-3

CMF C25 H26 N2 O




10/596,503

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856903-02-1 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(trifluoromethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-01-0


CMF C25 H24 Cl F3 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856903-04-3 CAPLUS


CN 1H-Benzotriazole-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-03-2

10/596,503


CMF C24 H29 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856903-06-5 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-(1-methylethyl)-2-(trifluoromethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-05-4

CMF C26 H29 F3 N4 O




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/596,503




RN 856903-09-8 CAPLUS

CN 2,1-Benzisoxazole-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856903-08-7


CMF C22 H23 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856903-12-3 CAPLUS


CN 1H-Pyrazole-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-methyl-3-propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-11-2

CMF C22 H30 N4 O


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856903-15-6 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-14-5

CMF C26 H30 N4 O2




CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/596,503



RN 856903-18-9 CAPLUS  
CN 2H-1,2,3-Triazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 856903-17-8  
CMF C18 H23 N5 O



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 856903-21-4 CAPLUS  
CN Benzo[b]thiophene-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 856903-20-3  
CMF C23 H24 N2 O S



10/596,503

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 856903-24-7 CAPLUS  
CN 1H-1,2,3-Triazole-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 856903-23-6  
CMF C23 H25 N5 O



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 856903-27-0 CAPLUS  
CN 1H-Pyrazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(4-methoxyphenyl)-5-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 856903-26-9  
CMF C26 H30 N4 O2

10/596,503



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 856903-30-5 CAPLUS  
CN 1H-Pyrazole-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-methyl-1-phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-29-2  
CMF C25 H28 N4 O




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



10/596,503




RN 856903-33-8 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(3-methoxyphenyl)-1-phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-32-7


CMF C31 H32 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856903-36-1 CAPLUS


CN 1H-Pyrazole-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(1,1-dimethylethyl)-1-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-35-0

CMF C23 H32 N4 O


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856903-39-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-2-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5,7-dimethyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-38-3

CMF C23 H27 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/596,503




RN 856903-43-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-methyl-1-phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-42-9


CMF C25 H28 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856903-46-3 CAPLUS


CN 1H-Benzotriazole-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-45-2

CMF C22 H25 N5 O


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856903-49-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-methyl-1-[(4-methylphenyl)methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-48-5


CMF C27 H32 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/596,503


RN 856903-52-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-ethyl-3-(2-thienyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-51-0


CMF C24 H28 N4 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856903-56-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-ethyl-5-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-55-4


CMF C21 H28 N4 O



10/596,503

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 856903-59-8 CAPLUS  
CN 1H-1,2,3-Triazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(4-fluorophenoxy)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 856903-58-7  
CMF C23 H24 F N5 O2



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 856903-62-3 CAPLUS  
CN 1H-1,2,3-Triazole-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-ethyl-1-phenyl-, 2,2,2-trifluoroacetate (1:?) (CA


10/596,503

INDEX NAME)

CM 1

CRN 856903-61-2


CMF C25 H29 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856903-66-7 CAPLUS

CN 1H-1,2,3-Triazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-ethyl-1-phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-65-6

CMF C25 H29 N5 O




CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/596,503



RN 856903-70-3 CAPLUS  
CN 2H-1,2,3-Triazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-methyl-5-phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 856903-69-0  
CMF C24 H27 N5 O



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 856903-73-6 CAPLUS  
CN 1H-1,2,3-Triazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-methyl-1-phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 857284-97-0  
CMF C24 H27 N5 O




10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856903-78-1 CAPLUS

CN 2H-1-Benzopyran-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856903-77-0


CMF C24 H26 N2 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856903-82-7 CAPLUS


10/596,503

CN 2H-Indazole-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4,5,6,7-tetrahydro-2-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-81-6


CMF C23 H30 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856903-84-9 CAPLUS

CN 1H-1,2,3-Triazole-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(3,4-dimethoxyphenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-83-8


CMF C25 H29 N5 O3



10/596,503

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 856903-86-1 CAPLUS  
CN 1H-1,2,3-Triazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-(2,2,2-trifluoroethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 856903-85-0  
CMF C19 H22 F3 N5 O



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 856903-88-3 CAPLUS  
CN 1H-Pyrazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3,5-dimethyl-1-phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-87-2  
CMF C26 H30 N4 O


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856903-90-7 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-89-4


CMF C19 H24 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/596,503


RN 856903-92-9 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-methyl-3-(trifluoromethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-91-8


CMF C20 H23 F3 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856903-94-1 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 1-(2-chlorophenyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-93-0


CMF C27 H31 Cl N4 O



CM 2

10/596,503


CRN 76-05-1  
CMF C2 H F3 O2



RN 856903-96-3 CAPLUS  
CN 1H-Pyrazole-4-carboxamide, 1-(4-cyanophenyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(trifluoromethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 856903-95-2  
CMF C26 H24 F3 N5 O



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 856903-98-5 CAPLUS  
CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-propyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856903-97-4  
CMF C27 H31 Cl N4 O


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856904-00-2 CAPLUS

CN 2H-1-Benzopyran-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3,4-dihydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856903-99-6


CMF C24 H28 N2 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856904-02-4 CAPLUS


10/596,503

CN 1H-Pyrazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,3,5-trimethyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856904-01-3


CMF C21 H28 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856904-04-6 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-(4-fluorophenyl)-3,5-dimethyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856904-03-5

CMF C26 H29 F N4 O




CM 2



10/596,503


CRN 76-05-1  
CMF C2 H F3 O2



RN 856904-06-8 CAPLUS  
CN 5-Benzofurancarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 856904-05-7  
CMF C23 H24 N2 O2



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 856904-08-0 CAPLUS  
CN 1H-Indole-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-07-9  
CMF C23 H25 N3 O


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856904-10-4 CAPLUS

CN 1H-Indazole-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856904-09-1


CMF C22 H24 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856904-12-6 CAPLUS

CN 2-Benzofurancarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2,3-dihydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


10/596,503

NAME)

CM 1

CRN 856904-11-5


CMF C23 H26 N2 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856904-14-8 CAPLUS

CN 1H-Indole-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-13-7

CMF C23 H25 N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/596,503



RN 856904-16-0 CAPLUS  
CN 5-Benzofurancarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2,3-dihydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 856904-15-9  
CMF C23 H26 N2 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 856904-18-2 CAPLUS  
CN 6-Benzothiazolecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856904-17-1  
CMF C22 H23 N3 O S




10/596,503

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856904-20-6 CAPLUS

CN 1H-Indole-6-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-19-3


CMF C23 H25 N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856904-22-8 CAPLUS


CN 1,2,3-Benzothiadiazole-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856904-21-7

CMF C21 H22 N4 O S


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856904-24-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2,7-dimethyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856904-23-9


CMF C23 H27 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856904-26-2 CAPLUS


10/596,503

CN 1-Naphthalenecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-25-1


CMF C25 H26 N2 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856904-28-4 CAPLUS

CN 3-Quinolinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856904-27-3

CMF C24 H25 N3 O




CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/596,503



RN 856904-30-8 CAPLUS  
CN 2-Quinolinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-methoxy-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 856904-29-5  
CMF C25 H27 N3 O2



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 856904-32-0 CAPLUS  
CN 2,1,3-Benzothiadiazole-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856904-31-9  
CMF C21 H22 N4 O S




10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856904-34-2 CAPLUS

CN 1,4-Benzodioxin-2-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2,3-dihydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-33-1


CMF C23 H26 N2 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856904-36-4 CAPLUS


10/596,503

CN 2-Naphthalenecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-6-methoxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-35-3


CMF C26 H28 N2 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856904-38-6 CAPLUS

CN 3-Isoquinolinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856904-37-5

CMF C24 H25 N3 O




CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/596,503



RN 856904-40-0 CAPLUS  
CN 1H-Indole-2-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 856904-39-7  
CMF C24 H27 N3 O



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



IT 856904-42-2P 856904-44-4P 856904-46-6P  
856904-48-8P 856904-50-2P 856904-51-3P  
856904-53-5P 856904-55-7P 856904-57-9P  
856904-59-1P 856904-61-5P 856904-63-7P  
856904-65-9P 856904-67-1P 856904-69-3P  
856904-71-7P 856904-73-9P 856904-75-1P  
856904-77-3P 856904-79-5P 856904-81-9P  
856904-83-1P 856904-85-3P 856904-87-5P  
856904-89-7P 856904-91-1P 856904-92-2P  
856904-93-3P 856904-94-4P 856904-95-5P  
856904-96-6P 856904-97-7P 856904-98-8P  
856904-99-9P 856905-00-5P 856905-01-6P  
856905-02-7P 856905-03-8P 856905-05-0P  
856905-07-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

10/596,503

(preparation of benzazepine derivs. as histamine H3 antagonists)


RN 856904-42-2 CAPLUS

CN 2-Benzofurancarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-41-1


CMF C23 H24 N2 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856904-44-4 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-methoxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-43-3

CMF C22 H26 N2 O2




CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/596,503



RN 856904-46-6 CAPLUS  
CN 1H-Pyrazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,3-diphenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 856904-45-5  
CMF C30 H30 N4 O



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 856904-48-8 CAPLUS  
CN 2-Quinolinecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856904-47-7  
CMF C24 H25 N3 O


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856904-50-2 CAPLUS

CN 1,4-Benzodioxin-6-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2,3-dihydro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-49-9


CMF C23 H26 N2 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856904-51-3 CAPLUS


10/596,503

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(methylsulfonyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856901-36-5


CMF C22 H26 N2 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856904-53-5 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-phenoxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-52-4

CMF C27 H28 N2 O2




CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/596,503



RN 856904-55-7 CAPLUS  
CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-phenoxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 856904-54-6  
CMF C27 H28 N2 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 856904-57-9 CAPLUS  
CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-phenoxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-56-8  
CMF C27 H28 N2 O2






10/596,503

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856904-59-1 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-(trifluoromethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-58-0


CMF C22 H23 F3 N2 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856904-61-5 CAPLUS


CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(trifluoromethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-60-4

CMF C22 H23 F3 N2 O


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856904-63-7 CAPLUS

CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-62-6


CMF C22 H23 F3 N2 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856904-65-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

10/596,503


CM 1

CRN 856904-64-8  
CMF C27 H28 N2 O



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 856904-67-1 CAPLUS  
CN 2-Propenamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-phenyl-, (2E)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-66-0  
CMF C23 H26 N2 O


Double bond geometry as shown.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2


10/596,503



RN 856904-69-3 CAPLUS  
CN 1H-Benzimidazole-2-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 856904-68-2  
CMF C22 H24 N4 O



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 856904-71-7 CAPLUS  
CN 2-Propenamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(2-methoxyphenyl)-, (2E)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-70-6  
CMF C24 H28 N2 O2

Double bond geometry as shown.


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856904-73-9 CAPLUS


CN 2-Propenamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(3-methoxyphenyl)-, (2E)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-72-8

CMF C24 H28 N2 O2

Double bond geometry as shown.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/596,503



RN 856904-75-1 CAPLUS


CN 2-Propenamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(4-methoxyphenyl)-, (2E)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-74-0

CMF C24 H28 N2 O2


Double bond geometry as shown.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856904-77-3 CAPLUS

CN 2-Propenamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(2-fluorophenyl)-, (2E)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 856904-76-2

CMF C23 H25 F N2 O

Double bond geometry as shown.


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856904-79-5 CAPLUS


CN 2-Propenamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(3-fluorophenyl)-, (2E)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-78-4

CMF C23 H25 F N2 O

Double bond geometry as shown.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/596,503



RN 856904-81-9 CAPLUS


CN 2-Propenamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(4-fluorophenyl)-, (2E)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-80-8

CMF C23 H25 F N2 O


Double bond geometry as shown.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856904-83-1 CAPLUS

CN Benzamide, 3,5-dichloro-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 856904-82-0

CMF C21 H22 Cl2 N2 O




10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856904-85-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-ethyl-3-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856904-84-2

CMF C21 H28 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/596,503




RN 856904-87-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-(2-furanyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856904-86-4


CMF C22 H24 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 856904-89-7 CAPLUS


CN 1H-Pyrazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-(3,4-dichlorophenyl)-3,5-dimethyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856904-88-6

CMF C26 H28 Cl2 N4 O


10/596,503



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856904-91-1 CAPLUS

CN 2-Naphthalenecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-methoxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 856904-90-0


CMF C26 H28 N2 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



10/596,503

RN 856904-92-2 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-(4-fluorophenyl)-5-phenyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 856904-93-3 CAPLUS


CN 1H-Pyrazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,5-diphenyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 856904-94-4 CAPLUS

CN 2H-1,2,3-Triazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-methyl-2-(4-methylphenyl)-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 856904-95-5 CAPLUS

10/596,503


CN 1H-Pyrazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-phenyl-5-(1H-pyrrol-1-yl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 856904-96-6 CAPLUS


CN 1H-Pyrazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-(4-fluorophenyl)-5-methyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 856904-97-7 CAPLUS


CN 1H-Pyrazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-phenyl-5-(trifluoromethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


10/596,503

RN 856904-98-8 CAPLUS  
CN 1H-Pyrazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-phenyl-5-propyl-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 856904-99-9 CAPLUS  
CN 1H-Pyrazole-4-carboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-methyl-1-(2-methylphenyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 856905-00-5 CAPLUS  
CN 2-Naphthalenecarboxamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-methoxy-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 856905-01-6 CAPLUS

10/596,503


CN 1H-Pyrazole-4-carboxamide, 1-(4-chlorophenyl)-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-methyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 856905-02-7 CAPLUS


CN 2H-1,2,3-Triazole-4-carboxamide, 5-methyl-2-phenyl-N-[2,3,4,5-tetrahydro-3-(3-methylcyclopentyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 856905-03-8 CAPLUS

CN 2H-1,2,3-Triazole-4-carboxamide, N-(3-cyclohexyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-methyl-2-phenyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 856905-05-0 CAPLUS

CN 2H-1,2,3-Triazole-4-carboxamide, 5-methyl-2-phenyl-N-[2,3,4,5-tetrahydro-3-


10/596,503

(2-methylcyclopentyl)-1H-3-benzazepin-7-yl]-, 2,2,2-trifluoroacetate (1:?)  
(CA INDEX NAME)

CM 1

CRN 856905-04-9


CMF C26 H31 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 856905-07-2 CAPLUS

CN 2H-1,2,3-Triazole-4-carboxamide, N-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-5-methyl-2-phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 856905-06-1

CMF C25 H29 N5 O




CM 2


CRN 76-05-1

CMF C2 H F3 O2







IT 856905-08-3P 856905-09-4P 856905-15-2P  
 856905-16-3P 856905-17-4P 856905-18-5P  
 856905-19-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of benzazepine derivs. as histamine H3 antagonists)  
 RN 856905-08-3 CAPLUS  
 CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-nitro- (CA INDEX  
 NAME)



RN 856905-09-4 CAPLUS  
 CN 1H-3-Benzazepin-7-amine, 3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 856905-15-2 CAPLUS  
 CN Benzamide, N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-iodo-  
 (CA INDEX NAME)




RN 856905-16-3 CAPLUS  
 CN 2-Pyrazinecarboxylic acid, 5-[[ (3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-  
 benzazepin-7-yl)amino]carbonyl]- (CA INDEX NAME)

10/596,503




RN 856905-17-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 856905-18-5 CAPLUS

CN 2-Pyridinecarboxamide, 5-bromo-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 856905-19-6 CAPLUS

CN 2-Pyrazinecarboxamide, 5-chloro-N-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:547557 CAPLUS

DOCUMENT NUMBER: 143:53543

TITLE: The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist, and therapeutic use thereof

INVENTOR(S): Cremers, Thomas Ivo Franciscus Hubert; Hogg Willigers, Sandra

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005056056	A2	20050623	WO 2004-DK862	20041214
WO 2005056056	A3	20060202		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004296531	A1	20050623	AU 2004-296531	20041214
CA 2549574	A1	20050623	CA 2004-2549574	20041214
EP 1696896	A2	20060906	EP 2004-803015	20041214
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
BR 2004015899	A	20070109	BR 2004-15899	20041214
CN 1893935	A	20070110	CN 2004-80037386	20041214
JP 2007513896	T	20070531	JP 2006-543369	20041214
MX 2006PA05127	A	20060711	MX 2006-PA5127	20060508
NO 2006003267	A	20060713	NO 2006-3267	20060713
US 20070066601	A1	20070322	US 2006-596348	20060714
PRIORITY APPLN. INFO.:			DK 2003-1854	A 20031215
			US 2003-529491P	P 20031215
			WO 2004-DK862	W 20041214

AB The invention discloses the use of a serotonin reuptake inhibitor and a H3 receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitor.

IT 720690-73-3, GSK 189254A

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


10/596,503

(Biological study); USES (Uses)

(combination of serotonin reuptake inhibitor and H3 receptor  
antagonist, inverse agonist or partial agonist, and therapeutic use)

RN 720690-73-3 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-  
7-yl)oxy]-N-methyl- (CA INDEX NAME)



L17 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:547254 CAPLUS

DOCUMENT NUMBER: 143:59852

TITLE: A preparation of tetrahydrobenzazepine derivatives,  
useful as dopamine D3 receptor ligandsINVENTOR(S): Braje, Wilfried M.; Haupt, Andreas; Lubisch, Wilfried;  
Grandel, Roland; Drescher, Karla; Geneste, Herve;  
Unger, Liliane; Sauer, Daryl R.

PATENT ASSIGNEE(S): Abbott G.m.b.H. &amp; Co. Kg., Germany

SOURCE: U.S. Pat. Appl. Publ., 23 pp.

CODEN: USXXCO



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050137186	A1	20050623	US 2003-740092	20031218
CA 2550053	A1	20050630	CA 2004-2550053	20041217
WO 2005058328	A1	20050630	WO 2004-EP14428	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1694334	A1	20060830	EP 2004-820441	20041217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
JP 2007514696	T	20070607	JP 2006-544363	20041217
MX 2006PA06858	A	20060904	MX 2006-PA6858	20060616
PRIORITY APPLN. INFO.:			US 2003-530806P	P 20031218
			US 2003-740092	A 20031218
			WO 2004-EP14428	W 20041217
OTHER SOURCE(S):			CASREACT 143:59852; MARPAT 143:59852	
GI				



AB The invention relates to a preparation of tetrahydrobenzazepines of formula I [wherein: A is a single bond or CH<sub>2</sub>; B is a single bond, NH, or N(alkyl), etc.; Y is a single bond, CH<sub>2</sub>, NH, or n(alkyl), etc.; Ar is (hetero)aryl; R<sub>1</sub> is H, (halo)alkyl, or alk(en/yn)yl, etc.; R<sub>2</sub> is H, halogen, (halo)alkyl, or alkoxy, etc.], useful as dopamine D<sub>3</sub> receptor ligands. The invention also relates to a pharmaceutical composition that comprises at least one tetrahydrobenzazepine compound of the formula I, phys. tolerated acid addition salt of I, N-oxide of compound of the formula I and/or phys. tolerated acid addition salts of the N-oxides of I, and further to the use of a compound according to the present invention for treating disorders that respond beneficially to dopamine D<sub>3</sub> receptor antagonists or dopamine D<sub>3</sub> agonists. The compds. according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders. For instance, tetrahydrobenzazepine derivative II [K<sub>i</sub>(D<sub>3</sub>) = 4.1 nM] was prepared via amidation of 4-chlorobenzenesulfonyl chloride by 3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-amine.


IT 854680-36-7P 854680-40-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrahydrobenzazepine derivs. useful as selective dopamine D<sub>3</sub> receptor ligands)


RN 854680-36-7 CAPLUS

CN Benzenesulfonamide, N-(3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 854680-40-3 CAPLUS  
 CN Benzenesulfonamide, N-(3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)



IT 690206-52-1P 777035-67-3P 854678-36-7P  
 854678-43-6P 854678-82-3P 854679-17-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of tetrahydrobenzazepine derivs. useful as selective dopamine D3 receptor ligands)  
 RN 690206-52-1 CAPLUS  
 CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-nitro- (CA INDEX NAME)




RN 777035-67-3 CAPLUS  
 CN 1H-3-Benzazepine, 3-cyclopropyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 854678-36-7 CAPLUS  
 CN 1H-3-Benzazepine, 3-cyclopropyl-2,3,4,5-tetrahydro- (CA INDEX NAME)

10/596,503




RN 854678-43-6 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopropyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 854678-82-3 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-nitro- (CA INDEX NAME)



RN 854679-17-7 CAPLUS

CN 1H-3-Benzazepin-7-amine, 3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)







L17 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:140980 CAPLUS  
 DOCUMENT NUMBER: 142:204628  
 TITLE: Radiolabeled imaging agents  
 INVENTOR(S): Bender, Dirk; Aburel, Pompiliu Sorin  
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
 SOURCE: PCT Int. Appl., 22 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014479	A2	20050217	WO 2004-EP8830	20040805
WO 2005014479	A3	20060601		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2536659	A1	20050217	CA 2004-2536659	20040805
EP 1663868	A2	20060607	EP 2004-763865	20040805
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007501764	T	20070201	JP 2006-522964	20040805
US 20070059230	A1	20070315	US 2006-567524	20061012
PRIORITY APPLN. INFO.:			GB 2003-18728	A 20030808
			GB 2004-16141	A 20040719
			WO 2004-EP8830	W 20040805
AB	A novel process for preparing radiolabeled compds. by incorporation of radioactive carbonyl groups into precursors, which are then used to make the radiolabeled compds. These radiolabeled compds. have a number of uses including in vivo imaging techniques such as positron emission tomog. [11C]-Borane carbonyl is used as the labeled agent.			
IT	836611-32-6P RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) ([11C]-borane carbonyl in preparation of radiopharmaceuticals)			
RN	836611-32-6 CAPLUS			
CN	3-Pyridinecarboxamide-11C, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (9CI) (CA INDEX NAME)			

10/596,503



IT 720691-59-8  
RL: RCT (Reactant); RACT (Reactant or reagent)  
([ $^{11}\text{C}$ ]-borane carbonyl in preparation of radiopharmaceuticals)  
RN 720691-59-8 CAPLUS  
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(5-iodo-2-pyridinyl)oxy]- (CA INDEX NAME)



L17 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:565187 CAPLUS

DOCUMENT NUMBER: 141:123486

TITLE: Preparation of naphthalene derivatives as selective estrogen receptor modulators

INVENTOR(S): Hamaoka, Shinichi; Kitazawa, Noritaka; Nara, Kazumasa; Sasaki, Atsushi; Kamada, Atsushi; Okabe, Tadashi

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 982 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058682	A1	20040715	WO 2003-JP16808	20031225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2512000	A1	20040715	CA 2003-2512000	20031225
AU 2003292625	A1	20040722	AU 2003-292625	20031225
AU 2003292625	B2	20080724		
EP 1577288	A1	20050921	EP 2003-782904	20031225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060116364	A1	20060601	US 2005-158245	20050622
PRIORITY APPLN. INFO.:			JP 2002-378729	A 20021226
			WO 2003-JP16808	W 20031225
OTHER SOURCE(S):		MARPAT 141:123486		
GI				



AB The title compds. I [wherein T = a single bond, (un)substituted alkylene, alkenylene, or alkynylene; A = a single bond, (un)substituted heterocycle, (hetero)arylene, or cyclohydrocarbyl; Y = a single bond, O, S, etc.; Z = CH<sub>2</sub>O, O, S, etc.; ring G = (hetero)arylene, heterocycle, etc.; Q1 and Q2 = independently N or C; Ra and Rb = independently H, (un)substituted alkyl, alkenyl, alkynyl, etc.; W = a single bond, CO, (un)substituted alkylene, NH, etc.; R' = H, O, S, etc.; R'' = H, OH, halo, etc.; R = H, OH, halo, etc.; L = a single bond, (un)substituted alkylene, alkenylene, or alkynylene] or salts, or hydrates thereof are prepared as selective estrogen receptor modulators. For example, the compound II was prepared in a multi-step synthesis. I showed affinity towards estrogen receptor with K<sub>i</sub> of 0.2 to 94 nM in cow.


IT 722519-31-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of naphthalene derivs. as selective estrogen receptor modulators)

RN 722519-31-5 CAPLUS

CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-[5-hydroxy-2-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]phenyl]- (CA INDEX NAME)



IT 722536-24-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

10/596,503

(intermediate; preparation of naphthalene derivs. as selective estrogen receptor modulators)

RN 722536-24-5 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-[5-methoxy-2-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]phenyl]- (CA INDEX NAME)



L17 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:546416 CAPLUS

DOCUMENT NUMBER: 141:106391

TITLE: Preparation of benzo[d]azepine derivatives as antagonists and/or inverse agonists of the histamine H3 receptor for the treatment of neurological disorders

INVENTOR(S): Bamford, Mark James; Dean, David Kenneth; Sehmi, Sanjeet Singh; Wilson, David Matthew; Witherington, Jason

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 106 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056369	A1	20040708	WO 2003-EP14556	20031218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509413	A1	20040708	CA 2003-2509413	20031218
AU 2003294909	A1	20040714	AU 2003-294909	20031218
AU 2003294909	B2	20070517		
EP 1572215	A1	20050914	EP 2003-785885	20031218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017483	A	20051116	BR 2003-17483	20031218
CN 1726042	A	20060125	CN 2003-80106364	20031218
JP 2006512412	T	20060413	JP 2005-502553	20031218
NZ 540148	A	20071130	NZ 2003-540148	20031218
ZA 2005004270	A	20060726	ZA 2005-4270	20050525
IN 2005DN02232	A	20070105	IN 2005-DN2232	20050526
US 20060040918	A1	20060223	US 2005-539385	20050616
MX 2005PA06567	A	20050816	MX 2005-PA6567	20050617
KR 765027	B1	20071009	KR 2005-711441	20050617
NO 2005003384	A	20050915	NO 2005-3384	20050712
US 20070299056	A1	20071227	US 2007-831191	20070731
KR 2007089762	A	20070831	KR 2007-719049	20070820
PRIORITY APPLN. INFO.:			GB 2002-29820	A 20021220
			GB 2003-12607	A 20030602
			WO 2003-EP14556	W 20031218
			US 2005-539385	A3 20050616
			KR 2005-711441	A3 20050617
OTHER SOURCE(S):		MARPAT 141:106391		
GI				



AB The title compds. [I; R1 = cycloalkyl optionally substituted by alkyl; R2 = H, alkyl, X(cycloalkyl), X(aryl), etc.; X = a bond, alkyl; R3 = halo, alkyl, alkoxy, CN, NH2, CF3; n = 0-2], useful in the treatment of neurol. and psychiatric disorders, were prepared Thus, reacting 7-benzyloxy-1,2,4,5-tetrahydrobenzo[d]azepine (preparation given) with cyclobutanone in the presence of NaBH(OAc)3 afforded I [R1 = cyclobutyl; R2 = CH2Ph; n = 0] which showed pKb of 9.0-10.5 in the histamine H3 functional antagonist assay. The pharmaceutical composition comprising the compound I is claimed.


IT 720689-52-1P 720689-53-2P 720689-55-4P  
 720689-56-5P 720689-57-6P 720689-58-7P  
 720689-59-8P 720689-60-1P 720689-61-2P  
 720689-62-3P 720689-63-4P 720689-64-5P  
 720690-40-4P 720690-41-5P 720690-46-0P  
 720690-47-1P 720690-74-4P 720691-00-9P  
 720691-01-0P 720691-02-1P 720691-59-8P  
 720691-60-1P 720691-63-4P 720691-66-7P  
 720691-78-1P 720691-83-8P 720691-84-9P  
 720691-85-0P 720691-86-1P 720691-88-3P  
 720692-09-1P 720692-11-5P 720692-24-0P  
 720692-25-1P 720692-27-3P 720693-38-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of benzo[d]azepine derivs. as antagonists and/or inverse agonists of the histamine H3 receptor for the treatment of neurol. disorders)

RN 720689-52-1 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(phenylmethoxy)- (CA INDEX NAME)



RN 720689-53-2 CAPLUS


CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-(phenylmethoxy)- (CA INDEX NAME)

10/596,503




RN 720689-55-4 CAPLUS

CN 1H-3-Benzazepin-7-ol, 3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 720689-56-5 CAPLUS

CN 1H-3-Benzazepin-7-ol, 3-cyclopentyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 720689-57-6 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-(4-piperidinyloxy)-  
(CA INDEX NAME)



RN 720689-58-7 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(4-piperidinyloxy)-  
(CA INDEX NAME)




RN 720689-59-8 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(4-piperidinylmethoxy)-  
(CA INDEX NAME)




10/596,503



RN 720689-60-1 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(2R)-2-pyrrolidinylmethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 720689-61-2 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(3R)-3-pyrrolidinyl-2-ylmethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 720689-62-3 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(3S)-3-pyrrolidinyl-2-ylmethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 720689-63-4 CAPLUS

10/596,503


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(2S)-2-pyrrolidinylmethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 720689-64-5 CAPLUS

CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-(4-piperidinylmethoxy)- (CA INDEX NAME)




RN 720690-40-4 CAPLUS

CN Benzoic acid, 4-[[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-, methyl ester (CA INDEX NAME)



RN 720690-41-5 CAPLUS


CN Benzoic acid, 4-[[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]- (CA INDEX NAME)



RN 720690-46-0 CAPLUS


10/596,503

CN Benzoic acid, 3-[[[3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-, methyl ester (CA INDEX NAME)




RN 720690-47-1 CAPLUS

CN Benzoic acid, 3-[[[3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]- (CA INDEX NAME)



RN 720690-74-4 CAPLUS


CN 2-Pyrazinecarboxylic acid, 5-[[[3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-, methyl ester (CA INDEX NAME)



RN 720691-00-9 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(3S)-3-pyrrolidinylmethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 720691-01-0 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(3S)-3-piperidinylmethoxy]- (CA INDEX NAME)

10/596,503


Absolute stereochemistry.



RN 720691-02-1 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(3S)-3-piperidinyloxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 720691-59-8 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(5-iodo-2-pyridinyl)oxy]- (CA INDEX NAME)



RN 720691-60-1 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(5-nitro-2-pyridinyl)oxy]- (CA INDEX NAME)



RN 720691-63-4 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(5-nitro-2-thienyl)oxy]- (CA INDEX NAME)

10/596,503




RN 720691-66-7 CAPLUS

CN Ethanone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)




RN 720691-78-1 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-iodo-8-(phenylmethoxy)- (CA INDEX NAME)



RN 720691-83-8 CAPLUS


CN 2,3-Pyridinedicarboxylic acid, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-, 2,3-dimethyl ester (CA INDEX NAME)



RN 720691-84-9 CAPLUS

CN 2,3-Pyridinedicarboxylic acid, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-, sodium salt (1:2) (CA INDEX NAME)


10/596,503



● 2 Na


RN 720691-85-0 CAPLUS

CN 5H-Pyrrolo[3,4-b]pyridine-5,7(6H)-dione, 2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)




RN 720691-86-1 CAPLUS

CN 5H-Pyrrolo[3,4-b]pyridin-5-one, 2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-6,7-dihydro-7-hydroxy- (CA INDEX NAME)



RN 720691-88-3 CAPLUS


CN 3-Pyridinamine, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)




RN 720692-09-1 CAPLUS

CN 1H-3-Benzazepine, 7-[(5-chloro-2-pyrazinyl)oxy]-3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)


10/596,503




RN 720692-11-5 CAPLUS  
CN 1H-3-Benzazepine, 7-[(5-bromo-2-pyrazinyl)oxy]-3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 720692-24-0 CAPLUS  
CN Benzonitrile, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-fluoro- (CA INDEX NAME)




RN 720692-25-1 CAPLUS  
CN Benzoic acid, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-fluoro- (CA INDEX NAME)



RN 720692-27-3 CAPLUS  
CN 1H-3-Benzazepine, 3-cyclobutyl-7-(2-fluoro-4-iodophenoxy)-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720693-38-9 CAPLUS  
 CN 2-Pyridinecarbonitrile, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



IT	720689-65-6P	720689-66-7P	720689-67-8P
	720689-68-9P	720689-69-0P	720689-70-3P
	720689-71-4P	720689-72-5P	720689-73-6P
	720689-74-7P	720689-75-8P	720689-76-9P
	720689-77-0P	720689-78-1P	720689-79-2P
	720689-80-5P	720689-81-6P	720689-82-7P
	720689-83-8P	720689-84-9P	720689-85-0P
	720689-86-1P	720689-87-2P	720689-88-3P
	720689-89-4P	720689-90-7P	720689-91-8P
	720689-92-9P	720689-93-0P	720689-94-1P
	720689-95-2P	720689-96-3P	720689-97-4P
	720689-98-5P	720689-99-6P	720690-00-6P
	720690-01-7P	720690-02-8P	720690-03-9P
	720690-04-0P	720690-05-1P	720690-06-2P
	720690-07-3P	720690-08-4P	720690-09-5P
	720690-10-8P	720690-11-9P	720690-12-0P
	720690-13-1P	720690-14-2P	720690-15-3P
	720690-16-4P	720690-17-5P	720690-18-6P
	720690-19-7P	720690-20-0P	720690-21-1P
	720690-22-2P	720690-23-3P	720690-24-4P
	720690-25-5P	720690-26-6P	720690-27-7P
	720690-28-8P	720690-29-9P	720690-30-2P
	720690-31-3P	720690-32-4P	720690-33-5P
	720690-34-6P	720690-35-7P	720690-36-8P
	720690-37-9P	720690-38-0P	720690-39-1P
	720690-42-6P	720690-43-7P	720690-44-8P
	720690-45-9P	720690-48-2P	720690-49-3P
	720690-50-6P	720690-51-7P	720690-52-8P
	720690-53-9P	720690-54-0P	720690-55-1P
	720690-56-2P	720690-57-3P	720690-58-4P
	720690-59-5P	720690-60-8P	720690-61-9P
	720690-62-0P	720690-63-1P	720690-64-2P
	720690-65-3P	720690-66-4P	720690-67-5P
	720690-68-6P	720690-69-7P	720690-70-0P
	720690-71-1P	720690-72-2P	720690-73-3P
	720690-75-5P	720690-76-6P	720690-77-7P
	720690-78-8P	720690-79-9P	720690-80-2P
	720690-81-3P	720690-82-4P	720690-83-5P
	720690-84-6P	720690-85-7P	720690-86-8P
	720690-87-9P	720690-88-0P	720690-89-1P
	720690-90-4P	720690-91-5P	720690-92-6P
	720690-93-7P	720690-94-8P	720690-95-9P
	720690-96-0P	720690-97-1P	720690-98-2P
	720690-99-3P	720691-04-3P	720691-05-4P
	720691-06-5P	720691-07-6P	720691-08-7P




720691-09-8P 720691-10-1P 720691-11-2P  
 720691-12-3P 720691-13-4P 720691-14-5P  
 720691-15-6P 720691-16-7P 720691-17-8P  
 720691-18-9P 720691-19-0P 720691-20-3P  
 720691-21-4P 720691-22-5P 720691-23-6P  
 720691-24-7P 720691-25-8P 720691-26-9P  
 720691-27-0P 720691-28-1P 720691-29-2P  
 720691-30-5P 720691-31-6P 720691-32-7P  
 720691-33-8P 720691-34-9P 720691-35-0P  
 720691-36-1P 720691-37-2P 720691-38-3P  
 720691-39-4P 720691-40-7P 720691-41-8P  
 720691-42-9P 720691-43-0P 720691-44-1P  
 720691-45-2P 720691-46-3P 720691-47-4P  
 720691-48-5P 720691-49-6P 720691-50-9P  
 720691-51-0P 720691-52-1P 720691-53-2P  
 720691-54-3P 720691-55-4P 720691-56-5P  
 720691-57-6P 720691-58-7P 720691-61-2P  
 720691-62-3P 720691-64-5P 720691-65-6P  
 720691-67-8P 720691-68-9P 720691-69-0P  
 720691-70-3P 720691-71-4P 720691-72-5P  
 720691-73-6P 720691-74-7P 720691-75-8P  
 720691-76-9P 720691-77-0P 720691-79-2P  
 720691-80-5P 720691-81-6P 720691-82-7P  
 720691-87-2P 720691-89-4P 720691-90-7P  
 720691-91-8P 720691-92-9P 720691-93-0P  
 720691-94-1P 720691-95-2P 720691-96-3P  
 720691-97-4P 720691-98-5P 720691-99-6P  
 720692-00-2P 720692-01-3P 720692-02-4P  
 720692-03-5P 720692-04-6P 720692-05-7P  
 720692-06-8P 720692-07-9P 720692-08-0P  
 720692-10-4P 720692-12-6P 720692-13-7P  
 720692-14-8P 720692-15-9P 720692-17-1P  
 720692-18-2P 720692-19-3P 720692-20-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of benzo[d]azepine derivs. as antagonists and/or inverse  
 agonists of the histamine H3 receptor for the treatment of neurol.  
 disorders)

RN 720689-65-6 CAPLUS


CN Benzonitrile, 4-[[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]carbonyl]- (CA INDEX NAME)



RN 720689-66-7 CAPLUS


CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

10/596,503




RN 720689-67-8 CAPLUS

CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]cyclohexyl- (CA INDEX NAME)



RN 720689-68-9 CAPLUS


CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-1-isoquinolinyl- (CA INDEX NAME)



RN 720689-69-0 CAPLUS

CN Benzonitrile, 4-[(1E)-3-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-3-oxo-1-propen-1-yl]- (CA INDEX NAME)


Double bond geometry as shown.



10/596,503


RN 720689-70-3 CAPLUS

CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-6-isoquinolinyl- (CA INDEX NAME)




RN 720689-71-4 CAPLUS

CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl](5-methyl-3-isoxazolyl)- (CA INDEX NAME)




RN 720689-72-5 CAPLUS

CN Methanone, 6-benzothiazolyl[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]- (CA INDEX NAME)



RN 720689-73-6 CAPLUS

CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-4-pyridinyl- (CA INDEX NAME)




RN 720689-74-7 CAPLUS

CN Piperidine, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-


10/596,503

1-[4-(1-pyrrolidinylcarbonyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 720689-75-8 CAPLUS

CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-3-thienyl- (CA INDEX NAME)




RN 720689-76-9 CAPLUS

CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-3-furanyl- (CA INDEX NAME)



RN 720689-77-0 CAPLUS

CN Methanone, [4-[[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-piperidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720689-78-1 CAPLUS

10/596,503

CN Methanone, [(2R)-2-[[[3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]methyl]-1-pyrrolidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 720689-79-2 CAPLUS

CN Methanone, [(3R)-3-[[[3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-1-pyrrolidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 720689-80-5 CAPLUS

CN Methanone, [(3S)-3-[[[3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-1-pyrrolidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 720689-81-6 CAPLUS

CN Methanone, [(2S)-2-[[[3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]methyl]-1-pyrrolidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.

10/596,503




RN 720689-82-7 CAPLUS

CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl][4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 720689-83-8 CAPLUS

CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-2-pyrazinyl- (CA INDEX NAME)



RN 720689-84-9 CAPLUS


CN 2(1H)-Pyridinone, 5-[[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]carbonyl]- (CA INDEX NAME)



10/596,503


RN 720689-85-0 CAPLUS

CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl](2,3-dihydro-5-benzofuranyl)- (CA INDEX NAME)




RN 720689-86-1 CAPLUS

CN 1-Propanone, 1-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-3-methoxy- (CA INDEX NAME)



RN 720689-87-2 CAPLUS


CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl](2,3-dihydro-7-benzofuranyl)- (CA INDEX NAME)



RN 720689-88-3 CAPLUS


CN Benzonitrile, 4-[[4-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-piperidinyl]carbonyl]- (CA INDEX NAME)






RN 720689-89-4 CAPLUS

CN Piperidine, 4-[[4-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-[4-(1-pyrrolidinylcarbonyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 720689-90-7 CAPLUS

CN Benzonitrile, 4-[[4-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]carbonyl]- (CA INDEX NAME)



RN 720689-91-8 CAPLUS

CN Methanone, [4-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-4-pyridinyl- (CA INDEX NAME)






10/596,503


RN 720689-92-9 CAPLUS

CN Methanone, [4-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-6-quinolinyl- (CA INDEX NAME)




RN 720689-93-0 CAPLUS

CN Piperidine, 4-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-[4-(1-pyrrolidinylcarbonyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 720689-94-1 CAPLUS


CN Methanone, [1,1'-biphenyl]-4-yl[4-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]- (CA INDEX NAME)



RN 720689-95-2 CAPLUS


CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]cyclopentyl- (CA INDEX NAME)

10/596,503



RN 720689-96-3 CAPLUS


CN Benzonitrile, 4-[[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-piperidinyl]carbonyl]- (CA INDEX NAME)



RN 720689-97-4 CAPLUS

CN Benzonitrile, 4-[(3R)-2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 720689-98-5 CAPLUS

CN Benzonitrile, 4-[(3R)-3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/596,503



RN 720689-99-6 CAPLUS

CN Benzonitrile, 4-[[[(3S)-3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 720690-00-6 CAPLUS

CN Benzonitrile, 4-[[[(2S)-2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 720690-01-7 CAPLUS


CN 1-Propanone, 1-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-2,2-dimethyl- (CA INDEX NAME)

10/596,503




RN 720690-02-8 CAPLUS

CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]cyclopropyl- (CA INDEX NAME)




RN 720690-03-9 CAPLUS

CN Methanone, cyclobutyl[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]- (CA INDEX NAME)



RN 720690-04-0 CAPLUS


CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-4-morpholinyl- (CA INDEX NAME)



RN 720690-05-1 CAPLUS

CN Methanone, [4-[[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-piperidinyl]-4-morpholinyl]- (CA INDEX NAME)


10/596,503



RN 720690-06-2 CAPLUS

CN Methanone, [(2R)-2-[[[3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]methyl]-1-pyrrolidinyl]-4-morpholinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 720690-07-3 CAPLUS

CN Methanone, [(3R)-3-[[[3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-1-pyrrolidinyl]-4-morpholinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 720690-08-4 CAPLUS


CN Methanone, [(3S)-3-[[[3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-1-pyrrolidinyl]-4-morpholinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 720690-09-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-bis(1-methylethyl)- (CA INDEX NAME)




RN 720690-10-8 CAPLUS

CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 720690-11-9 CAPLUS

CN Piperidine, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 720690-12-0 CAPLUS


CN Methanone, [(2S)-2-[[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-pyrrolidinyl]-4-morpholinyl]- (CA INDEX NAME)

10/596,503


Absolute stereochemistry.




RN 720690-13-1 CAPLUS  
CN 1-Piperidinecarboxamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-diethyl- (CA INDEX NAME)



RN 720690-14-2 CAPLUS  
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl](1,3-dihydro-2H-isoindol-2-yl)- (CA INDEX NAME)




RN 720690-15-3 CAPLUS  
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl][4-(2-pyrazinyl)-1-piperazinyl]- (CA INDEX NAME)



RN 720690-16-4 CAPLUS


10/596,503

CN 1-Piperidinecarboxamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(2-methoxyethyl)-N-(1-methylethyl)- (CA INDEX NAME)




RN 720690-17-5 CAPLUS

CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl](1,1-dioxido-4-thiomorpholinyl)- (CA INDEX NAME)



RN 720690-18-6 CAPLUS


CN 1-Piperidinecarboxamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 720690-19-7 CAPLUS


CN 1-Piperidinecarboxamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(4-fluorophenyl)- (CA INDEX NAME)






RN 720690-20-0 CAPLUS

CN Acetamide, 2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 720690-21-1 CAPLUS

CN Acetamide, 2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-phenyl- (CA INDEX NAME)




RN 720690-22-2 CAPLUS

CN Ethanone, 2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 720690-23-3 CAPLUS

CN Ethanone, 2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-(4-morpholinyl)- (CA INDEX NAME)




RN 720690-24-4 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[1-(methanesulfonyl)-4-piperidinyl]oxy]- (CA INDEX NAME)




RN 720690-25-5 CAPLUS

CN Benzonitrile, 4-[[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)



RN 720690-26-6 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-7-[[1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-4-piperidinyl]oxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720690-27-7 CAPLUS

CN Benzonitrile, 4-[[4-[[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)


10/596,503



RN 720690-28-8 CAPLUS

CN Benzonitrile, 4-[[[(2R)-2-[[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-pyrrolidinyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 720690-29-9 CAPLUS

CN Benzonitrile, 4-[[[(3R)-3-[[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-pyrrolidinyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 720690-30-2 CAPLUS

CN Benzonitrile, 4-[[[(3S)-3-[[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-pyrrolidinyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

10/596,503




RN 720690-31-3 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-7-[(2,4-difluorophenyl)methoxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 720690-32-4 CAPLUS

CN Benzonitrile, 3-[[ (3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]- (CA INDEX NAME)



RN 720690-33-5 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(3-methoxyphenyl)methoxy]- (CA INDEX NAME)



RN 720690-34-6 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(2-pyridinylmethoxy)- (CA INDEX NAME)

10/596,503




RN 720690-35-7 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(3-pyridinylmethoxy)-  
(CA INDEX NAME)




RN 720690-36-8 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(4-pyridinylmethoxy)-  
(CA INDEX NAME)




RN 720690-37-9 CAPLUS

CN Benzonitrile, 2-[[ (3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-  
(CA INDEX NAME)



RN 720690-38-0 CAPLUS


CN Benzonitrile, 4-[[ (3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-  
(CA INDEX NAME)



10/596,503


RN 720690-39-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)methyl]-1-methyl- (CA INDEX NAME)




RN 720690-42-6 CAPLUS

CN Methanone, [4-[[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)methyl]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 720690-43-7 CAPLUS

CN Methanone, [4-[[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)methyl]phenyl]-4-morpholinyl- (CA INDEX NAME)




RN 720690-44-8 CAPLUS

CN Methanone, [4-[[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)methyl]phenyl][4-(4-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 720690-45-9 CAPLUS

CN Methanone, [4-[[[3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]methyl]phenyl][4-(4-fluorophenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 720690-48-2 CAPLUS

CN Methanone, [3-[[[3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]methyl]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 720690-49-3 CAPLUS

CN Methanone, [3-[[[3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]methyl]phenyl]-4-morpholinyl- (CA INDEX NAME)




RN 720690-50-6 CAPLUS

CN Methanone, [3-[[[3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]methyl]phenyl][4-(4-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 720690-51-7 CAPLUS

CN Methanone, [3-[[3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]phenyl][4-(4-fluorophenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 720690-52-8 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)




RN 720690-53-9 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(2-pyridinyloxy)- (CA INDEX NAME)



RN 720690-54-0 CAPLUS


CN Methanone, [6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-4-morpholinyl- (CA INDEX NAME)






RN 720690-55-1 CAPLUS

CN Methanone, [6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 720690-56-2 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)




RN 720690-57-3 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 720690-58-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl-N-methyl- (CA INDEX NAME)




RN 720690-59-5 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-cyclopentyl- (CA INDEX NAME)




10/596,503




RN 720690-60-8 CAPLUS

CN Methanone, [6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-1-piperidinyl- (CA INDEX NAME)




RN 720690-61-9 CAPLUS

CN Methanone, [2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-4-pyridinyl]-1-piperidinyl- (CA INDEX NAME)




RN 720690-62-0 CAPLUS

CN Methanone, [2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-4-pyridinyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 720690-63-1 CAPLUS


CN Methanone, [2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-4-pyridinyl]-4-morpholinyl- (CA INDEX NAME)



RN 720690-64-2 CAPLUS


10/596,503

CN Methanone, [6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]-1-piperidinyl- (CA INDEX NAME)




RN 720690-65-3 CAPLUS

CN Methanone, [6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl](1,1-dioxido-4-thiomorpholinyl)- (CA INDEX NAME)



RN 720690-66-4 CAPLUS


CN Methanone, [6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 720690-67-5 CAPLUS


CN Methanone, [6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]-4-morpholinyl- (CA INDEX NAME)

10/596,503




RN 720690-68-6 CAPLUS

CN Methanone, [2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-4-morpholinyl- (CA INDEX NAME)



RN 720690-69-7 CAPLUS


CN Methanone, [2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-1-piperidinyl- (CA INDEX NAME)



RN 720690-70-0 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(2-pyrazinyloxy)- (CA INDEX NAME)

10/596,503




RN 720690-71-1 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(2-pyrimidinyl-oxy)-  
(CA INDEX NAME)




RN 720690-72-2 CAPLUS

CN 1H-3-Benzazepine, 7-[(5-bromo-2-pyrimidinyl)oxy]-3-cyclobutyl-2,3,4,5-tetrahydro-  
(CA INDEX NAME)




RN 720690-73-3 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-  
(CA INDEX NAME)



RN 720690-75-5 CAPLUS


CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]-4-morpholinyl-  
(CA INDEX NAME)



RN 720690-76-6 CAPLUS


CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl-N-methyl-  
(CA INDEX NAME)

10/596,503




RN 720690-77-7 CAPLUS

CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)




RN 720690-78-8 CAPLUS

CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]-1-piperidinyl- (CA INDEX NAME)




RN 720690-79-9 CAPLUS

CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 720690-80-2 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-phenoxy- (CA INDEX NAME)



RN 720690-81-3 CAPLUS


CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-

yl)oxy]phenyl]-4-morpholinyl- (CA INDEX NAME)




RN 720690-82-4 CAPLUS

CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 720690-83-5 CAPLUS

CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 720690-84-6 CAPLUS

CN Benzamide, N-cyclobutyl-4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)




RN 720690-85-7 CAPLUS

CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-diethyl- (CA INDEX NAME)




RN 720690-86-8 CAPLUS

CN Benzamide, N-(2-cyanoethyl)-4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)




RN 720690-87-9 CAPLUS

CN Methanone, [3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]phenyl]-4-morpholinyl- (CA INDEX NAME)



RN 720690-88-0 CAPLUS

CN Benzamide, 3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 720690-89-1 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[4-(4-morpholinylsulfonyl)phenoxy]- (CA INDEX NAME)




10/596,503




RN 720690-90-4 CAPLUS

CN Benzenesulfonamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-diethyl- (CA INDEX NAME)




RN 720690-91-5 CAPLUS

CN 1H-3-Benzazepine, 3-cyclohexyl-2,3,4,5-tetrahydro-7-(phenylmethoxy)- (CA INDEX NAME)




RN 720690-92-6 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[2-(1-piperidiny1)-5-pyrimidinyl]oxy]- (CA INDEX NAME)



RN 720690-93-7 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[2-(1-pyrrolidinyl)-5-pyrimidinyl]oxy]- (CA INDEX NAME)



10/596,503


RN 720690-94-8 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-7-[[2-(1,1-dioxido-4-thiomorpholinyl)-5-pyrimidinyl]oxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 720690-95-9 CAPLUS

CN 2-Pyrimidinamine, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)




RN 720690-96-0 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(2-methoxy-5-pyrimidinyl)oxy]- (CA INDEX NAME)



RN 720690-97-1 CAPLUS

CN 2-Pyrrolidinone, 1-[4-[[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 720690-98-2 CAPLUS

CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-


10/596,503

1-piperidinyl][3-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 720690-99-3 CAPLUS


CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl](3,4-dihydro-1,1-dioxido-2H-1-benzothiopyran-6-yl)- (CA INDEX NAME)



RN 720691-04-3 CAPLUS

CN Methanone, [(3S)-3-[[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-piperidinyl]-4-morpholinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 720691-05-4 CAPLUS

CN Methanone, [(3S)-3-[[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-pyrrolidinyl]-4-morpholinyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/596,503



RN 720691-06-5 CAPLUS

CN Methanone, [(3S)-3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-4-morpholinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 720691-07-6 CAPLUS

CN Benzonitrile, 4-[[[(3S)-3-[[[3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-piperidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 720691-08-7 CAPLUS

CN Benzonitrile, 4-[[[(3S)-3-[[[3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/596,503



RN 720691-09-8 CAPLUS

CN Benzonitrile, 4-[[[(3S)-3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 720691-10-1 CAPLUS

CN Methanone, [(3S)-3-[[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-pyrrolidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 720691-11-2 CAPLUS

CN Methanone, [(3S)-3-[[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-piperidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.

10/596,503




RN 720691-12-3 CAPLUS  
CN Methanone, [(3S)-3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidiny]-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 720691-13-4 CAPLUS  
CN 3-Pyridinecarbonitrile, 6-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidiny]- (CA INDEX NAME)




RN 720691-14-5 CAPLUS  
CN 3-Pyridinecarboxamide, 6-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidiny]-N-(cyclopropylmethyl)- (CA INDEX NAME)



RN 720691-15-6 CAPLUS


10/596,503

CN Methanone, 1-azetidiny[6-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-3-pyridinyl]- (CA INDEX NAME)




RN 720691-16-7 CAPLUS

CN Methanone, [6-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-3-pyridinyl]-4-morpholinyl- (CA INDEX NAME)




RN 720691-17-8 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-N-methyl- (CA INDEX NAME)



RN 720691-18-9 CAPLUS


CN 4-Pyridinecarbonitrile, 2-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]- (CA INDEX NAME)



RN 720691-19-0 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[1-(2-pyrazinyl)-4-piperidinyl]oxy]- (CA INDEX NAME)

10/596,503




RN 720691-20-3 CAPLUS

CN 1-Butanone, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-  
1-(1-piperidinyl)- (CA INDEX NAME)




RN 720691-21-4 CAPLUS

CN 1-Butanone, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-  
1-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 720691-22-5 CAPLUS

CN Butanamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-  
N-cyclopentyl- (CA INDEX NAME)




RN 720691-23-6 CAPLUS

CN Butanamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-  
N-methyl- (CA INDEX NAME)




10/596,503




RN 720691-24-7 CAPLUS

CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(1-methylethyl)- (CA INDEX NAME)




RN 720691-25-8 CAPLUS

CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720691-26-9 CAPLUS

CN Methanone, 1-azetidiny1[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]- (CA INDEX NAME)




RN 720691-27-0 CAPLUS

CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-diethyl- (CA INDEX NAME)




RN 720691-28-1 CAPLUS

CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 720691-29-2 CAPLUS

CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl- (CA INDEX NAME)




RN 720691-30-5 CAPLUS

CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrimidinyl]-4-morpholinyl- (CA INDEX NAME)



RN 720691-31-6 CAPLUS


CN 2-Pyrimidinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(cyclopropylmethyl)- (CA INDEX NAME)



10/596,503


RN 720691-32-7 CAPLUS

CN 2-Pyrimidinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl- (CA INDEX NAME)




RN 720691-33-8 CAPLUS

CN Methanone, 1-azetidiny[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrimidinyl]- (CA INDEX NAME)




RN 720691-34-9 CAPLUS

CN 2-Pyrimidinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl-N-methyl- (CA INDEX NAME)



RN 720691-35-0 CAPLUS


CN 2-Pyrimidinecarboxamide, N-cyclobutyl-5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720691-36-1 CAPLUS


CN 2-Pyrimidinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-

benzazepin-7-yl)oxy]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720691-37-2 CAPLUS

CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrimidinyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 720691-38-3 CAPLUS

CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrimidinyl]-1-piperidinyl- (CA INDEX NAME)




RN 720691-39-4 CAPLUS

CN 2-Pyrimidinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)




RN 720691-40-7 CAPLUS

CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)




10/596,503


RN 720691-41-8 CAPLUS  
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl- (CA INDEX NAME)




RN 720691-42-9 CAPLUS  
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl-N-methyl- (CA INDEX NAME)




RN 720691-43-0 CAPLUS  
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-diethyl- (CA INDEX NAME)



RN 720691-44-1 CAPLUS  
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 720691-45-2 CAPLUS  
CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 720691-46-3 CAPLUS

CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]-4-morpholinyl- (CA INDEX NAME)




RN 720691-47-4 CAPLUS

CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl](tetrahydro-1,4-oxazin-4(5H)-yl)- (CA INDEX NAME)




RN 720691-48-5 CAPLUS

CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-cyclopentyl- (CA INDEX NAME)



RN 720691-49-6 CAPLUS


CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-cyclopropyl- (CA INDEX NAME)



RN 720691-50-9 CAPLUS


CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(1-methylethyl)- (CA INDEX NAME)

10/596,503




RN 720691-51-0 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl- (CA INDEX NAME)




RN 720691-52-1 CAPLUS

CN 3-Pyridinecarboxamide, N-cyclobutyl-6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720691-53-2 CAPLUS


CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720691-54-3 CAPLUS


CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-diethyl- (CA INDEX NAME)

10/596,503




RN 720691-55-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 720691-56-5 CAPLUS

CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 720691-57-6 CAPLUS

CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)




RN 720691-58-7 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(3-pyridinyloxy)- (CA INDEX NAME)




10/596,503




RN 720691-61-2 CAPLUS

CN Acetamide, N-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)




RN 720691-62-3 CAPLUS

CN Acetamide, N-[2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-5-thiazolyl]- (CA INDEX NAME)




RN 720691-64-5 CAPLUS

CN Acetamide, N-[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-thienyl]- (CA INDEX NAME)



RN 720691-65-6 CAPLUS


CN 2(1H)-Pyridinone, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720691-67-8 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-(1H-pyrazol-3-yl)-2-pyridinyl]oxy]- (CA INDEX NAME)

10/596,503




RN 720691-68-9 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-(5-methyl-1,3,4-oxadiazol-2-yl)-2-pyridinyl]oxy]- (CA INDEX NAME)




RN 720691-69-0 CAPLUS

CN 2-Pyrrolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)




RN 720691-70-3 CAPLUS

CN 2-Piperidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-71-4 CAPLUS


CN 2-Azetidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



10/596,503


RN 720691-72-5 CAPLUS

CN 2-Oxazolidinone, 3-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)




RN 720691-73-6 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-(1H-pyrazol-1-yl)-2-pyridinyl]oxy]- (CA INDEX NAME)




RN 720691-74-7 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-7-[[5-(3,5-dimethyl-4-isoxazolyl)-2-pyridinyl]oxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720691-75-8 CAPLUS


CN 3-Pyridinecarboxamide, 6-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 720691-76-9 CAPLUS


CN 3-Pyridinecarboxamide, N-methyl-6-[[2,3,4,5-tetrahydro-3-(2-methylcyclopentyl)-1H-3-benzazepin-7-yl]oxy]- (CA INDEX NAME)

10/596,503




RN 720691-77-0 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-8-iodo-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)




RN 720691-79-2 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(4-methoxy-6-methyl-2-quinolinyl)oxy]- (CA INDEX NAME)




RN 720691-80-5 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(4-methoxy-1,7-naphthyridin-2-yl)oxy]- (CA INDEX NAME)




RN 720691-81-6 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(1,5-naphthyridin-2-yloxy)- (CA INDEX NAME)




RN 720691-82-7 CAPLUS

CN Acetamide, N-[7-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-6-methyl-1,8-naphthyridin-2-yl]- (CA INDEX NAME)




RN 720691-87-2 CAPLUS

CN 5H-Pyrrolo[3,4-b]pyridin-5-one, 2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-6,7-dihydro- (CA INDEX NAME)




RN 720691-89-4 CAPLUS

CN 4-Morpholinecarboxamide, N-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)




RN 720691-90-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)




RN 720691-91-8 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)




RN 720691-92-9 CAPLUS

CN Propanamide, N-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-2-methyl- (CA INDEX NAME)




RN 720691-93-0 CAPLUS

CN 2H-Pyran-4-carboxamide, N-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]tetrahydro- (CA INDEX NAME)



RN 720691-94-1 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-7-[[5-(4,6-dimethoxy-2-pyrimidinyl)-2-pyridinyl]oxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720691-95-2 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-[4-(methylsulfonyl)phenyl]-2-pyrazinyl]oxy]- (CA INDEX NAME)

10/596,503




RN 720691-96-3 CAPLUS

CN Acetamide, N-[4-[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]phenyl]- (CA INDEX NAME)




RN 720691-97-4 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-7-[(3,5-dimethyl-2-pyridinyl)oxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720691-98-5 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-(4-morpholinylsulfonyl)-2-pyridinyl]oxy]- (CA INDEX NAME)



RN 720691-99-6 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(2-methylfuro[2,3-c]pyridin-7-yl)oxy]- (CA INDEX NAME)

10/596,503




RN 720692-00-2 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-4-ethoxy- (CA INDEX NAME)




RN 720692-01-3 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-methyl- (CA INDEX NAME)



RN 720692-02-4 CAPLUS

CN 2-Pyrrolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-5-methyl- (CA INDEX NAME)




RN 720692-03-5 CAPLUS

CN 2-Imidazolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-3-methyl- (CA INDEX NAME)




10/596,503



RN 720692-04-6 CAPLUS


CN 2-Pyrrolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-4-hydroxy-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 720692-05-7 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-6-[[2,3,4,5-tetrahydro-3-(3-methylcyclopentyl)-1H-3-benzazepin-7-yl]oxy]- (CA INDEX NAME)



RN 720692-06-8 CAPLUS


CN 2-Pyrazinecarboxamide, N-methyl-5-[[2,3,4,5-tetrahydro-3-(3-methylcyclopentyl)-1H-3-benzazepin-7-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 720692-07-9 CAPLUS


CN 2-Pyrazinecarboxamide, N-methyl-5-[[2,3,4,5-tetrahydro-3-(3-methylcyclopentyl)-1H-3-benzazepin-7-yl]oxy]- (CA INDEX NAME)

10/596,503




RN 720692-08-0 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]- (CA INDEX NAME)




RN 720692-10-4 CAPLUS

CN 2-Pyrrolidinone, 1-[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]- (CA INDEX NAME)



RN 720692-12-6 CAPLUS


CN 2-Oxazolidinone, 3-[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]- (CA INDEX NAME)



RN 720692-13-7 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-7-[[5-(1,1-dioxido-2-isothiazolidinyl)-2-pyridinyl]oxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)

10/596,503




RN 720692-14-8 CAPLUS

CN 2-Imidazolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)




RN 720692-15-9 CAPLUS

CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)




RN 720692-17-1 CAPLUS

CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-methoxy-N-methyl- (CA INDEX NAME)




RN 720692-18-2 CAPLUS

CN Benzonitrile, 2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)




RN 720692-19-3 CAPLUS

CN Benzamide, 3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-4-methoxy-N-methyl- (CA INDEX NAME)



RN 720692-20-6 CAPLUS

CN Benzamide, 3-chloro-4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)




IT 720692-21-7P 720692-22-8P 720692-23-9P  
 720692-26-2P 720692-28-4P 720692-29-5P  
 720692-30-8P 720692-31-9P 720692-32-0P  
 720692-33-1P 720692-34-2P 720692-35-3P  
 720692-36-4P 720692-38-6P 720692-39-7P  
 720692-40-0P 720692-41-1P 720692-42-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of benzo[d]azepine derivs. as antagonists and/or inverse  
 agonists of the histamine H3 receptor for the treatment of neurol.  
 disorders)


RN 720692-21-7 CAPLUS

CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,3-dimethyl- (CA INDEX NAME)




RN 720692-22-8 CAPLUS

CN 1H-3-Benzazepine-7-carbonitrile, 3-cyclobutyl-2,3,4,5-tetrahydro-8-(phenylmethoxy)- (CA INDEX NAME)




RN 720692-23-9 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-7-(2-fluorophenoxy)-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720692-26-2 CAPLUS


CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-fluoro-N-methyl- (CA INDEX NAME)



RN 720692-28-4 CAPLUS


CN 2-Pyrrolidinone, 1-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-fluorophenyl]- (CA INDEX NAME)

10/596,503




RN 720692-29-5 CAPLUS

CN Acetamide, N-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-fluorophenyl]- (CA INDEX NAME)




RN 720692-30-8 CAPLUS

CN Methanone, [3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 720692-31-9 CAPLUS

CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720692-32-0 CAPLUS

CN Benzamide, 3-cyano-4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)




RN 720692-33-1 CAPLUS

CN Methanone, [6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridazinyl]-4-morpholinyl- (CA INDEX NAME)




RN 720692-34-2 CAPLUS

CN 3-Pyridazinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 720692-35-3 CAPLUS


CN 3-Pyridazinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl-N-methyl- (CA INDEX NAME)



RN 720692-36-4 CAPLUS


CN 1-Butanone, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-(4-morpholinyl)- (CA INDEX NAME)

10/596,503




RN 720692-38-6 CAPLUS

CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl][4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 720692-39-7 CAPLUS


CN Ethanone, 1-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-2-cyclopropyl- (CA INDEX NAME)



RN 720692-40-0 CAPLUS

CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl][(2R,6S)-2,6-dimethyl-4-morpholinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 720692-41-1 CAPLUS



10/596,503


CN Methanone, [trans-4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]cyclohexyl]-4-morpholinyl- (CA INDEX NAME)

Relative stereochemistry.



RN 720692-42-2 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[6-(4-morpholinyl)-2-pyrazinyl]oxy]- (CA INDEX NAME)




IT 720692-58-0P 720692-59-1P 720692-62-6P  
720692-63-7P 720692-64-8P 720692-65-9P  
720692-66-0P 720692-67-1P 720692-68-2P  
720692-69-3P 720692-70-6P 720692-71-7P  
720692-72-8P 720692-73-9P 720692-74-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of benzo[d]azepine derivs. as antagonists and/or inverse agonists of the histamine H3 receptor for the treatment of neurol. disorders)

RN 720692-58-0 CAPLUS

CN 2-Propen-1-one, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-3-(dimethylamino)-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 720692-59-1 CAPLUS


CN 3-Pyridinecarboxylic acid, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-

benzazepin-7-yl)oxy]-, hydrazide (CA INDEX NAME)




RN 720692-62-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 720692-63-7 CAPLUS

CN 2-Pyrazinecarboxylic acid, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-64-8 CAPLUS


CN 2-Pyrazinecarbonyl chloride, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-65-9 CAPLUS


CN Butanoic acid, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-, ethyl ester (CA INDEX NAME)

10/596,503




RN 720692-66-0 CAPLUS

CN Butanoic acid, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)




RN 720692-67-1 CAPLUS

CN 1-Butanone, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-(1H-imidazol-1-yl)- (CA INDEX NAME)




RN 720692-68-2 CAPLUS

CN 2-Pyrimidinecarbonitrile, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)




RN 720692-69-3 CAPLUS

CN 2-Pyrimidinecarboxylic acid, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)




RN 720692-70-6 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)




RN 720692-71-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-, methyl ester (CA INDEX NAME)




RN 720692-72-8 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-73-9 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(5-nitro-2-thiazolyl)oxy]- (CA INDEX NAME)



RN 720692-74-0 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(6-methoxy-3-pyridinyl)oxy]- (CA INDEX NAME)

10/596,503



L17 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:354915 CAPLUS

DOCUMENT NUMBER: 140:375086

TITLE: A preparation of benzo[d]azepine derivatives as a histamine H3 receptor antagonists useful for the treatment of neurological and psychiatric disorders

INVENTOR(S): Heightman, Thomas Daniel; Wilson, David Matthew

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035544	A1	20040429	WO 2003-EP11421	20031014
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003278084	A1	20040504	AU 2003-278084	20031014
PRIORITY APPLN. INFO.:			GB 2002-24083	A 20021016
			WO 2003-EP11421	W 20031014
OTHER SOURCE(S):	MARPAT 140:375086			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to novel benzoazepine derivs. of formula I [wherein: R1 = H, (un)substituted (cyclo)alkyl, (hetero)aryl, or alkyl-aryl, etc.; R2 = H, alkyl, alkoxy, CN, NH2, or CF3; R3 represents -(CH2)2-4-NR4R5 or a group of formula II; R4 and R5 independently represent alkyl or, together with the nitrogen atom to which they are attached, represent an N-linked nitrogen-containing (un)substituted heterocycle; X represents bond, alkyl, C(O), or SO2, etc.; Z = (CH2)0-3; Y = (CH2)0-2; R6 = H, (cyclo)alkyl, alkyl-aryl, or heterocyclyl; R7 = halogen, (halo)alkyl, or OH, etc.] useful for the treatment of neurol. and psychiatric disorders. The invented compds. were screened for histamine H3 receptor activity (histamine H3 binding assay and functional antagonist assay). The prepared compds. exhibited antagonism in the range 6.0-10.0 pKb. For instance, compound III (8.0-10.0 pKb) was prepared via decarboxylation of the prepared benzoazepine IV by treatment with CF3CO2H in CH2Cl2 at 0 °C (example 1, no yield data).

IT 684250-63-3P, 3-Phenyl-7-[[3-(1-piperidinyl)propyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine 684250-64-4P, 4-[7-[[3-(1-piperidinyl)propyl]oxy]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-


yl)benzonitrile 684250-65-5P, 3-(3,4-Dichlorophenyl)-7-[[3-(1-piperidinyl)propyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzo[d]azepine derivs. useful for treatment of neurol. and psychiatric disorders)


RN 684250-63-3 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-phenyl-7-[3-(1-piperidinyl)propoxy]-(CA INDEX NAME)




RN 684250-64-4 CAPLUS

CN Benzonitrile, 4-[1,2,4,5-tetrahydro-7-[3-(1-piperidinyl)propoxy]-3H-3-benzazepin-3-yl]-(CA INDEX NAME)



RN 684250-65-5 CAPLUS

CN 1H-3-Benzazepine, 3-(3,4-dichlorophenyl)-2,3,4,5-tetrahydro-7-[3-(1-piperidinyl)propoxy]-(CA INDEX NAME)



REFERENCE COUNT:



7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2001:851111 CAPLUS  
 DOCUMENT NUMBER: 136:5926  
 TITLE: Preparation of benzoaromatic derivatives as melanin  
 concentrating hormone antagonists  
 INVENTOR(S): Ishihara, Yuji; Terauchi, Jun; Suzuki, Nobuhiro;  
 Takekawa, Shiro; Aso, Kazuyoshi  
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
 SOURCE: PCT Int. Appl., 285 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087834	A1	20011122	WO 2001-JP4015	20010515
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2408913	A1	20011122	CA 2001-2408913	20010515
JP 2002371059	A	20021226	JP 2001-145691	20010515
EP 1283199	A1	20030212	EP 2001-930132	20010515
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20030158177	A1	20030821	US 2002-276288	20021112
US 7229986	B2	20070612		
PRIORITY APPLN. INFO.:			JP 2000-148647	A 20000516
			JP 2001-116219	A 20010413
			WO 2001-JP4015	W 20010515
OTHER SOURCE(S):	MARPAT 136:5926			
GI				





AB Title compds. [I; R = H, halo, cyclic; X = bond, spacer containing a chain with one to six atoms; Y = spacer with one to six atoms; A = benzene; B = 5-9 membered nitrogen containing nonarom. heterocycle; R1 = H, hydrocarbon, heterocycle; R2 = H, hydrocarbon, heterocycle; R1R2 = nitrogen containing heterocycle; YR2 = nitrogenous heterocycle], melanin-concentrating hormone antagonist, which contains a compound represented by the formula or a salt thereof are prepared useful as prevention or remedy for adiposity, diabetes, or high blood pressure. Thus, the title compound II was prepared and biol. tested.


IT 374812-69-8P 374812-70-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoarom. derivs. as melanin concentrating hormone antagonists)

RN 374812-69-8 CAPLUS


CN 1,4-Butanedione, 1-[4-(4-chlorophenyl)-1-piperidinyl]-4-(3-cyclohexyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 374812-70-1 CAPLUS

CN 1,4-Butanedione, 1-[4-(4-chlorophenyl)-1-piperidinyl]-4-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/596,503



REFERENCE COUNT:

531

THERE ARE 531 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L17 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:98457 CAPLUS

DOCUMENT NUMBER: 134:147611

TITLE: Preparation of tetrahydrobenzo[d]azepines as  
metabotropic glutamate receptor 1 antagonists

INVENTOR(S): Adam, Geo; Binggeli, Alfred; Maerki, Hans-Peter;  
Mutel, Vincent; Wilhelm, Maurice; Wostl, Wolfgang

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: Eur. Pat. Appl., 85 pp.

CODEN: EPXXDW



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1074549	A2	20010207	EP 2000-116091	20000727
EP 1074549	A3	20020731		
EP 1074549	B1	20031119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 254614	T	20031215	AT 2000-116091	20000727
ES 2209728	T3	20040701	ES 2000-116091	20000727
CA 2314798	A1	20010206	CA 2000-2314798	20000801
US 6218385	B1	20010417	US 2000-630702	20000801
NZ 506096	A	20020828	NZ 2000-506096	20000801
ZA 2000003927	A	20010206	ZA 2000-3927	20000802
AU 2000048979	A	20010208	AU 2000-48979	20000802
AU 774485	B2	20040701		
HR 2000000520	A1	20010630	HR 2000-520	20000802
SG 93251	A1	20021217	SG 2000-4344	20000802
IN 2000MA00616	A	20050304	IN 2000-MA616	20000802
NO 2000003966	A	20010207	NO 2000-3966	20000804
CN 1283623	A	20010214	CN 2000-122523	20000804
CN 1146455	C	20040421		
TR 200002298	A2	20010321	TR 2000-2298	20000804
JP 2001089472	A	20010403	JP 2000-236848	20000804
JP 3260350	B2	20020225		
MX 2000PA07661	A	20020312	MX 2000-PA7661	20000804
HU 2000003112	A2	20021128	HU 2000-3112	20000804
HU 2000003112	A3	20030728		
RU 2240317	C2	20041120	RU 2000-120522	20000804
BR 2000003375	A	20010313	BR 2000-3375	20000807
PRIORITY APPLN. INFO.:			EP 1999-115557	A 19990806
OTHER SOURCE(S):	MARPAT	134:147611		
GI				



- AB The title compds. (I) [wherein R1 = H, alkyl, O, halo, OR, cycloalkoxy, (un)substituted cycloalkylalkoxy, cyanoalkoxy, (fluoro)alkoxy, aminoalkoxy, alkenyloxy, phenylalkoxy, heterocyclylalkoxy, sulfonyloxyalkoxy, SR, carboxyalkylthio, NR2, hydroxyalkylamino, or heterocyclylalkylamino; n = 1-6; R = independently H, alkyl, or alkenyl; R2 = NO2 or CN; R3 = H, alkyl, O, S, SR, alkylsulfonyl, cycloalkyl, CONR2, NR2, alkyl, OR, or (un)substituted piperazino, carbamoylalkyl, alkoxyalkyl, fluoroalkyl, trifluoroacetoxyalkyl, carboxyalkyl, phenylthioalkyl, heterocyclylalkoxy, acylamino, alkylamino, phenoxyalkylamino, heterocyclylalkylamino, fluoroalkoxy, etc.; R4 = H, alkyl, alkenyl, NO2, OR, NR2, or (un)substituted fluoroalkoxy, fluoroalkyl, phenylalkyl, alkoxyalkanol, aminoalkyl, carboxyalkyl, alkylsulfonyloxyalkyl, fluoroalkenyl, heterocyclylalkyl, heterocyclylalkylamino, alkoxycarbonylamino, alkoxycarbonylhydrazino, aminofluoroalkenylamino; or R4 and R1 or R3 and R4 form an addnl. ring; R5 and R6 = independently H, alkyl, alkoxy, NH2, HO2, SO2NH2, or halo; or R5 and R6 = OCH2O; R7 and R8 = independently H, alkyl, alkoxy, NH2, NO2, or halo; R9 and R10 = independently H or alkyl; R11 and R12 = independently H, alkyl, OH, alkoxy, alkoxycarbonyloxy, or alkanoyloxy; R13 and R14 = independently H, T, or alkyl; R15 and R16 = independently H, T, alkyl, OH, alkoxy, alkoxycarbonyloxy, or alkanoyloxy; or R15 and R16 = O; X = N or C; Y = N, NH, or CH] were prepared. For example, addition of Et 2-cyano-3,3-bis(methylthio)acrylate to 2,3,4,5-tetrahydro-1H-benzo[d]azepine•HCl using TEA and K2CO3 in EtOH gave 2-cyano-3-methylsulfonyl-3-(1,2,4,5-tetrahydrobenzo[d]azepin-3-yl)acrylic acid Et ester (64%). The benzazepinylacrylate ester was treated with NH2C(NH)NH2•HNO3 and 1,8-diazabicyclo[5.4.0]undec-7-ene in DMF to give II (R = H). Ethylation of II (R = H) with EtI in DMF in the presence of K2CO3 afforded the preferred metabotropic glutamate receptor 1 (mGluR1) antagonist II (R = Et), which gave an IC50 values of 0.009  $\mu$ M and 0.003

$\mu\text{M}$ , resp. in functional and binding assays for the characterization of mGluR1 antagonist properties. I are useful in the prevention or control of acute and/or chronic neurol. disorders and as radiolabeled mGluR1 receptor antagonists in binding assays (no data).


IT 324553-98-2P 324554-03-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrahydrobenzo[d]azepine mGluR1 antagonists by addition of chloroheterocycles or halobenzenes to tetrahydrobenzo[d]azepines or by cycloaddn. of guanidines to 3-methylthio-3-(tetrahydrobenzo[d]azepin-3-yl)acrylates)


RN 324553-98-2 CAPLUS

CN Benzonitrile, 2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)- (CA INDEX NAME)



RN 324554-03-2 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(2-nitrophenyl)- (CA INDEX NAME)




L17 ANSWER 27 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:294876 CAPLUS  
 DOCUMENT NUMBER: 124:343273  
 ORIGINAL REFERENCE NO.: 124:63759a,63762a  
 TITLE: Preparation of urea moiety-containing benzazepine  
 blood platelet aggregation inhibitors  
 INVENTOR(S): Himmelsbach, Frank; Austel, Volkhard; Pieper, Helmut;  
 Weisenberger, Johannes; Guth, Brian  
 PATENT ASSIGNEE(S): Dr. Karl Thomae GmbH, Germany  
 SOURCE: Ger. Offen., 41 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4429079	A1	19960222	DE 1994-4429079	19940817
CA 2197789	A1	19960222	CA 1995-2197789	19950816
WO 9605194	A1	19960222	WO 1995-EP3233	19950816
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SK, TJ, TM, TT, UA, UG, UZ, VN RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9533459	A	19960307	AU 1995-33459	19950816
EP 777667	A1	19970611	EP 1995-929874	19950816
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10504298	T	19980428	JP 1995-507030	19950816
PRIORITY APPLN. INFO.:			DE 1994-4429079	A 19940817
			WO 1995-EP3233	W 19950816

OTHER SOURCE(S): MARPAT 124:343273  
 GI



I

AB The title compds. [I; (un)substituted (un)branched alkylene, alkenylene, 1,2-arylene, etc.; (un)substituted alkylene, arylene, cycloalkylene, etc.; E = (un)substituted alkylene, etc.; F = alkoxy carbonyl, hydroxy carbonyl, etc.; Ra, Rb = H, F, Cl, Br, I, alkyl, CF<sub>3</sub>, CN, alkoxy, etc.; R1, R3 = H, alkyl, aryl, HO, alkoxy, CN, (un)substituted CO<sub>2</sub>H, etc.; R2, R4, R6, R8 = H, alkyl; R5, R7 = H, alkyl, aryl, CO<sub>2</sub>H, alkoxy carbonyl, (un)substituted CONH<sub>2</sub>, etc.; R9 = H, (un)substituted alkyl, cycloalkyl, etc.], useful as blood platelet aggregation inhibitors, are prepared and I-containing formulations presented. Thus, N-(2,2-diethoxyethyl)-N-(1,4-dioxaspiro[4.5]decan-8-yl)-N'-(3-trifluoroacetyl-2,3,4,5-tetrahydro-1H-3-

10/596,503

benzazepin-7-yl)urea was prepared and demonstrated EC50 for blood platelet aggregation of 150 nM.

IT 163066-96-4P 176492-45-8P 176492-52-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of urea moiety-containing benzazepine blood platelet aggregation inhibitors)

RN 163066-96-4 CAPLUS

CN Cyclohexanepropanoic acid, 4-[3-(3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-1-imidazolidinyl]-, monohydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 176492-45-8 CAPLUS

CN Cyclohexanepropanoic acid, 4-[3-(3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-1-imidazolidinyl]-, methyl ester, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 176492-52-7 CAPLUS


CN Cyclohexanepropanoic acid, 4-[3-(3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-1-imidazolidinyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.

10/596,503




IT 176492-67-4P 176492-80-1P 176492-81-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of urea moiety-containing benzazepine blood platelet  
aggregation inhibitors)  
RN 176492-67-4 CAPLUS  
CN 1H-3-Benzazepin-7-amine, 3-cyclopropyl-2,3,4,5-tetrahydro-, hydrochloride  
(1:2) (CA INDEX NAME)



●2 HCl

RN 176492-80-1 CAPLUS  
CN Cyclohexanepropanoic acid, 4-[[[(3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-  
benzazepin-7-yl)amino]carbonyl](2-hydroxyethyl)amino]-, methyl ester,  
trans- (CA INDEX NAME)


Relative stereochemistry.



RN 176492-81-2 CAPLUS  
CN 1H-3-Benzazepine, 3-cyclopropyl-2,3,4,5-tetrahydro-7-nitro-, hydrochloride  
(1:1) (CA INDEX NAME)



10/596,503



● HCl

L17 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:550906 CAPLUS  
 DOCUMENT NUMBER: 122:314547  
 ORIGINAL REFERENCE NO.: 122:57205a,57208a  
 TITLE: Preparation of urea residue-substituted heterocyclic compounds with antithrombotic, antineoplastic and blood platelet-aggregation inhibition activities  
 INVENTOR(S): Himmelsbach, Frank; Pieper, Helmut; Austel, Volkhard; Linz, Guenter; Guth, Brian; Mueller, Thomas; Weisenberger, Johannes  
 PATENT ASSIGNEE(S): Dr. Karl Thomae GmbH, Germany  
 SOURCE: Eur. Pat. Appl., 81 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 612741	A1	19940831	EP 1994-102557	19940221
EP 612741	B1	19980610		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4305388	A1	19940825	DE 1993-4305388	19930222
DE 4332168	A1	19950323	DE 1993-4332168	19930922
EE 3397	B1	20010416	EE 1994-311	19941123
PRIORITY APPLN. INFO.:			DE 1993-4305388	A 19930222
			DE 1993-4332168	A 19930922

OTHER SOURCE(S): MARPAT 122:314547

AB The title compds., which contain urea-like moieties, often in the form of divalent imidazolidinone groups, which demonstrate a combination of antithrombotic, antineoplastic (no data), and blood platelet-aggregation inhibition activities, are prepared and pharmaceutical dosage forms containing them presented. Thus, 1-[4-(2-carboxyethyl)phenyl]-3-(1,2,3,4-tetrahydroisoquinolin-6-yl)imidazolidin-2-one was prepared and demonstrated ED50 for blood platelet aggregation inhibition of 40 nM.

IT 163066-96-4P 163066-98-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of urea residue-substituted heterocyclic compds. with antithrombotic, antineoplastic and blood platelet aggregation inhibition activities)

RN 163066-96-4 CAPLUS

CN Cyclohexanepropanoic acid, 4-[3-(3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-1-imidazolidinyl]-, monohydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/596,503



● HCl

RN 163066-98-6 CAPLUS  
CN Cyclohexanepropanoic acid, 4-[3-(3-cyclohexyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-1-imidazolidinyl]-, monohydrochloride, trans- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.



● HCl

L17 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:612295 CAPLUS

DOCUMENT NUMBER: 117:212295

ORIGINAL REFERENCE NO.: 117:36663a,36666a


TITLE: 6-Hydroxy-3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine  
and analogs: new centrally acting 5-HT1a receptor  
agonistsAUTHOR(S): Wikstroem, Haakan; Andersson, Bengt; Elebring, Thomas;  
Lagerkvist, Soeren; Hallnemo, Gerd; Pettersson,  
Ingrid; Jovall, Per Aake; Svensson, Kjell; Ekman,  
Agneta; Carlsson, ArvidCORPORATE SOURCE: Dep. Pharmacol., Univ. Goeteborg, Goeteborg, S-400 33,  
Swed.SOURCE: Journal of Medicinal Chemistry (1992), 35(22), 3984-90  
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 117:212295

GI




AB The ring-closed phenylethylamine analog 6-hydroxy-3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine (I) is a 5-HT1a receptor agonist of moderate potency, according to both in vivo biochem. data and in vitro binding data. The active compds. of this series also induce the 5-HT behavioral syndrome. Mol. modeling studies were performed with mol. mechanics calcns., and a tentative explanation for the relatively low potency of these serotonergic benzazepines is provided.

IT 143620-28-4P 143620-39-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as 5-HT1a- and D2-receptor agonist)

RN 143620-28-4 CAPLUS


CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-6-methoxy-,  
hydrochloride (1:1) (CA INDEX NAME)

● HC1

10/596,503

RN 143620-39-7 CAPLUS



CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-6-methoxy- (CA INDEX  
NAME)



L17 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1981:515322 CAPLUS  
 DOCUMENT NUMBER: 95:115322  
 ORIGINAL REFERENCE NO.: 95:19345a,19348a  
 TITLE: Carboxylic acid derivatives and medicaments containing them  
 INVENTOR(S): Griss, Gerhart; Sauter, Robert; Grell, Wolfgang; Hurnaus, Rudolf; Rupprecht, Eckhard; Kaubisch, Nikolaus; Kaehling, Joachim; Eisele, Bernhard; Piper, Helmut; Noll, Klaus  
 PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.  
 SOURCE: Eur. Pat. Appl., 271 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 23569	A1	19810211	EP 1980-103670	19800628
EP 23569	B1	19830622		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
DE 2928352	A1	19810115	DE 1979-2928352	19790713
DE 2949259	A1	19810611	DE 1979-2949259	19791207
DE 3016650	A1	19811105	DE 1980-3016650	19800430
DE 3016651	A1	19811105	DE 1980-3016651	19800430
EP 63826	A2	19821103	EP 1982-104991	19800628
EP 63826	A3	19821229		
EP 63826	B1	19841205		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 3862	T	19830715	AT 1980-103670	19800628
AT 10632	T	19841215	AT 1982-104991	19800628
AU 8060362	A	19810115	AU 1980-60362	19800711
AU 535924	B2	19840412		
HU 27876	A2	19831128	HU 1983-1085	19800711
HU 186675	B	19850930	HU 1980-1085	19800711
ES 507620	A3	19821116	ES 1981-507620	19811201
ES 524224	A3	19841216	ES 1983-524224	19830719
NO 8403735	A	19810114	NO 1984-3735	19840919
PRIORITY APPLN. INFO.:			DE 1979-2928352	A 19790713
			DE 1979-2949259	A 19791207
			DE 1980-3016650	A 19800430
			DE 1980-3016651	A 19800430
			US 1978-892534	19780403
			EP 1980-103670	A 19800628
			EP 1982-104991	19800628
			US 1980-198461	A 19801020
			US 1980-204726	A 19801106
OTHER SOURCE(S):			CASREACT 95:115322; MARPAT 95:115322	
GI				



AB Carboxamides I [R = H, Cl, Br, C4-7 cyclic alkylenimins; R1 = H, F, Cl, Br, C1-6 alkyl or alkoxy, Ph-substituted C1-3 alkoxy, OH, NO<sub>2</sub>, NH<sub>2</sub>, cyano, CO<sub>2</sub>H, alkanoylamine, alkoxycarbonyl, di-C1-3-alkylamidodisulfonyl; R<sub>2</sub>, R<sub>3</sub> independently = C1-7 alkyl C3-7 alkenyl or cycloalkyl, Ph-substituted C1-3 alkyl, Ph, adamantyl; NR<sub>2</sub>R<sub>3</sub> = C4-6 cyclic (un)substituted alkylenimins optionally with CH<sub>2</sub> replaced by O, S, CO, S(O), S(O<sub>2</sub>), C7-10 azabicycloalkyl, alkyl-substituted piperidino, C6-9 1,4-dioxo-8-azaspiroalkyl, (CH<sub>2</sub>)<sub>n</sub>N (n = 3-5, 7-12); R<sub>4</sub> = H, C1-3 alkyl; R<sub>5</sub> = H, halo, NO<sub>2</sub>, NH<sub>2</sub>, cyano, CHO, CH<sub>2</sub>OH, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, (esterified) CO<sub>2</sub>H, substituted Me, Ac, Et, H<sub>2</sub>NCO, piperidino-, morpholino-, thiomorpholino-, or N-alkylpiperazinocarbonyl; X = N or CH; Z = O, an imino group, or a methylene group optionally subst. with 1 or 2 C1-C3 alkyl groups] and their physiol. tolerable salts, useful as hypoglycemics, anticholesteremics, and hypolipemics (data tabulated), were prepared by numerous methods. Refluxing 2,5-Cl(O<sub>2</sub>N)C<sub>6</sub>H<sub>3</sub>CO<sub>2</sub>H and 2-methylpiperidine in EtOH gave 85% 2-(3-methylpiperidino)-5-nitrobenzoic acid which was hydrogenated over Pd/C to 75% the 5-amino analog II. Gattermann reaction of II gave 47% 5-chloro-3-(2-methylpiperidino) benzoic acid which reacted with N,N'-carbonyldiimidazole in THF to give the imidazolide. Treating this with 4-(H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>)C<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>Me gave 51% benzamide III (R<sub>6</sub> = Me),

saponification


of which gave 83% III (R<sub>6</sub> = H). At 5 mg/kg (rats), III (R = H) lowered blood sugar 44, 42, 38, and 35% after 1, 2, 3, and 4 h, resp.

IT 78251-56-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and Gattermann reaction of)

RN 78251-56-6 CAPLUS


CN Benzoic acid, 5-amino-2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)- (CA INDEX NAME)



IT 78243-34-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and hydrogenation of)  
 RN 78243-34-2 CAPLUS  
 CN Benzoic acid, 5-nitro-2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)- (CA  
 INDEX NAME)




IT 77266-44-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and reaction of, with carbonyldiimidazole and  
 aminoethylbenzoate)  
 RN 77266-44-5 CAPLUS  
 CN Benzoic acid, 5-chloro-2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)- (CA  
 INDEX NAME)



IT 77266-43-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and saponification of)  
 RN 77266-43-4 CAPLUS  
 CN Benzoic acid, 4-[2-[[5-chloro-2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-  
 yl)benzoyl]amino]ethyl]-, methyl ester (CA INDEX NAME)



10/596,503




IT 77266-45-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 77266-45-6 CAPLUS

CN Benzoic acid, 4-[2-[[5-chloro-2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)benzoyl]amino]ethyl]- (CA INDEX NAME)




IT 78254-84-9

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, with alkyl (aminoethyl)benzoate)

RN 78254-84-9 CAPLUS

CN 1H-Imidazole, 1-[5-chloro-2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)benzoyl]- (9CI) (CA INDEX NAME)





L17 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1981:156575 CAPLUS  
 DOCUMENT NUMBER: 94:156575  
 ORIGINAL REFERENCE NO.: 94:25585a,25588a  
 TITLE: Pharmaceutical aminobenzoic acid amides  
 INVENTOR(S): Griss, Gerhart; Sauter, Robert; Grell, Wolfgang;  
 Hurnaus, Rudolf; Rupprecht, Eckhard; Kaubisch,  
 Nikolaus; Kaehling, Joachim; Eisele, Bernhard; Pieper,  
 Helmut; Noll, Klaus  
 PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.  
 SOURCE: Ger. Offen., 75 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2928352	A1	19810115	DE 1979-2928352	19790713
EP 23569	A1	19810211	EP 1980-103670	19800628
EP 23569	B1	19830622		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AT 3862	T	19830715	AT 1980-103670	19800628
DK 8002941	A	19810114	DK 1980-2941	19800708
DD 153207	A5	19811230	DD 1980-222511	19800709
DD 200152	A5	19830323	DD 1980-231669	19800709
FI 8002228	A	19810114	FI 1980-2228	19800711
NO 8002087	A	19810114	NO 1980-2087	19800711
NO 152005	B	19850409		
NO 152005	C	19850717		
ZA 8004204	A	19820331	ZA 1980-4204	19800711
HU 25537	A2	19830728	HU 1980-1750	19800711
HU 183178	B	19840428		
IL 60554	A	19850228	IL 1980-60554	19800711
DE 3100535	A1	19820812	DE 1981-3100535	19810110
ES 507620	A3	19821116	ES 1981-507620	19811201
ES 524224	A3	19841216	ES 1983-524224	19830719
PRIORITY APPLN. INFO.:				
			US 1978-892534	19780403
			DE 1979-2928352	A 19790713
			DE 1979-2949259	A 19791207
			DE 1980-3016650	A 19800430
			DE 1980-3016651	A 19800430
			EP 1980-103670	A 19800628
			US 1980-198461	A 19801020
			US 1980-204726	A 19801106

GI




AB Aminobenzamides I [R1 = H, halo, NO2, NH2, alkanamido, alkoxy, cyano, CO2H, alkoxy carbonyl, dialkylamidodisulfonyl (alkyl = C1-3); R2, R3 independently = C1-7 alkyl, C3-7 cycloalkyl; NR2R3 = 4-8 membered ring optionally substituted with 1-2 C1-3 alkyl, C1-3 alkoxy, OH, Ph, CO2H, C2-4 alkoxy carbonyl, or CH2 replaced by C3-4 cyclic ketal, O, S, S(O), NH optionally substituted with Ph or pyridyl; R4 = H, C1-3 alkyl; R5 = H, C1-4 alkyl] and their salts with inorg. or organic acids and bases, useful as hypoglycemics, were prepared 5,2-Cl(Me2N)C6H3CO2H was converted to its acid chloride with SOCl2 which, in pyridine, reacted with 4-(H2NCH2CH2)C6H4CO2Me in 2 h at room temperature and 20 min at 50-70° to give 73% benzamide II (R6 = Me) whose hydrolysis in 2:1 MeOH-dioxane by aqueous KOH gave 70% II (R6 = H). At 5 mg/kg (rat), I (R1 = Cl, NR2R3 = 3-methylpiperidino, R4 = R5 = H) lowered blood sugar 44, 42, 38, and 35% after 1, 2, 3, and 4 h, resp.

IT 77266-44-5

RL: RCT (Reactant); RACT (Reactant or reagent)  
(amidation of, with (aminoethyl)benzoates)

RN 77266-44-5 CAPLUS

CN Benzoic acid, 5-chloro-2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)- (CA INDEX NAME)




IT 77266-43-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and saponification of)

RN 77266-43-4 CAPLUS

CN Benzoic acid, 4-[2-[[5-chloro-2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)benzoyl]amino]ethyl]-, methyl ester (CA INDEX NAME)

10/596,503




IT 77266-45-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 77266-45-6 CAPLUS


CN Benzoic acid, 4-[2-[[5-chloro-2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)benzoyl]amino]ethyl]- (CA INDEX NAME)



L17 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1980:620611 CAPLUS  
 DOCUMENT NUMBER: 93:220611  
 ORIGINAL REFERENCE NO.: 93:35222h,35223a  
 TITLE: Alkylthio-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity  
 INVENTOR(S): Holden, Kenneth G.  
 PATENT ASSIGNEE(S): Smithkline Corp., USA  
 SOURCE: U.S., 8 pp. Cont.-in-part of U.S. Ser. No. 760,500, abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4206210	A	19800603	US 1978-912131	19780602
ZA 7707444	A	19781025	ZA 1977-7444	19771214
GB 1597911	A	19810916	GB 1978-953	19780110
GB 1597912	A	19810916	GB 1978-20952	19780110
BE 862878	A1	19780713	BE 1978-184290	19780113
FR 2378017	A1	19780818	FR 1978-998	19780113
FR 2378017	B1	19810710		
DK 7800199	A	19780720	DK 1978-199	19780116
SE 7800455	A	19780720	SE 1978-455	19780116
SE 437265	B	19850218		
SE 437265	C	19850606		
AU 7832465	A	19790726	AU 1978-32465	19780116
AU 510459	B2	19800626		
CA 1090334	A1	19801125	CA 1978-294973	19780116
NL 7800637	A	19780721	NL 1978-637	19780118
JP 53090281	A	19780808	JP 1978-4769	19780118
JP 60040423	B	19850911		
HU 175836	B	19801028	HU 1978-SI1612	19780118
CH 642634	A5	19840430	CH 1978-525	19780118
FR 2384759	A1	19781020	FR 1978-16583	19780602
FR 2384759	B1	19800718		
AU 516608	B2	19810611	AU 1980-57822	19800424
AU 8057822	A	19800731		
CH 640228	A5	19831230	CH 1982-3573	19820609
PRIORITY APPLN. INFO.:			US 1977-760500	A2 19770119
			GB 1978-953	A 19780110
			CH 1978-525	A 19780118
OTHER SOURCE(S):	MARPAT	93:220611		
GI				




AB The benzodiazepines I (R = H, alkylthio, alkylsulfinyl, alkylsulfonyl, F3CS, F3CSO, F3SO2; R1 = H, alkyl, C3-5 alkenyl; R2 = H, halo, F3C, MeO, HO; R3 = H, alkylthio) were prepared. Thus, I.HBr (R-R3 = H) was oxidized to the dione, which was treated with MeSH to give 11% I (R = MeS, R1-R3 = H) and 22% I (R-R2 = H, R3 = MeS). The dopaminergic ED15 of I (R = MeS, R1-R3 = H) was 372 mg/kg. I had antiparkinsonism activity.

IT 75549-05-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 75549-05-2 CAPLUS

CN 1H-3-Benzazepine, 6-bromo-2,3,4,5-tetrahydro-7,8-dimethoxy-3-phenyl- (CA INDEX NAME)



10/596,503

=> => d his

(FILE 'HOME' ENTERED AT 12:30:08 ON 26 AUG 2008)

FILE 'REGISTRY' ENTERED AT 12:30:16 ON 26 AUG 2008

L1           STRUCTURE UPLOADED  
L2           43429 S C6-C6N/EA  
L3           41 S C3-C6-C6N/EA  
L4           81 S C4-C6-C6N/EA  
L5           713 S C5-C6-C6N/EA  
L6           16282 S C6-C6-C6N/EA  
L7           82 S C6-C6N-C7/EA  
L8           17199 S L3 OR L4 OR L5 OR L6 OR L7  
L9           909 S L8 AND SPIRO  
L10          44338 S L9 OR L2  
L11          50 S L1   SUB=L10 SAM  
L12          13163 S L1   SUB=L10 FUL

FILE 'CAPLUS' ENTERED AT 12:41:55 ON 26 AUG 2008

FILE 'REGISTRY' ENTERED AT 12:43:25 ON 26 AUG 2008

FILE 'CAPLUS' ENTERED AT 12:45:01 ON 26 AUG 2008

FILE 'REGISTRY' ENTERED AT 12:53:09 ON 26 AUG 2008

FILE 'CAPLUS' ENTERED AT 12:57:40 ON 26 AUG 2008

FILE 'REGISTRY' ENTERED AT 12:58:59 ON 26 AUG 2008

FILE 'CAPLUS' ENTERED AT 13:02:26 ON 26 AUG 2008

FILE 'REGISTRY' ENTERED AT 13:05:19 ON 26 AUG 2008

L13           STRUCTURE UPLOADED  
L14          10188 S L13   SUB=L12 FUL  
L15           STRUCTURE UPLOADED  
L16          1173 S L15   SUB=L14 FUL

FILE 'CAPLUS' ENTERED AT 13:16:02 ON 26 AUG 2008

L17          32 S L16

FILE 'REGISTRY' ENTERED AT 13:18:27 ON 26 AUG 2008


L18          990 S L16 AND CAPLUS/LC  
L19          183 S L16 NOT L18

=> d 183

10/596,503

L19 ANSWER 183 OF 183 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 702633-35-0 REGISTRY  
ED Entered STN: 02 Jul 2004  
CN Cyclohexanepropanoic acid, 4-[3-(3-cyclohexyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-1-imidazolidinyl]-, trans- (CA INDEX NAME)  
FS STEREOSEARCH  
MF C28 H41 N3 O3  
CI COM  
SR CA

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*




10/596,503

=> d 182

10/596,503

L19 ANSWER 182 OF 183 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 791586-43-1 REGISTRY  
ED Entered STN: 02 Dec 2004  
CN 2,3-Pyridinedicarboxylic acid, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)  
MF C21 H22 N2 O5  
CI COM  
SR CA




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/596,503

=> d 181

10/596,503

L19 ANSWER 181 OF 183 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 854813-89-1 REGISTRY  
ED Entered STN: 13 Jul 2005  
CN Benzenesulfonamide, N-(3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)  
MF C20 H21 F3 N2 O3 S  
CI COM  
SR CA



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/596,503

=>